

DETAILED METHODOLOGY FOR THE 2018 VALUE MODIFIER AND THE 2016 QUALITY AND RESOURCE USE REPORT

CONTENTS

| | |
|---|----|
| ABOUT THE DETAILED METHODOLOGY | 1 |
| I. OVERVIEW OF THE 2018 VALUE MODIFIER AND 2016 ANNUAL QUALITY AND RESOURCE USE REPORTS..... | 2 |
| A. Statutory Authority and Phased Approach to Implementation | 2 |
| B. The 2018 Value Modifier | 2 |
| 1. Physician Quality Reporting System (PQRS) Participation | 3 |
| 2. Category 1 and Category 2 Determination Based on PQRS Participation..... | 3 |
| 3. Quality-Tiering..... | 4 |
| C. Relationship between the 2018 Value Modifier and the 2016 Annual Quality and Resource Use Reports (QRURs) | 6 |
| II. COMPUTATION OF THE 2018 VALUE MODIFIER..... | 7 |
| A. Overview..... | 7 |
| B. TINs Subject to the Value Modifier | 7 |
| C. Quality Measures Included in the Quality Composite Score | 9 |
| 1. Quality Measures Reported by Groups and Individual Eligible Professionals..... | 9 |
| 2. CMS-Calculated Claims-Based Quality Outcome Measures..... | 12 |
| 3. CAHPS for PQRS and ACOs..... | 13 |
| D. Cost Measures Included in the Cost Composite Score..... | 14 |
| E. TINs Reporting Quality Measures Impacted by International Classification of Diseases, 10th Revision (ICD-10) | 15 |
| F. Determining Which Measures Have the Required Number of Eligible Cases to be included in the 2018 Value Modifier Calculations..... | 16 |
| G. Computing Measure Benchmarks and Standard Deviations | 16 |
| H. Standardizing Scores and Computing Domain Scores | 18 |
| I. Computing Mean Domain Scores and Standardized Composite Scores | 18 |
| J. Categorizing TINs on Quality and Cost Performance Based on Composite Scores and Statistical Significance (Quality-Tiering)..... | 19 |

| | | |
|------------|---|-----|
| K. | Assessing Whether the TIN Treats a Disproportionate Share of Beneficiaries with High-Risk Scores..... | 21 |
| L. | Computation of Budget-Neutral Adjustment Factor (AF) | 21 |
| M. | Value Modifier Informal Review Policies | 22 |
| III. | COMPUTATION OF ADDITIONAL STATISTICS..... | 25 |
| A. | Hospital Admissions for Any Cause | 25 |
| B. | Categorical Breakdown of Costs by Type of Service | 27 |
| C. | Physicians and Nonphysician Eligible Professionals Billing Under the TIN..... | 29 |
| APPENDIX A | DESCRIPTION OF DATA SOURCES..... | A.1 |
| APPENDIX B | QUALITY MEASURES, BY DOMAIN..... | B.1 |
| APPENDIX C | APPROACH TO PQRS MEASURES AND NON-PQRS QCDR MEASURES WITH MULTIPLE PERFORMANCE RATES OR TECHNICAL ISSUES..... | C.1 |
| APPENDIX D | METHOD FOR DEFINING SERVICE CATEGORIES..... | D.1 |
| APPENDIX E | PROVIDER SPECIALTIES AND PROFESSIONAL STRATIFICATION CATEGORIES | E.1 |
| APPENDIX F | HIERARCHY OF PQRS DATA USED IN THE 2018 VALUE MODIFIER | F.1 |
| APPENDIX G | LIST OF ACRONYMS | G.1 |

EXHIBITS

| | | |
|--------|---|------|
| I.1. | Overview of the Application of the 2018 Value Modifier..... | 5 |
| II.1. | Methodology for Determining the 2018 Value Modifier for Category 1 TINs | 8 |
| II.2. | 2018 Value Modifier Payment Adjustments Based on Quality-Tiering..... | 20 |
| II.3. | Quality and Cost Composite Status for TINs due to Informal Review Decisions and Widespread Quality and Cost Data Issues..... | 22 |
| III.1. | Medicare Hospital Claim Patient Discharge Status Codes | 26 |
| III.2. | Service Categories Displayed for Per Capita Costs Measures in the 2016 QRURs | 28 |
| III.3. | Service Categories Displayed for the MSPB Measure in the 2016 QRURs | 29 |
| B.1. | Effective Clinical Care Domain Quality Indicators | B.2 |
| B.2. | Person and Caregiver-Centered Experience and Outcomes Domain Quality Indicators | B.22 |
| B.3. | Community/Population Health Domain Quality Indicators | B.29 |
| B.4. | Patient Safety Domain Quality Indicators..... | B.32 |
| B.5. | Communication and Care Coordination Domain Quality Indicators..... | B.42 |
| B.6. | Communication and Care Coordination Domain Quality Indicators (CMS-Calculated Quality Outcome Measures)..... | B.49 |
| B.7. | Efficiency and Cost Reduction Domain Quality Indicators | B.50 |
| C.1. | Approach to PQRS Measures and non-PQRS QCDR Measures with Multiple Performance Rates..... | C.2 |
| C.2. | Approach to PQRS Measures and non-PQRS QCDR Measures with Technical Issues | C.11 |
| D.1. | Categorization Codes for Type of Service Categories for Per Capita Cost Measures | D.2 |
| D.2. | Definitions for Service Categories for the MSPB Measure | D.9 |
| D.3. | 2016 BETOS Codes and Descriptions | D.12 |
| E.1. | Provider Specialties and Professional Stratification Categories | E.2 |
| F.1. | PQRS Data Used in the 2018 Value Modifier | F.2 |
| G.1. | List of Acronyms in the Detailed Methodology | G.2 |

ABOUT THE DETAILED METHODOLOGY

The Detailed Methodology for the 2018 Value-Based Payment Modifier (Value Modifier) describes the process and methodology used to compute the Value Modifier that the Centers for Medicare & Medicaid Services (CMS) will use to adjust Medicare Physician Fee Schedule (PFS) payments in 2018 for physicians, physician assistants (PAs), nurse practitioners (NPs), clinical nurse specialists (CNSs), and certified registered nurse anesthetists (CRNAs) in groups with two or more eligible professionals and those who are solo practitioners. CMS identifies these groups and solo practitioners by their Medicare-enrolled Taxpayer Identification Number (TIN) and will apply the 2018 Value Modifier at the TIN level.

Section I provides an overview of the 2018 Value Modifier, including the relationship between the 2018 Value Modifier and the 2016 Annual Quality and Resource Use Reports (QRURs) that CMS will make available to groups and solo practitioners. Section II describes the methodology for computing the 2018 Value Modifier, and Section III explains the methodology for producing additional statistics included in the 2016 Annual QRURs to help physicians and other eligible professionals better understand the measures included in the 2018 Value Modifier and support practice improvement.

I. OVERVIEW OF THE 2018 VALUE MODIFIER AND 2016 ANNUAL QUALITY AND RESOURCE USE REPORTS

A. Statutory Authority and Phased Approach to Implementation

As established by Section 3007 of the Affordable Care Act (ACA), the Value Modifier provides for differential payment, for items and services furnished under the Medicare PFS, to physicians and other eligible professionals. Value Modifier payment adjustments are based on the quality of care furnished to their Medicare Fee-for-Service (FFS) beneficiaries compared to the cost of care during a performance period. The ACA requires application of the Value Modifier to all physicians and groups of physicians by January 1, 2017. As finalized in the 2016 Medicare Physician Fee Schedule Final Rule (80 FR 71274), CMS will also apply the Value Modifier to PAs, NPs, CNSs, and CRNAs beginning January 1, 2018. CMS computes the Value Modifier at the TIN level, which means that all eligible professionals who are subject to the Value Modifier in 2018 and billing under a given TIN will receive the Value Modifier computed for that TIN. The 2018 Value Modifier will not be applied to nonphysician eligible professionals who are not PAs, NPs, CNSs, or CRNAs.

B. The 2018 Value Modifier

CMS will apply the 2018 Value Modifier to payments for physicians, PAs, NPs, CNSs, and CRNAs in groups with two or more eligible professionals and those who are solo practitioners, as identified by their TIN. This includes physicians, PAs, NPs, CNSs, and CRNAs in TINs that participated in a Medicare Shared Savings Program (subsequently Shared Savings Program) Accountable Care Organization (ACO) in 2016.¹ The 2018 Value Modifier will be waived for TINs if at least one eligible professional who billed for Medicare PFS items and services under the TIN in 2016 participated in the Pioneer ACO Model, the Comprehensive Primary Care (CPC) initiative, the Next Generation ACO Model, the Oncology Care Model, or the Comprehensive End Stage Renal Disease (ESRD) Care Model in 2016, and the TIN did not participate in a Shared Savings Program ACO in 2016.

¹ See [Section II.C.1](#) for more information on determining quality performance for TINs that participated in more than one Shared Savings Program ACO in 2016 and for TINs that participated in a Shared Savings Program ACO in 2016 that did not avoid the 2018 Physician Quality Reporting System (PQRS) payment adjustment. For additional information on Shared Savings Program ACO TINs and the PQRS, see the document entitled “Medicare Shared Savings Program Interaction with the Physician Quality Reporting System (PQRS),” available at the following URL: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/sharedsavingsprogram/Downloads/PQRS-FAQs.pdf>.

1. Physician Quality Reporting System (PQRS) Participation

In 2016, eligible professionals were required to participate in the PQRS to avoid the 2018 PQRS downward payment adjustment as a group or as individuals.² Groups can avoid the automatic downward Value Modifier payment adjustment in 2018 by participating in one of four reporting mechanisms under the 2016 PQRS Group Practice Reporting Option (GPRO): (1) Web Interface (for TINs with 25 or more eligible professionals), (2) qualified PQRS registry, (3) electronic health record (EHR),³ or (4) qualified clinical data registry (QCDR), and avoiding the 2018 PQRS payment adjustment. Alternatively, groups can avoid the automatic downward Value Modifier payment adjustment in 2018 if at least 50 percent of the eligible professionals in the group avoided the 2018 PQRS payment adjustment as individuals. Solo practitioners can avoid the automatic downward Value Modifier payment adjustment in 2018 if they avoided the 2018 PQRS payment adjustment as individuals. See [Section II.C.1](#) for quality data included in the calculation of the 2018 Value Modifier.

Additional information on avoiding the 2018 PQRS payment adjustment is available at the following URL: <http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/Payment-Adjustment-Information.html>.

2. Category 1 and Category 2 Determination Based on PQRS Participation

CMS uses the term Category 1 to refer to TINs subject to the 2018 Value Modifier that avoided the 2018 PQRS payment adjustment. This includes:

- 1) TINs that reported through the GPRO and avoided the 2018 PQRS payment adjustment as a group,
- 2) TINs with at least 50 percent of the eligible professionals who avoided the 2018 PQRS payment adjustment as individuals,
- 3) TINs that are solo practitioners who avoided the 2018 PQRS payment adjustment as individuals,
- 4) TINs that participated in a Shared Savings Program ACO in 2016 that reported through the GPRO Web Interface and avoided the 2018 PQRS payment adjustment on their behalf, and
- 5) TINs that participated in a Shared Savings Program ACO that did not avoid the 2018 PQRS payment adjustment on their behalf, but the TIN avoided the 2018 PQRS payment adjustment by reporting outside of the ACO either as a group, a solo

² For a list of eligible professionals required to participate in the PQRS in 2016, see “2016 Physician Quality Reporting System (PQRS) List of Eligible Professionals,” available at the following URL: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/Downloads/2016_PQRS_List_of_EPs.pdf.

³ EHR data submitted through a direct EHR product that is Certified EHR Technology (CEHRT) or through data submission vendor that is CEHRT.

practitioner, or by ensuring at least 50 percent of the eligible professionals in the TIN avoided the 2018 PQRS payment adjustment as individuals.

TINs subject to the 2018 Value Modifier that do not meet the criteria for inclusion in Category 1 are classified as Category 2 TINs. In the 2018 Medicare Physician Fee Schedule Proposed Rule (82 FR 34125), CMS proposed that Category 2 TINs will be subject to different automatic Value Modifier downward payment adjustments in 2018 based on the composition of their eligible professionals:

- 1) TINs with at least one physician and 10 or more eligible professionals will be subject to an automatic Value Modifier downward payment adjustment of negative two percent (-2.0%) in 2018,
- 2) TINs with at least one physician and fewer than 10 eligible professionals, including physician solo practitioners, will be subject to an automatic Value Modifier downward payment adjustment of negative one percent (-1.0%) in 2018, and
- 3) TINs with no physicians and at least one nonphysician eligible professional, including solo practitioners, who are subject to the 2018 Value Modifier will be subject to an automatic Value Modifier downward payment adjustment of negative one percent (-1.0%) in 2018.


3. Quality-Tiering

Quality-tiering is mandatory for all Category 1 TINs. As described in [Section II.J](#), quality-tiering determines the direction (upward or neutral) and size of the 2018 Value Modifier payment adjustment for each TIN based on the TIN's performance on quality and cost measures in 2016.⁴ High-performing TINs treating high-risk beneficiaries, as determined by mean CMS-Hierarchical Condition Category (CMS-HCC) risk scores, are eligible for higher upward payment adjustments (see [Section II.K](#) for more information on determining whether TINs treat high-risk beneficiaries). As described in the 2018 Medicare Physician Fee Schedule Proposed Rule (82 FR 34125), CMS proposed to hold all Category 1 TINs harmless from any Value Modifier downward payment adjustment to their Medicare PFS payments in 2018 under the quality-tiering methodology.

Exhibit I.1 summarizes how the Value Modifier will be applied in 2018.

⁴ See [Section II.C.1](#) for more information on determining quality performance for TINs that participated in more than one Shared Savings Program ACO in 2016 and for TINs that participated in a Shared Savings Program ACO in 2016 that did not avoid the 2018 PQRS payment adjustment on behalf of the TIN.

Exhibit I.1. Overview of the Application of the 2018 Value Modifier



*High-performing TINs treating high-risk beneficiaries (based on mean CMS-HCC risk scores) are eligible for an additional adjustment of +1.0 x the adjustment factor (AF).

C. Relationship between the 2018 Value Modifier and the 2016 Annual Quality and Resource Use Reports (QRURs)

In fall 2017, CMS will make the 2016 Annual QRURs available to every TIN nationwide, including those not subject to the 2018 Value Modifier. These confidential feedback reports provide information on the TINs' performance on all available quality and cost measures used to calculate the 2018 Value Modifier. For TINs that are subject to the Value Modifier in 2018, the 2016 Annual QRURs provide information on how the TINs' quality and cost performance will affect the Medicare PFS payments for the TIN's physicians, PAs, NPs, CNSs, and CRNAs in 2018.

For detailed information about the 2018 Value Modifier and 2016 Annual QRURs, including how to access a QRUR, please see the "2016 QRUR and 2018 Value Modifier" page at the following URL: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/2016-QRUR.html>.

II. COMPUTATION OF THE 2018 VALUE MODIFIER

A. Overview

To calculate the Value Modifier for TINs that are subject to the Value Modifier in 2018, CMS computes a Quality Composite Score that summarizes a TIN's performance on quality measures and a Cost Composite Score that summarizes a TIN's performance on cost measures for its attributed beneficiaries. For each measure for which a TIN has at least the minimum number of required eligible cases, CMS uses benchmark data to standardize measure-level performance to permit valid cross-measure comparisons. Standardized quality measures are categorized into one of six domains. Standardized cost measures are categorized into one of two domains. From the standardized measures, CMS computes performance scores for each domain, which are then averaged and standardized to yield the Quality Composite Score and the Cost Composite Score.


Using the Quality and Cost Composite Scores, quality-tiering analysis determines the direction of a TIN's Value Modifier payment adjustment (upward or neutral) and the magnitude of the adjustment. Each Quality and Cost Composite Score indicates how many standard deviations a TIN's overall quality or cost performance is from the peer group mean. Only composite scores that are statistically significantly different and at least one standard deviation from the peer group mean are assigned to the High or Low Quality or Cost Tiers. Composite scores that are not statistically significantly different from the peer group mean or not at least one standard deviation from the peer group mean are deemed Average Quality or Cost for the purpose of quality-tiering. Exhibit II.1 summarizes the methodology for calculating the 2018 Value Modifier.

B. TINs Subject to the Value Modifier

CMS will apply the 2018 Value Modifier to physicians, PAs, NPs, CNSs, and CRNAs in TINs, provided that at least one eligible professional subject to the Value Modifier is associated with the TIN. To determine the size of a TIN for purposes of applying the 2018 Value Modifier, CMS first determines whether an eligible professional is associated with the TIN in the Provider Enrollment, Chain and Ownership System (PECOS) as of July 16, 2016. Specifically, CMS first identifies actively enrolled medical professionals, as identified by their National Provider Identifier (NPI), who have reassigned their billing rights to a TIN. CMS then examines each NPI's specialty under that TIN to determine whether the individual is (1) a physician, PA, NP, CNS, or CRNA, or (2) an eligible professional not subject to the Value Modifier. Exhibit E.1 in Appendix E provides a list of eligible professional specialties. CMS then identifies eligible professionals who submitted claims to Medicare under the TIN for services furnished during 2016 through March 31, 2017 (to account for lags in claims submissions). If CMS identifies at least one physician, PA, NP, CNS, or CRNA in PECOS and in Medicare claims, then the TIN is

subject to the 2018 Value Modifier.⁵ The size of the TIN (10 or more eligible professionals, or one to nine eligible professionals) for the purpose of applying the Value Modifier is the lower of the TIN’s number of eligible professionals identified in PECOS and the number of eligible professionals who submitted claims to Medicare under the TIN during 2016.⁶ Both full-time and part-time eligible professionals, as well as those who billed under the TIN for only part of 2016, are included in the calculation.

Exhibit II.1. Methodology for Determining the 2018 Value Modifier for Category 1 TINs



*The performance rates of TINs with fewer than the minimum number of required eligible cases for a given quality or cost measure are excluded from the calculation of the benchmark for the measure.

⁵ The 2016 Medicare Physician Fee Schedule Final Rule (80 FR 71276) states that a TIN is not subject to the 2018 Value Modifier if CMS does not identify eligible professionals who are physicians, PAs, NPs, CNSs, or CRNAs in either PECOS or Medicare claims.

⁶ If a TIN-NPI is associated with both an individual practice and a group practice in PECOS, CMS applies the group size associated with the TIN-NPIs that billed Medicare FFS during 2016. If a TIN-NPI that is listed as a solo practice in PECOS is associated with more than one eligible professional, CMS drops the TIN-NPIs that have no billings.

CMS will also apply the 2018 Value Modifier to physicians, PAs, NPs, CNSs, and CRNAs in TINs that participated in a Shared Savings Program ACO in 2016. CMS uses 2016 participation lists from the Shared Savings Program to identify these TINs.

C. Quality Measures Included in the Quality Composite Score

In calculating the Quality Composite Score for the 2018 Value Modifier, CMS uses at least two types of quality measures for all TINs:

- 1) PQRS measures and/or non-PQRS QCDR measures reported by the TIN (or its Shared Savings Program ACO) if the TIN (or ACO) avoided the 2018 PQRS payment adjustment as a group, or by individual eligible professionals in the TIN, including solo practitioners, who avoided the 2018 PQRS payment adjustment as individuals; and
- 2) up to three claims-based quality outcome measures calculated from Medicare FFS claims submitted for Medicare beneficiaries attributed to the TIN.

In addition, Consumer Assessment of Healthcare Providers and Systems (CAHPS) for PQRS and CAHPS for ACOs survey measures are included in the Quality Composite Score, as applicable. See [Section II.C.3](#) for more information on CAHPS data included in the Quality Composite Score.

Each PQRS measure and non-PQRS QCDR measure is assigned to one of the following six quality domains: (1) Effective Clinical Care, (2) Person and Caregiver-Centered Experience and Outcomes, (3) Community/Population Health, (4) Patient Safety, (5) Communication and Care Coordination, and (6) Efficiency and Cost Reduction. These six domains align with the National Quality Strategy's six priorities for achieving better and more affordable care for individuals and communities.⁷ The three CMS-calculated claims-based quality outcome measures are assigned to the Communication and Care Coordination Domain, and the CAHPS survey measures are assigned to the Person and Caregiver-Centered Experience and Outcomes Domain. See Appendix B for a list of PQRS measures and non-PQRS QCDR measures included in each quality domain. For PQRS measures and non-PQRS QCDR measures with multiple performance rates, CMS determines an overall rate for inclusion in the 2018 Value Modifier by calculating a mean of the component parts or by selecting one component part that represents overall performance, depending on the particular measure. See Appendix C for details on PQRS measures and non-PQRS QCDR measures with multiple performance rates, and measures that CMS has excluded from calculations of the 2018 Value Modifier for technical reasons.

1. Quality Measures Reported by Groups and Individual Eligible Professionals

For purposes of calculating the Quality Composite Score, CMS uses either quality data reported through a GPRO mechanism by the TIN (or its Shared Savings Program ACO if the ACO reported on its behalf and avoided the 2018 PQRS payment adjustment), if it avoided the 2018 PQRS payment adjustment as a group, or quality data reported by individual eligible

⁷ More information on the National Quality Strategy is available at the following URL: <https://www.ahrq.gov/workingforquality/about/nqs-fact-sheets/fact-sheet.html>.

professionals if they avoided the 2018 PQRS payment adjustment as individuals under the TIN. In general, for Category 1 TINs that registered to report quality data through the GPRO in 2016, CMS uses the data reported via the mechanism for which the TIN registered—Web Interface, qualified PQRS registry, QCDR, or EHR. For Category 1 TINs that did not register to report quality data through the GPRO, CMS uses the data reported by individual eligible professionals, provided that at least 50 percent of the eligible professionals under the TIN avoided the 2018 PQRS payment adjustment. For solo practitioners who are physicians, PAs, NPs, CNSs, or CRNAs, CMS calculates the Quality Composite Score based on the quality measures reported as individuals, if they avoided the 2018 PQRS payment adjustment. See [Section II.E](#) for more information on the impact of the new International Classification of Diseases, 10th Revision (ICD-10) diagnosis and procedure codes on which PQRS measures are included in the Quality Composite Score for certain TINs.

If a TIN that registered to report through the GPRO did not avoid the 2018 PQRS payment adjustment through the mechanism for which it registered, or if a TIN did not register to report through the GPRO but avoided the 2018 PQRS payment adjustment by reporting through a GPRO mechanism, CMS uses the rule outlined in Appendix F to select the data for computing the Quality Composite Score. In particular:

- If a Category 1 TIN registered to report quality data through the GPRO, but the TIN did not avoid the 2018 PQRS payment adjustment through the registered GPRO mechanism and instead avoided it through a different GPRO mechanism, CMS uses the quality data reported through the GPRO mechanism for which the TIN did not register.
- If a Category 1 TIN registered to report quality data through the GPRO, but the TIN did not avoid the PQRS payment adjustment through any GPRO mechanism, CMS uses the quality data reported by the individual eligible professionals in the TIN provided that at least 50 percent of the eligible professionals in the TIN avoided the 2018 PQRS payment adjustment as individuals.
- If a Category 1 TIN did not register to report quality data through the GPRO, but the TIN avoided the 2018 PQRS payment adjustment through a GPRO mechanism, CMS uses the quality data reported through the GPRO to calculate the 2018 Value Modifier.

For TINs that participated in a Shared Savings Program ACO that reported quality data through the GPRO Web Interface on their behalf and avoided the 2018 PQRS payment adjustment, CMS calculates the Quality Composite Score at the ACO level based on the quality data submitted by the ACO. For TINs that participated in more than one ACO that avoided the 2018 PQRS payment adjustment, CMS calculates the Quality Composite Score based on the data of the best performing ACO (that is, the ACO with the highest numerical Quality Composite Score, among the ACOs that avoided the 2018 PQRS payment adjustment).

For TINs that participated in a Shared Savings Program ACO that did not avoid the 2018 PQRS payment adjustment on their behalf but the TIN reported data outside the ACO, CMS does not use quality data submitted by the TIN to determine the Value Modifier if the TIN:

- 1) reported outside of the ACO through an accepted GPRO mechanism and avoided the 2018 PQRS payment adjustment as a group,

- 2) had at least 50 percent of the eligible professionals in the TIN avoid the 2018 PQRS payment adjustment as individuals, or
- 3) is a solo practitioner and avoided the 2018 PQRS payment adjustment as an individual.

However, for these TINs, CMS still computes the Quality Composite Score based on the data submitted by the TIN for informational purposes. These TINs are classified as Average Quality and Average Cost for the purpose of determining their Value Modifier. See [Section II.J](#) for more details on quality-tiering for these TINs.

For more information on reporting requirements under the different GPRO reporting mechanisms, see the document entitled “2016 Physician Quality Reporting System (PQRS) Group Practice Reporting Option (GPRO) Training Guide,” available at the following URL: <https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/Downloads/2016GPROTrainingGuide.pdf>.

Calculating the percentage of eligible professionals avoiding the PQRS payment adjustment as individuals. CMS calculates the percentage of eligible professionals in a TIN who avoided the 2018 PQRS payment adjustment as the total number of eligible professionals in the TIN who avoided the 2018 PQRS payment adjustment as individuals, divided by the total number of eligible professionals in the TIN (as determined by the lower of the number of eligible professionals identified in PECOS and the number of eligible professionals submitting claims to Medicare under the TIN in 2016), multiplied by 100. Both full-time and part-time eligible professionals, as well as those who billed under the TIN for only part of 2016, are included in the calculation. Specifically:

- The numerator is the number of eligible professionals in the TIN who avoided the 2018 PQRS payment adjustment as individuals and either (a) were associated with the TIN in PECOS as of July 16, 2016, or (b) billed under the TIN for services furnished during 2016, and reported PQRS data in 2016.
- The denominator is the lower of the number of eligible professionals indicated by a query of PECOS as of July 16, 2016 as having reassigned their billing rights to the TIN and the number of eligible professionals who submitted at least one claim to Medicare under the TIN for services furnished in 2016.

Only the quality measures that were reported by eligible professionals in the TIN who avoided the 2018 PQRS payment adjustment as individuals are computed at the TIN-NPI level. To convert these TIN-NPI level submissions to TIN-level measures to use in the calculation of the Quality Composite Score, performance numerators and denominators are summed across all of the eligible professionals reporting the same measure under the TIN who avoided the 2018 PQRS payment adjustment, and the TIN-level performance rates are computed as the ratio of the aggregated performance numerator to the aggregated performance denominator, multiplied by 100.

Detailed specifications and additional information about the 2016 PQRS measures and non-PQRS QCDR measures can be found at the following URL: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/2016_Physician_Quality_Reporting_System.html.

2. CMS-Calculated Claims-Based Quality Outcome Measures

The Quality Composite Score also includes up to three claims-based quality outcome measures calculated from Medicare FFS claims submitted for Medicare beneficiaries attributed to the TIN.

Hospital Admissions for Ambulatory Care-Sensitive Conditions (ACSCs): Acute Conditions Composite. This is the risk-adjusted rate of hospital admissions among Medicare beneficiaries for three acute ACSCs—bacterial pneumonia, urinary tract infection, and dehydration—that are potentially avoidable with appropriate primary and preventive care. This measure is computed at the TIN level for TINs subject to the Value Modifier, including TINs that participated in a Shared Savings Program ACO that reported data outside the ACO in 2016 and avoided the 2018 PQRS payment adjustment.⁸ This measure is not computed for TINs that participated in a Shared Savings Program ACO that avoided the 2018 PQRS payment adjustment on behalf of the TIN.

Hospital Admissions for ACSCs: Chronic Conditions Composite. This is the risk-adjusted rate of hospital admissions among Medicare beneficiaries for three chronic ACSCs—diabetes, chronic obstructive pulmonary disease (COPD) or asthma, and heart failure—that are potentially avoidable with appropriate primary and preventive care. This measure is computed at the TIN level for TINs subject to the Value Modifier, including TINs that participated in a Shared Savings Program ACO that reported data outside the ACO in 2016 and avoided the 2018 PQRS payment adjustment.⁹ This measure is not computed for TINs that participated in a Shared Savings Program ACO that avoided the 2018 PQRS payment adjustment on behalf of the TIN. See [Section II.E](#) for more information on the impact of the new ICD-10 diagnosis and procedure codes on the Hospital Admissions for ACSCs Chronic Conditions Composite.

⁸ For TINs that participated in a Shared Savings Program ACO that did not avoid the 2018 PQRS payment adjustment, but the TIN avoided the 2018 PQRS payment adjustment outside the ACO, the ACSC Acute Conditions Composite measure is calculated and displayed in the Annual QRUR for informational purposes only. The measure is not used in the calculation of the TIN's Value Modifier.

⁹ For TINs that participated in a Shared Savings Program ACO that did not avoid the 2018 PQRS payment adjustment, but the TIN avoided the 2018 PQRS payment adjustment outside the ACO, the ACSC Chronic Conditions Composite measure is calculated and displayed in the Annual QRUR for informational purposes only. The measure is not used in the calculation of the TIN's Value Modifier.

For more information on the ACSC measures, please refer to the Measure Information Form, entitled “2016 Measure Information About the Hospital Admissions for Acute and Chronic Ambulatory Care-Sensitive Condition (ACSC) Composite Measures, Calculated for the 2018 Value-Based Payment Modifier Program,” available at the following URL: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/Downloads/2016-ACSC-MIF.pdf>.

30-Day All-Cause Hospital Readmission Measure. This is the risk-adjusted rate of unplanned hospital readmissions for any cause within 30 days after discharge from an acute care or critical access hospital. For TINs that did not participate in a Shared Savings Program ACO in 2016 and for TINs that participated in a Shared Savings Program ACO but reported data to the PQRS outside the ACO in 2016, this measure is computed at the TIN level.¹⁰ This measure is not included in the domain score for any TINs with fewer than 10 eligible professionals. For TINs that participated in a Shared Savings Program ACO in 2016 that avoided the PQRS payment adjustment on behalf of the TIN, this measure is computed at the ACO level and is based on the ACO’s performance. See [Section II.E](#) for more information on the impact of the new ICD-10 diagnosis and procedure codes on the 30-day All-Cause Hospital Readmission measure.

For more information on the 30-day All-Cause Hospital Readmission measure, please refer to the Measure Information Form, entitled “2016 Measure Information about the 30-day All-Cause Hospital Readmission Measure, Calculated for the 2018 Value-Based Payment Modifier Program,” available at the following URL: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/Downloads/2016-ACR-MIF.pdf>.

For additional information about the two-step process used to attribute beneficiaries to TINs for the claims-based quality outcome measures, please refer to the document entitled, “Two-Step Attribution for Claims-Based Quality Outcome Measures and Per Capita Cost Measures Included in the Value Modifier,” available at the following URL: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/Downloads/2016-Attribution-Fact-Sheet.pdf>.

3. CAHPS for PQRS and ACOs

The CAHPS for PQRS and CAHPS for ACOs surveys assess beneficiaries' experience of care in a group practice. For the 2018 Value Modifier, the Quality Composite Score includes CAHPS for PQRS or CAHPS for ACOs survey measures for certain types of TINs.

TINs with 100 or more eligible professionals that registered for the GPRO were required to participate in the CAHPS for PQRS survey, while it was optional for TINs with 2 to 99 eligible

¹⁰ For TINs that participated in a Shared Savings Program ACO that did not avoid the 2018 PQRS payment adjustment, but the TIN avoided the 2018 PQRS payment adjustment outside the ACO, the 30-day All-Cause Hospital Readmission measure is calculated and displayed in the Annual QRUR for informational purposes only. The measure is not used in the calculation of the TIN’s Value Modifier.

professionals that registered for the GPRO. CAHPS for PQRS survey measures are only included in the Quality Composite Score if the TIN elected to include these survey results in the calculation of the TIN's 2018 Value Modifier. See Exhibit B.2 in Appendix B for a list of CAHPS measures that are included in the 2018 Value Modifier.¹¹

In 2016, all ACOs were required to participate in the CAHPS for ACOs survey. For the 2018 Value Modifier, CMS includes the CAHPS for ACOs survey measures in the Quality Composite Score for TINs that participated in a Shared Savings Program ACO in 2016 that avoided the 2018 PQRS payment adjustment on behalf of the TIN. No CAHPS measures are included in the Quality Composite Score for TINs that participated in a Shared Savings Program ACO in 2016 that did not avoid the PQRS payment adjustment on behalf of the TIN, even if the TIN avoided the PQRS payment adjustment outside the ACO.

Additional information about participating in the CAHPS for PQRS survey is provided in the document entitled “2016 Physician Quality Reporting System (PQRS): CMS-Certified Survey Vendor Reporting Consumer Assessment of Healthcare Providers and Systems (CAHPS) for PQRS Made Simple,” available at the following URL: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/downloads/2016PQRS_CAHPS_MadeSimple.pdf.

Additional information about quality reporting for Shared Savings Program ACOs is available at the following URL: <https://www.cms.gov/medicare/medicare-fee-for-service-payment/sharedsavingsprogram/quality-measures-standards.html>.

D. Cost Measures Included in the Cost Composite Score

In calculating the Cost Composite Score for the 2018 Value Modifier, CMS calculates six cost measures based on Medicare FFS claims submitted for Medicare beneficiaries (or episodes, for the Medicare Spending per Beneficiary [MSPB] measure) attributed to the TIN. These measures are categorized into one of two cost domains. The Costs for All Attributed Beneficiaries Domain includes two distinct measures—Per Capita Costs for All Attributed Beneficiaries and MSPB. The Costs for Beneficiaries with Specific Conditions Domain includes four condition-specific per capita cost measures for beneficiaries with the following conditions: diabetes, coronary artery disease (CAD), COPD, and heart failure.

Per Capita Costs for All Attributed Beneficiaries. This measure represents the mean of all Medicare Part A and Part B allowed charges for a TIN's attributed beneficiaries during 2016. Medicare Part D outpatient drug costs are not included.

Per Capita Costs for Beneficiaries with Specific Conditions. These four measures are computed analogously to the Per Capita Cost for All Attributed Beneficiaries measure, but are only computed for attributed beneficiaries with diabetes, CAD, COPD, or heart failure. See

¹¹ Data on the “Health Status/Functional Status” CAHPS measure, a descriptive measure of beneficiary characteristics, are provided to TINs for their information only. This measure is not used in the calculation of the 2018 Value Modifier.

[Section II.E](#) for more information on the impact of the new ICD-10 diagnosis and procedure codes on the Per Capita Costs for Beneficiaries with Diabetes measure.

Medicare Spending per Beneficiary (MSPB). This measure captures Medicare Part A and Part B payments for services for episodes spanning from three days before an inpatient hospital admission through 30 days after discharge.

Although the methodologies for calculating the per capita cost and MSPB measures differ in key respects, all cost measures are adjusted to account for variations in Medicare payment rates unrelated to resource use (such as differences due to geographic location or add-on payments for special programs), a process known as payment standardization. They are also adjusted to account for differences in beneficiary characteristics, including prior health conditions that can affect their medical costs or utilization (risk adjustment) and differences in the mix of specialties across TINs (specialty adjustment).¹²

More detailed information about the cost measures, including detailed descriptions of beneficiary and episode attribution, risk adjustment, and specialty adjustment, is available in the Measure Information Forms at the following URL: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/2016-QRUR.html>.

Additional details relating to the payment-standardization algorithm are available at the following URL: <http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228772057350>.¹³

E. TINs Reporting Quality Measures Impacted by ICD-10

New ICD-10 diagnosis and procedure codes came into effect on October 1, 2016. The new codes relevant to the Value Modifier program primarily include new diabetes diagnosis codes and cardiac procedure codes. Diabetes diagnosis codes are used when flagging chronic conditions for both the Per Capita Costs for Beneficiaries with Diabetes measure and for the denominator of the diabetes component measure included in the Hospital Admissions for ACSCs Chronic Conditions Composite. Cardiac procedure codes are an exclusion for the numerator of the heart failure component measure included in the Hospital Admissions for ACSCs Chronic Conditions Composite. For the 30-day All-Cause Hospital Readmission measure, diabetes diagnosis codes are used for identifying condition categories and cardiac procedure codes are used in identifying planned procedures. Finally, eighteen new pancreatitis codes are relevant when flagging planned readmissions in the 30-day All-Cause Hospital Readmission measure.

¹² Additional information on risk adjustment can be found in the document entitled, “Risk Adjustment,” available at the following URL: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/Downloads/2016-RiskAdj-FactSheet.pdf>. Additional information on specialty adjustment can be found in the document entitled, “Specialty Adjustment,” available at the following URL: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/Downloads/2016-SpecAdj-FactSheet.pdf>.

¹³ The CMS document available on QualityNet refers to this process as “price standardization” rather than “payment standardization”; however, the two terms are equivalent.

CMS does not include the new ICD-10 codes in algorithms used to compute the quality and cost measures for the 2018 Value Modifier or the 2016 Annual QRURs. Consistent with the Measure Information Forms publicly posted at: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/2016-QRUR.html>, CMS uses the algorithms that accommodate all ICD-10 codes available prior to October 1, 2016 and are the same ones used to calculate the benchmarks (see [Section II.G](#) for computing measure benchmarks). Depending on the mechanism TINs and eligible professionals used to report quality measures impacted by the new ICD-10 codes, CMS may not have access to the PQRS quality data for certain TINs. To calculate the Quality Composite Score for such TINs, CMS uses the data reported to the PQRS through another reporting mechanism (if the TIN reported through multiple mechanisms), or only the claims-based quality outcome measures (if the TIN reported only through the impacted mechanism).

F. Determining Which Measures Have the Required Number of Eligible Cases to be Included in the 2018 Value Modifier Calculations

All quality and cost measures must have a minimum number of eligible cases to be included in the calculation of the 2018 Value Modifier. The minimum number of eligible cases is 20, with two exceptions. The MSPB measure requires at least 125 eligible episodes to be included in the Cost Composite Score. The 30-day All-Cause Hospital Readmission measure requires at least 200 eligible cases to be included in the Quality Composite Score for non-Shared Savings Program ACO TINs and for Shared Savings Program ACO TINs whose ACO did not avoid the 2018 PQRS payment adjustment on their behalf. The 30-day All-Cause Hospital Readmission measure is included in the Quality Composite Score only for TINs with 10 or more eligible professionals. However, the ACO-level 30-day All-Cause Hospital Readmission measure calculated for Shared Savings Program ACO TINs whose ACO avoided the 2018 PQRS payment adjustment on their behalf is included in the Quality Composite Score regardless of case size. All measures that do not have the minimum number of cases or episodes are calculated and reported in the Annual QRUR for informational purposes only, and they are not included in the composite scores for the Value Modifier.

For PQRS measures and non-PQRS QCDR measures reported by individual eligible professionals, the total number of eligible cases across all eligible professionals submitting the measure under the TIN and avoiding the 2018 PQRS payment adjustment is used to determine if the minimum case threshold was reached. For measures with multiple performance rates rolled up to a single performance rate based on an equally-weighted mean, the number of eligible cases is the number of eligible cases for any one of the component rates. For measures with multiple performance rates that are rolled up to a single performance rate based on a *non*-equally-weighted mean of the component rates, the number of eligible cases for the rolled-up measure is the sum of the number of eligible cases for each component rate. For more information about calculating the performance rates for these measures, please refer to Appendix C.

G. Computing Measure Benchmarks and Standard Deviations

With the exception of the 30-day All-Cause Hospital Readmission measure, the benchmark for each quality measure in the 2018 Value Modifier calculations is the case-weighted national mean performance rate during 2015 (the year prior to the 2016 performance period) among all

TINs in the measure's peer group. For each quality measure, the peer group is defined as all TINs nationwide that had at least 20 eligible cases for the measure.

Benchmarks are calculated for quality measures where at least 20 TINs have at least the minimum number of required eligible cases during 2015. For the calculation of the 2018 Value Modifier, PQRS measures that can be reported as electronic Clinical Quality Measures (eCQMs) via EHR and QCDR have separate benchmarks from the non-eCQM versions of the measures.¹⁴ Quality measures that do not have a 2015 benchmark (for example, measures new to PQRS in 2016) are not included in the calculation of the Quality Composite Score, but performance on these measures is reported in the 2016 Annual QRUR for informational purposes only.

The benchmark for the 30-day All-Cause Hospital Readmission measure is the case-weighted national mean performance rate during 2015 among all TINs that did not participate in the Shared Savings Program ACO as well as Shared Savings Program ACOs in the measure's peer group. The peer group for the 30-day All-Cause Hospital Readmission measure is defined as all TINs nationwide with 10 or more eligible professionals that had at least 200 eligible cases, and all ACOs in the Shared Savings Program with at least one eligible case.¹⁵

Benchmarks for the CAHPS survey measures are calculated from the 2015 CAHPS for PQRS and 2015 CAHPS for ACOs reporting. The benchmarks include data from ACOs that reported CAHPS measures, even if the ACO did not complete all ACO quality reporting. The peer group for the CAHPS measures is defined as all TINs that reported the CAHPS for PQRS survey and all ACOs that reported the CAHPS for ACOs survey in 2015. Data from ACOs that withdrew from the model are not included in the peer group.

Additional information on the quality benchmarks used in the calculation of the 2018 Value Modifier can be found in the document entitled "Benchmarks for Measures Included in the Performance Year 2016 Quality and Resource Use Reports," available at the following URL: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/Downloads/PY2016-Prior-Year-Benchmarks.pdf>.

The benchmark for each cost measure is the case-weighted national mean cost during 2016 among all TINs in the measure's peer group. For each of the five total per capita cost measures, the peer group is defined as all TINs nationwide that had at least 20 eligible cases for the measure. For the MSPB measure, the peer group is defined as all TINs nationwide that had at least 125 eligible episodes. Benchmarks are calculated for each cost measure where at least 20 TINs have at least the minimum number of required eligible cases (or episodes in the case of the MSPB measure) during 2016.

¹⁴ EHR submissions use eCQM versions of PQRS measures. TINs can also submit eCQM versions of measures via QCDR based on eCQM measure specifications. All other reporting mechanisms use non-eCQM versions of PQRS measures, including QCDR submissions based on non-eCQM specifications.

¹⁵ For all TINs that participated in a Shared Savings Program ACO in 2015, only their ACO-level performance rates, not their TIN-level performance rates, are included in the benchmark for the 30-day All-Cause Hospital Readmission measure.

In addition to computing benchmarks, CMS also computes each quality and cost measure's standard deviation. Peer group standard deviations for quality and cost measures are case weighted, with the measure performance rate for each TIN in the peer group receiving a weight equal to the number of eligible cases that the TIN had for the specific measure. As with the benchmarks, the standard deviations for quality measures are based on data from 2015 (the year prior to the 2016 performance period) and the standard deviations for cost measures are based on data from 2016.

H. Standardizing Scores and Computing Domain Scores

Standardizing measure performance transforms measures with disparate scales to a common scale, which enables different measures to be compared and combined with one another into a composite. Measure-level performance is standardized by subtracting the benchmark for the measure from the TIN's per capita or per episode cost or quality performance rate and dividing by the case-weighted peer group standard deviation of the measure. A standardized score for a measure reflects the number of standard deviations that a TIN's overall performance differs from the benchmark.

Quality and cost domain scores are calculated as the simple (equally-weighted) mean of the TIN's standardized measure scores within the domain, if the TIN has a score for at least one measure included in the quality or cost domain. Only measures with at least the minimum number of required eligible cases and where benchmarks are available are included in quality and cost domain scores for the 2018 Value Modifier. A domain score is not computed for any domain in which the TIN does not have at least one measure with at least the minimum number of required eligible cases and for which a benchmark is available.

I. Computing Mean Domain Scores and Standardized Composite Scores

For each TIN with at least the minimum number of eligible cases required to compute at least one quality measure with a benchmark for at least one quality domain score, CMS computes the simple (equally-weighted) mean of the TIN's quality domain scores. CMS standardizes this score to generate a distribution of mean quality domain scores centered at a mean of zero with a standard deviation of one. This involves subtracting the peer group mean from each TIN's average domain score and dividing the difference by the peer group standard deviation. For all other TINs, the peer group for the Quality Composite includes all TINs for which a Quality Composite Score could be calculated, with the exception of TINs that participated in the Pioneer ACO Model, Next Generation ACO Model, Oncology Care Model, Comprehensive ESRD Model, or the Comprehensive Primary Care (CPC) initiative in 2016, as well as TINs that participated in a Shared Savings Program ACO that did not avoid the PQRS payment adjustment on their behalf. The standardized score created through this process is the Quality Composite Score. If a TIN's Quality Composite Score cannot be calculated because the TIN does not have at least the minimum number of required eligible cases for at least one quality measure with a benchmark, then the TIN's quality performance is designated as Average Quality for the 2018 Value Modifier.

The Cost Composite Score is computed analogously to the Quality Composite Score. For each TIN with at least the required minimum number of eligible cases for at least one cost measure with a benchmark for at least one cost domain score, CMS computes the simple

(equally-weighted) mean of the TIN's cost domain scores. CMS standardizes this score to generate a distribution of mean cost domain scores centered at a mean of zero with a standard deviation of one. This involves subtracting the peer group mean from each TIN's average domain score and dividing the difference by the peer group standard deviation. For TINs subject to the 2018 Value Modifier, the peer group for the Cost Composite includes all TINs subject to the 2018 Value Modifier for which a Cost Composite Score could be calculated, with the exception of TINs that participated in the Shared Savings Program in 2016. For all other TINs, the peer group for the Cost Composite includes all TINs for which a Cost Composite Score could be calculated, with the exception of TINs that participated in the Shared Savings Program, the Pioneer ACO Model, Next Generation ACO Model, Oncology Care Model, Comprehensive ESRD Care Model, or the Comprehensive Primary Care (CPC) initiative in 2016. The standardized score created through this process is the Cost Composite Score. A Cost Composite Score is not calculated for TINs that do not have at least the minimum number of required eligible cases for at least one cost measure with a benchmark. If a TIN's Cost Composite Score cannot be calculated because the TIN does not have at least the minimum number of required eligible cases for at least one cost measure with a benchmark, then the TIN's cost performance is designated as Average Cost for the 2018 Value Modifier.

J. Categorizing TINs on Quality and Cost Performance Based on Composite Scores and Statistical Significance (Quality-Tiering)

For Category 1 TINs subject to the 2018 Value Modifier that avoided the 2018 PQRS payment adjustment, CMS calculates their Value Modifier using a quality-tiering approach based on the TIN's 2016 quality and cost performance.

To be considered either a high or low performer relative to its peers on the Quality Composite Score, a TIN's score must be at least one standard deviation above or below the peer group mean Quality Composite Score and statistically significantly different from the peer group mean. The peer groups are defined above in [Section II.I](#). This ensures that payment adjustments under the Value Modifier are only made to those TINs whose performance reflects a meaningful difference from the mean. A TIN is classified as Average Quality for purposes of calculating the Value Modifier if (1) the TIN's score is within one standard deviation of the peer group mean, regardless of its statistical significance, (2) the TIN's score is at least one standard deviation above or below the peer group mean Quality Composite Score, but the difference between the TIN's score and the mean is not statistically significant, or (3) the TIN does not have at least the minimum number of required eligible cases for at least one quality measure with a benchmark. Statistical significance is assessed using a two-tailed test.

High, average, and low performance is determined similarly for the Cost Composite Score as for the Quality Composite Score; however, lower Cost Composite Scores indicate better performance. To be considered either a high or low performer relative to its peers on the Cost Composite Score, a TIN's score must be at least one standard deviation above or below the peer group mean Cost Composite Score and statistically significantly different from the peer group mean. A TIN is classified as Average Cost for purposes of calculating the Value Modifier if (1) the TIN's score is within one standard deviation of the peer group mean, regardless of its statistical significance, (2) the TIN's score is at least one standard deviation above or below the peer group mean Cost Composite Score, but the difference between the TIN's score and the

mean is not statistically significant, or (3) the TIN does not have at least the minimum number of required eligible cases for at least one cost measure with a benchmark.

For TINs that participated in a Shared Savings Program ACO in 2016 that reported quality data through the GPRO Web Interface and avoided the 2018 PQRS payment adjustment, the Quality Composite Score is calculated based on the quality data submitted by the ACO through the GPRO Web Interface and the ACO's performance on the claims-based 30-day All-Cause Hospital Readmission measure calculated by Medicare for 2016. The Cost Composite Score for these TINs is classified as Average Cost.

For TINs that participated in a Shared Savings Program ACO in 2016 that did not avoid the 2018 PQRS payment adjustment, but are Category 1 as a result of reporting quality data to the PQRS outside of the ACO, their Quality and Cost Composite Scores are calculated and reported in the Annual QRUR for informational purposes only. These TINs are classified as Average Quality and Average Cost under the 2018 Value Modifier.

Exhibit II.2 below displays the basic structure of the 2018 Value Modifier under the quality-tiering approach. For the 2018 Value Modifier, CMS proposed to hold all Category 1 TINs harmless from any downward payment adjustment.¹⁶ Because the Value Modifier must be budget-neutral, the size of the upward payment adjustments will be based on an Adjustment Factor (AF) calculated to redistribute downward adjustments from Category 2 TINs to the high-performing TINs. The AF is derived from actuarial estimates of projected billings and is calculated after the conclusion of the 2016 performance period. It is reflected in the exhibit as the variable AF. Because it is based on the number and relative performance of TINs subject to quality-tiering, it varies from year to year with differences in actuarial estimates.

Exhibit II.2. 2018 Value Modifier Payment Adjustments Based on Quality-Tiering

| | Low Quality | Average Quality | High Quality |
|---|-------------|-----------------|--------------|
| Physicians, PAs, NPs, CNSs, and CRNAs in TINs that are subject to the Value Modifier | | | |
| Low Cost | 0.0% | +1.0 x AF* | +2.0 x AF* |
| Average Cost | 0.0% | 0.0% | +1.0 x AF* |
| High Cost | 0.0% | 0.0% | 0.0% |

*High-performing TINs treating high-risk beneficiaries (based on mean CMS-HCC risk scores) are eligible for an additional adjustment of +1.0 x AF.

The 2018 Value Modifier will be applied on a claim-by-claim basis to claims for services paid under the Medicare PFS and for which the Medicare provider has accepted assignment. A claim adjustment reason code (CARC) and a remittance advice remark code (RARC) are code sets used to report payment adjustments on an eligible professional's or group practice's Remittance Advice. The Value Modifier program currently uses CARC 237 –

¹⁶ This policy is proposed in the 2018 Medicare Physician Fee Schedule Proposed Rule (82 FR 34125).

Legislated/Regulatory Penalty, to designate the application of a negative or downward payment adjustment. At least one remark code must be provided (may be comprised of either the National Council for Prescription Drug Programs Reject Reason Code, or RARC that is not an alert) in combination with the Value Modifier RARC “VBM – N701 – Payment adjusted based on the Value-based Payment Modifier.”¹⁷

K. Assessing Whether the TIN Treats a Disproportionate Share of Beneficiaries with High-Risk Scores

TINs receiving an upward payment adjustment are eligible for an additional +1.0 x AF upward adjustment if the mean CMS-HCC risk score of the TIN’s attributed beneficiaries is at or above the 75th percentile of all beneficiary risk scores nationwide. The 2015 CMS-HCC risk scores are calculated by CMS and are used to measure the mean risk of each TIN’s attributed beneficiaries. For TINs that did not participate in a Shared Savings Program ACO in 2016, this includes the beneficiaries attributed to the TIN for the claims-based quality outcome and cost measures. TINs participating in a Shared Savings Program ACO in 2016 that are receiving an upward adjustment are eligible for an additional +1.0 x AF upward adjustment if the beneficiary population assigned to the ACO under the Shared Savings Program has a mean beneficiary CMS-HCC risk score at or above the 75th percentile of all beneficiary CMS-HCC risk scores nationwide.

The risk score assigned to each Medicare beneficiary predicts the beneficiary’s medical costs in 2016 relative to mean costs among all Medicare FFS beneficiaries nationwide based on the presence of factors known to affect costs and utilization. A score of 1.0 represents average risk, with higher scores corresponding to higher risk. The 2015 CMS-HCC risk score distribution, spanning the lowest beneficiary risk score to the highest beneficiary risk score, and percentile thresholds were determined for all Medicare FFS beneficiaries nationally. Mean risk scores for beneficiaries attributed to TINs subject to the Value Modifier were compared with these national thresholds to determine whether the beneficiaries attributed to a TIN had a mean risk score that was at or above the 75th percentile.

L. Computation of Budget-Neutral Adjustment Factor (AF)

For the CMS Office of the Actuary (OACT) to compute the budget-neutral AF for the 2018 Value Modifier, OACT must estimate the total value of both upward and downward payment adjustments under the Value Modifier in 2018. OACT’s calculations are based on a file of claim line amounts paid to physicians in 2016 under the Medicare PFS, aggregated to the TIN level. Prior to performing these calculations, CMS removes any payment adjustments resulting from incentive payment programs such as the Value Modifier, Medicare EHR Incentive Program, and PQRS adjustments. This file includes information about which TINs are subject to an upward,

¹⁷ Further information can be found in the document entitled “Understanding 2018 Medicare Quality Program Payment Adjustments,” available at the following URL: <https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/Downloads/Understand2018MedicarePayAdjs.pdf>.

neutral, or downward payment adjustment under the 2018 Value Modifier. Line items are considered to have been paid under the Medicare PFS if the Healthcare Common Procedure Coding System (HCPCS) code and modifiers on the claim line are associated with any of the following status codes: Active (A), Carriers Price the Code (C), Anesthesia Services (J), Restricted Coverage (R), or Injections (T). Certain pathology codes¹⁸ are paid under the Medicare PFS only if the line item includes a modifier value of 26 (professional component); otherwise, they are paid under the Clinical Laboratory Fee Schedule and thus are not included in the billings sum. The status codes associated with HCPCS and HCPCS/modifier combinations are found in the Medicare Physician Fee Schedule Relative Value File.¹⁹

M. Value Modifier Informal Review Policies

For TINs that are subject to the 2018 Value Modifier, CMS has established an Informal Review period for TINs to request a correction of a perceived error in their Value Modifier calculation after the release of the QRURs. CMS has established policies under four scenarios to determine how the Quality and Cost Composites under the Value Modifier would be affected as a result of Informal Review decisions or if unanticipated issues were to arise (for example, errors made by a third-party such as a vendor or errors in CMS’ calculation of the Quality and/or Cost Composites are identified). Exhibit II.3 below summarizes the four scenarios.

Exhibit II.3. Quality and Cost Composite Status for TINs due to Informal Review Decisions and Widespread Quality and Cost Data Issues

| | | Scenario 1: TINs Moving from Category 2 to Category 1 as a Result of PQRS or Value Modifier Informal Review Process | | Scenario 2: Non-GPRO Category 1 TINs with Additional Eligible Professionals Avoiding PQRS Payment Adjustment as a Result of PQRS Informal Review Process | | Scenario 3: Category 1 TINs with Widespread Quality Data Issues | | Scenario 4: Category 1 TINs with Widespread Claims Data Issues | |
|---------|---------|---|-------------------|--|-------------------|---|-------------------|--|-------------------|
| | | Initial Composite | Revised Composite | Initial Composite | Revised Composite | Initial Composite | Revised Composite | Recalculated Composite | Revised Composite |
| Quality | N/A | Average | Low | Average | N/A | Average | Low | Average | |
| | N/A | Average | Average | Average | N/A | Average | Average | Average | |
| | N/A | Average | High | High | N/A | Average | High | High | |
| Cost | Low | Low | Low | Low | Low | Low | Low | Low | |
| | Average | Average | Average | Average | Average | Average | Average | Average | |
| | High | Average | High | High | High | Average | High | Average | |

¹⁸ These include services with any of the following HCPCS codes: 83020, 84165, 84166, 84181, 84182, 85390, 85576, 86153, 86255, 86256, 86320, 86325, 86327, 86334, 86335, 87164, 87207, 88371, 88372, and 89060.

¹⁹ CMS typically publishes PFS Relative Value Files on a quarterly basis. To identify claims paid under the PFS, CMS uses the latest Relative Value File published in the fourth quarter of the relevant performance period. For 2016, PFS claims were identified using the Relative Value File “D” (RVU16D). Status code versions (by year and updates during the year) are found at the following URL: <http://cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-Relative-Value-Files.html>.

Scenario 1: TINs Moving from Category 2 to Category 1 as a result of PQRS or Value Modifier Informal Review Process

For the 2018 Value Modifier, if a TIN is initially classified as Category 2 and subsequently, through the PQRS or Value Modifier Informal Review process, it is reclassified as Category 1, then the TIN's Quality Composite will be classified as Average Quality. The TIN's Cost Composite will be calculated using the quality-tiering methodology. If the TIN is classified as High Cost based on its performance on the cost measures, then the TIN's Cost Composite will be reclassified as Average Cost. If the TIN is classified as Average Cost or Low Cost, then the TIN will retain the calculated cost tier designation.

Scenario 2: Non-GPRO Category 1 TINs with Additional Eligible Professionals Avoiding PQRS Payment Adjustment as a result of PQRS Informal Review Process

If a TIN is classified as Category 1 for the 2018 Value Modifier by having at least 50 percent of the TIN's eligible professionals avoid the 2018 PQRS payment adjustment as individuals, and subsequently, through the PQRS Informal Review process, it is determined that additional eligible professionals that are in the TIN also avoided the 2018 PQRS payment adjustment as individuals, then the following policies will be used to determine the TIN's Quality and Cost Composites:

- If the TIN's Quality Composite is initially classified as Low Quality, then the TIN's Quality Composite will be reclassified as Average Quality.
- If the TIN's Quality Composite is initially classified as Average Quality or High Quality, then the TIN will retain that quality tier designation.
- The TIN's Cost Composite that was initially calculated will be maintained.

Scenario 3: Category 1 TINs with Widespread Quality Data Issues

In cases where there is a systematic issue with any of a Category 1 TIN's quality data that renders it unusable for calculating a TIN's Quality Composite, the TIN's Quality Composite will be classified as Average Quality. CMS considers widespread quality data issues as issues that impact multiple TINs and for which CMS is unable to determine the accuracy of the data submitted via these TINs. The TIN's Cost Composite will be calculated using the quality-tiering methodology. If the TIN is classified as High Cost based on its performance on the cost measures, then the TIN's Cost Composite will be reclassified as Average Cost. If the TIN is classified as Average Cost or Low Cost, then the TIN will retain the calculated cost tier designation.

Scenario 4: Category 1 TINs with Widespread Claims Data Issues

If CMS determines after the release of the QRURs that there is a widespread claims data issue that impacts the calculation of the Quality and/or Cost Composites for Category 1 TINs, then the Quality and Cost Composites for affected TINs will be recalculated. CMS considers widespread claims data issues as issues that impact multiple TINs and require the recalculation of the Quality and/or Cost Composites.

After recalculating the composites, if the TIN's Quality Composite is classified as Low Quality, then the Quality Composite will be reclassified as Average Quality. If the TIN's Cost Composite is classified as High Cost, then the Cost Composite will be reclassified as Average Cost. If the TIN is classified as Average Quality, High Quality, Average Cost, or Low Cost, then the TIN will retain the calculated quality or cost tier designation.

Additional Upward Adjustment for the Treatment of Complex Beneficiaries

Under Scenarios 1 and 3, for TINs classified as Average Quality/Low Cost as a result of Informal Review, an additional +1.0 x AF upward payment adjustment will be applied to TINs if the mean CMS-HCC risk score of the TIN's attributed beneficiaries is at or above the 75th percentile of all beneficiary risk scores nationwide. Under Scenarios 2 and 4, for TINs classified as High Quality/Low Cost, High Quality/Average Cost, or Average Quality/Low Cost as a result of Informal Review, an additional +1.0 x AF upward payment adjustment will be applied if the mean CMS-HCC risk score of the TIN's attributed beneficiaries is at or above the 75th percentile of all beneficiary risk scores nationwide.

III. COMPUTATION OF ADDITIONAL STATISTICS

The 2016 Annual QRURs include tables to help report recipients better understand their TINs' quality and cost performance. These include data on hospital admissions for any cause, costs disaggregated by type of service, and medical professionals' specialties. This section describes the computational details behind these statistics.

A. Hospital Admissions for Any Cause

Because hospital costs are a large portion of per capita costs, Table 2B accompanying the 2016 Annual QRUR identifies hospitals that accounted for at least five percent of a TIN's attributed beneficiary hospital stays during 2016 to help TINs understand their per capita costs. CMS identifies beneficiary hospital stays by looking at admissions for beneficiaries attributed to each TIN via the two-step attribution process for per capita cost measures and claims-based quality outcome measures.²⁰ CMS identifies the names, CMS Certification Numbers (CCNs), and locations (city and state) of these hospitals by combining information from the Provider of Service files and PECOS.

Table 2C accompanying the 2016 Annual QRUR identifies each beneficiary-level hospital admission for beneficiaries attributed to each TIN via the two-step attribution process. Individual attributed beneficiaries are identified by an index variable, based on health insurance claim (HIC) number, sex, and date of birth, which allows users to link beneficiary-level information across tables without using personally identifiable information. Each hospital stay listed also indicates the date of discharge and discharge disposition based on the two-digit patient discharge status code on the last claim in a hospital stay (Exhibit III.1).

CMS provides similar information to help TINs understand hospital admissions reflected in the MSPB measure based on beneficiary MSPB episodes attributed to a TIN. However, admissions are reported for beneficiary MSPB episodes attributed to a TIN via the MSPB attribution rule instead of the two-step attribution process. Table 5A accompanying the 2016 Annual QRUR identifies hospitals that accounted for at least five percent of beneficiary MSPB episodes attributed to the TIN through the MSPB attribution rule during 2016. Table 5B accompanying the 2016 Annual QRUR provides information on the beneficiaries attributed to the TIN for the MSPB measure.

Hospital admissions with a principal diagnosis for conditions associated with alcohol and substance abuse are excluded from all patient-level data on hospital admissions for purposes of confidentiality but are included in total counts of hospital admissions in the Annual QRUR Table 2B.

²⁰ For additional information about the two-step attribution process, please refer to the document entitled "Two-Step Attribution for Claims-Based Quality Outcome Measures and Per Capita Cost Measures Included in the Value Modifier," available at the following URL: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/Downloads/2016-Attribution-Fact-Sheet.pdf>.

Exhibit III.1. Medicare Hospital Claim Patient Discharge Status Codes

| Discharge status code | Discharge status |
|-----------------------|--|
| 01 | Discharged to home |
| 02 | Transferred to another short-term general hospital |
| 03 | Discharged to skilled nursing facility (SNF) with Medicare certification |
| 04 | Discharged to intermediate care facility |
| 05 | Discharged to other hospital |
| 06 | Discharged to home health |
| 07 | Left against medical advice (AMA) |
| 08 | (Discontinued) |
| 09 | Admitted to same hospital |
| 20 | Expired |
| 21 | Discharged to court |
| 30 | Still patient |
| 40 | Expired at home – hospice |
| 41 | Expired at facility – hospice |
| 42 | Expired at unknown location – hospice |
| 43 | Discharged to federal hospital |
| 50 | Discharged to hospice – home |
| 51 | Discharged to hospice – facility |
| 61 | Transferred to Medicare-approved swing bed |
| 62 | Discharged to rehabilitation facility |
| 63 | Discharged to long-term care hospital |
| 64 | Discharged to SNF with Medicaid certification |
| 65 | Discharged to psychiatric hospital |
| 66 | Discharged to critical access hospital |
| 69 | Discharged to designated disaster alternate care |
| 70 | Discharged to other facility |
| 71 | (Discontinued) |
| 72 | (Discontinued) |
| 81 | Discharged to home – planned readmission |
| 82 | Transferred to short-term general hospital – planned readmission |
| 83 | Discharged to SNF with Medicare certification – planned readmission |
| 84 | Discharged to custodial or support care – planned readmission |
| 85 | Discharged to other hospital – planned readmission |
| 86 | Discharged to home health – planned readmission |
| 87 | Discharged to court – planned readmission |
| 88 | Discharged to federal hospital – planned readmission |
| 89 | Transferred to Medicare-approved swing bed – planned readmission |
| 90 | Discharged to rehabilitation facility – planned readmission |
| 91 | Discharged to long-term care hospital – planned readmission |
| 92 | Discharged to SNF with Medicaid certification – planned readmission |
| 93 | Discharged to psychiatric hospital – planned readmission |
| 94 | Discharged to critical access hospital – planned readmission |
| 95 | Discharged to other facility – planned readmission |

Source: Research Data Assistance Center (ResDAC): <http://www.resdac.org/cms-data/variables/patient-discharge-status-code>.

B. Categorical Breakdown of Costs by Type of Service

Several tables accompanying the 2016 Annual QRUR—one for each of the six cost measures—provide a breakdown of the TIN’s per capita or per episode costs in comparison to peers by type of service. Types of service include inpatient services and evaluation and management (E&M), among others. Each category of service includes the costs of *all* services in that category that were furnished to the TIN’s attributed beneficiaries and included in the cost measure (not only those services provided by the TIN). Taken together, these category of service amounts add up to the per capita or per episode cost measure value, to allow TINs to identify more readily which categories were particular drivers of their measure-level costs. The specific tables are Table 3A: Per Capita Costs, by Categories of Service, for the Per Capita Costs for All Attributed Beneficiaries Measure; Tables 4A – 4D: Per Capita Costs, by Categories of Service, for Beneficiaries with Specific Conditions; and Table 5C: Costs per Episode, by Category of Service, for the Medicare Spending per Beneficiary (MSPB) Measure. These data are reported for informational purposes to help TINs better understand what is driving their beneficiaries’ costs; they are not used individually in calculations of the Cost Composite Score.

In addition to separating costs by service category, services are further broken down based on whether the service was provided by eligible professionals in the TIN or by eligible professionals in another TIN for two categories: E&M services and procedures in non-emergency settings. For each of these two categories, service costs are further divided by the broad specialty category of the eligible professionals rendering them: primary care physicians (PCPs), medical specialists, surgeons, and other professionals (including PAs, NPs, CNSs, CRNAs, clinical social workers, clinical psychologists, dieticians, audiologists, physical and occupational therapists, and speech language therapists). The method for determining an eligible professional’s specialty is described in the next section ([Section III.C](#)).

To ensure that the costs displayed across all categories of service for a given TIN sum to the actual per capita or per episode cost measure amount for that TIN, costs for each category of service are scaled by a multiplier equal to the ratio of the TIN’s standardized, risk-adjusted, and specialty-adjusted cost measure to the TIN’s standardized but not risk-adjusted and not specialty-adjusted costs. For example, suppose for Per Capita Costs for Beneficiaries with Diabetes, a TIN’s payment-standardized but not risk-adjusted costs for its attributed beneficiaries with diabetes are \$10,000, \$2,000 of which is due to E&M and \$8,000 of which is due to inpatient services. Suppose further that the TIN’s risk- and specialty-adjusted costs for this measure are \$15,000. These costs are 1.5 times higher than the TIN’s corresponding unadjusted costs of \$10,000. Rescaling the costs for the E&M and inpatient services categories by that factor of 1.5—to \$3,000 and \$12,000, respectively—results in a distribution of costs across categories for the TIN that adds up to the measure-level cost while preserving the share of those costs due to E&M and inpatient services, respectively, that is reflected in the unadjusted costs.

Appendix D provides more detail on how Medicare claims are categorized into the mutually exclusive service categories for the per capita cost measures displayed in Exhibit D.1. Exhibit D.2 displays how cost categories are defined for the MSPB measure.

Exhibits III.2 and III.3 list the categories of services displayed in the 2016 QRURs and tables. The disaggregated statistics relate to the measure scores as follows:

Exhibit III.2. Service Categories Displayed for Per Capita Costs Measures in the 2016 QRURs

| Major category | Subcategories |
|---|---|
| Outpatient E&M services, procedures, and therapy (excluding emergency department) | E&M services billed by eligible professionals – Your TIN E&M services billed by eligible professionals – Other TINs Major procedures billed by eligible professionals – Your TIN Major procedures billed by eligible professionals – Other TINs Ambulatory/minor procedures billed by eligible professionals – Your TIN Ambulatory/minor procedures billed by eligible professionals – Other TINs Outpatient physical, occupational, or speech and language pathology therapy |
| Ancillary services | Laboratory, pathology, and other tests Imaging services Durable medical equipment and supplies |
| Hospital inpatient services | Inpatient hospital facility services Eligible professional services during hospitalization – Your TIN Eligible professional services during hospitalization – Other TINs |
| Emergency services not included in a hospital admission | Emergency E&M services Procedures Laboratory, Pathology, and Other Tests Imaging Services |
| Post-acute services | Home health SNF Inpatient rehabilitation or long-term care hospital |
| Hospice | No subcategories |
| All other services | Ambulance services Anesthesia services Chemotherapy and other Part B-covered drugs Dialysis Other facility-billed E&M expenses Other facility-billed expenses for major procedures Other facility-billed expenses for ambulatory/minor procedures All other services not otherwise classified |

Exhibit III.3. Service Categories Displayed for the MSPB Measure in the 2016 QRURs

| Major category | Subcategories |
|---|---|
| Acute inpatient services | Acute inpatient hospital: index admission Acute inpatient hospital: readmission Eligible professional services billed by your TIN during index hospitalization Eligible professional services billed by other TINs during index hospitalization Other physician or supplier Part B services billed during any hospitalization |
| Post-acute care | Home health SNF Inpatient rehabilitation or long-term care hospital |
| Emergency services not included in a hospital admission | Emergency E&M services Procedures Laboratory, pathology, and other tests Imaging services |
| Outpatient E&M services, procedures, and therapy (excluding emergency department) | Physical, occupational, or speech and language pathology therapy Dialysis E&M services Major procedures and anesthesia Ambulatory/minor procedures |
| Ancillary services | Laboratory, pathology, and other tests Imaging services Durable medical equipment and supplies |
| Hospice | No subcategories |
| All other services | Ambulance services Chemotherapy and other Part B-covered drugs All other services not otherwise classified |

C. Physicians and Nonphysician Eligible Professionals Billing Under the TIN

In order to attribute beneficiaries to TINs for the per capita cost measures and for the three claims-based quality outcome measures, CMS takes into account the level of primary care services received (as measured by Medicare-allowed charges during 2016) and the provider specialties that performed these services (PCPs, specialists, NPs, PAs, and CNSs). Information on eligible professionals' medical specialties is also used in category-of-service breakdowns, as described above. CMS uses the following broad specialty categories for the category-of-service breakdowns: PCP, medical specialist, surgeon, and other eligible professional. CMS uses the two-digit CMS specialty codes that appear on Medicare carrier claims files to define specialties. The Medicare Claims Processing Manual delineates which specialties are physician specialties and which are not. Assignment of medical professionals to broad specialty categories, referred to here as professional stratification categories, comprises two steps. First, each provider is assigned a medical specialty. Second, each specialty is assigned a professional stratification category.

The CMS specialty codes that appear on Medicare carrier claims files reflect self-reported specialties recorded in PECOS. To account for changes in specialties or multiple PECOS enrollments during a performance year, CMS determines the specialty from CMS carrier claims files based on the CMS specialty code associated with the plurality of total allowed charges on line items for services rendered by the professional during 2016. In the case of a tie, the specialty listed on the most recent claim is selected. Appendix E provides a mapping from CMS specialty codes to physician, eligible professional, and professional stratification categories.

APPENDIX A

DESCRIPTION OF DATA SOURCES

CMS uses multiple data sources, described briefly below, to calculate the quality and cost measures included in the 2018 Value Modifier. A more detailed discussion of how these sources are used in specific quality and cost measures is available in the Measure Information Forms available at the following URL: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/2016-QRUR.html>.

A. Quality Measure Data Reported by Groups and Individual Eligible Professionals

PQRS reporting and performance data included in the 2018 Value Modifier and displayed in the 2016 Annual QRURs are obtained from PQRS in a Universal Data Set (UDS). PQRS data from calendar year 2016 are used for the 2016 Annual QRUR and 2018 Value Modifier. The data include information on measures submitted by TINs as groups (through the GPRO) and individual eligible professionals, by TIN, including which measures were submitted, number of cases submitted, number of exclusions, number of cases that met the relevant measure criteria, and performance rates. The UDS contains similar data for non-PQRS QCDR measures. The UDS data also include information on which TINs and individual eligible professionals avoided the 2018 PQRS payment adjustment and the reporting mechanism(s) by which the measures were submitted: Medicare Part B claims, qualified PQRS registry, direct CEHRT, CEHRT via data submission vendor, QCDR, or GPRO Web Interface.

For TINs that reported CAHPS for PQRS survey measures and elected to have them included in the calculation of their Value Modifier, and for Shared Savings Program ACO participant TINs whose ACOs reported CAHPS for ACOs measures and avoided the 2018 PQRS payment adjustment, CMS uses CAHPS survey data collected by CMS-certified CAHPS survey vendors in the performance year. Like the other PQRS data, the CAHPS data include information on number of responses and performance rate. They also include additional information needed to incorporate CAHPS measures into the 2018 Value Modifier for TINs electing that option, such as CAHPS-specific standard errors.

B. Medicare Enrollment Data

CMS uses Medicare Part A and Part B enrollment data to attribute beneficiaries to TINs for the three claims-based quality outcome measures and six cost measures included in the 2018 Value Modifier. Medicare enrollment data from calendar year 2016 are used for the 2016 Annual QRUR and 2018 Value Modifier. These data contain demographic and enrollment information about each beneficiary enrolled in Medicare during a calendar year. The data include the beneficiary's unique Medicare identifier, state and county residence codes, zip code, date of birth, date of death, sex, race/ethnicity, age, monthly Medicare entitlement indicators, reasons for entitlement, whether the beneficiary's state of residence paid for the beneficiary's Medicare Part A or Part B monthly premiums ("state buy-in"), and monthly Medicare managed care enrollment indicators. These variables help determine whether a given beneficiary should be attributed to a TIN. For example, beneficiaries enrolled in Medicare managed care or living outside the U.S., its territories, and its possessions are excluded from the claims-based measures included in the Value Modifier. The enrollment data are accessed via CMS' Integrated Data Repository (IDR). The denominator table, updated quarterly, is accessed via the Medicare Enrollment Database. The beneficiary table, updated daily, is accessed via the Common Medicare Environment.

C. Medicare Claims Data

For the 2018 Value Modifier and the 2016 Annual QRURs, computations for the three claims-based quality outcome measures and six cost measures use all final action Medicare claims for services provided during the performance period. Specifically, CMS analyzes inpatient hospital; outpatient hospital; SNF; home health; hospice; carrier (physician/supplier); and durable medical equipment (DME), prosthetics, orthotics, and supplies (DMEPOS) claims, as appropriate for the relevant measure. These claims are identified from CMS' IDR based on at least a 90-day runout period. The date on which the claims are identified is the Wednesday following the first Saturday that occurs more than 90 days after the end of the performance period. This ensures that there is enough time for claims from the last few days of the run-out period to have been uploaded to the IDR during the weekly updates.²¹

Under Medicare procedures, when an error is discovered on a claim, a duplicate claim is submitted indicating that the prior claim was in error; a subsequent claim containing the corrected information can then be submitted. The National Claims History database is the source of Medicare FFS claims in the IDR. The IDR contains only the final action claims developed from the Medicare National Claims History database—that is, non-rejected claims for which a payment has been made after all disputes and adjustments have been resolved and details clarified—and these are the claims used to populate the Annual QRUR and calculate the Value Modifier. The scope of claims in the IDR is national. Medicare Administrative Contractors (MACs) submit data continually to CMS, which updates the IDR weekly as noted above. TINs submit claims to their MAC for processing and payment. For the purpose of computing the Value Modifier, the end date of the claim determines the performance period with which the claim is associated.

D. Other Data

CMS-HCC risk scores. Derived from Medicare enrollment and claims data, CMS-HCC risk scores are used to (1) risk adjust the Per Capita Costs for All Attributed Beneficiaries and Per Capita Costs for Beneficiaries with Specific Conditions measures²² and (2) determine which high-performing TINs are eligible for an additional upward payment adjustment if their mean beneficiary CMS-HCC risk score is at or above the 75th percentile of all beneficiary risk scores nationwide. Final risk scores for the 2018 Value Modifier are obtained directly from the contractor that produces these scores for CMS. CMS-HCC risk scores from calendar year 2015

²¹ Specifically, CMS calculates the date that is 90 days after the close of the performance period. If the date falls on a weekday, all claims through at least that date are captured the following Tuesday and claims are locked the following Wednesday. If the date falls on a weekend, the data are captured a week later (two Wednesdays after the 90-day runout).

²² For additional details about the risk adjustment methodology for the per capita cost measures, see the per capita cost Measure Information Forms available at the following URL: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/2016-QRUR.html>.

(2016 Final Model scores using Version 22) are used for the 2016 Annual QRUR and 2018 Value Modifier.

Standardized payments. Standardized Medicare allowed charges are used for the cost measures included in the 2018 Value Modifier. These data associate a standardized amount with each actual allowed amount for each service billed by Medicare providers. These data are obtained directly from the contractor responsible for producing CMS' agency-wide standardized payments. Standardized payments data from calendar year 2016 are used for the 2016 Annual QRUR and 2018 Value Modifier.²³

PECOS. PECOS data are used to develop an initial list of TINs that could be subject to the 2018 Value Modifier, based on the number of eligible professionals associated with the TIN in PECOS as of July 16, 2016. The PECOS database includes information on enrolled eligible professionals, including their NPIs, any TINs to which they have reassigned their billing rights, and their primary and secondary specialties (if applicable). PECOS data were obtained by querying the PECOS reporting database 10 calendar days after the 2016 PQRS GPRO registration period ended.

Pioneer ACO Model, Next Generation ACO Model, Oncology Care Model, Comprehensive ESRD Care Model, and Comprehensive Primary Care (CPC) initiative participation lists. To assess which TINs will be exempt from the 2018 Value Modifier because eligible professionals billing under the TIN participated in the Pioneer ACO Model, Next Generation ACO Model, Oncology Care Model, Comprehensive ESRD Care Model, or the Comprehensive Primary Care (CPC) initiative during 2016, TIN-level and TIN-NPI-level participation lists are obtained directly from the contractors supporting these programs and initiatives.

²³ Additional details relating to the payment-standardization algorithm are available at the following URL: <http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=OnetPublic%2FPage%2FOnetTier4&cid=1228772057350>.

APPENDIX B

QUALITY MEASURES, BY DOMAIN

The exhibits in this appendix display, by quality domain, the PQRS measures and non-PQRS QCDR measures considered for inclusion in the 2018 Value Modifier, and included in the 2016 Annual QRURs. The six domains are Effective Clinical Care, Person and Caregiver-Centered Experience and Outcomes, Community/Population Health, Patient Safety, Communication and Care Coordination, and Efficiency and Cost Reduction. Measures for which lower performance is better are indicated by an asterisk following the measure number. For the 2018 Value Modifier calculation, PQRS measures that can be reported as eCQMs have separate benchmarks from the non-eCQM versions of measures.²⁴ The three CMS-calculated claims-based quality outcome measures, as shown in Exhibit B.6, are also included in the 2016 Annual QRURs.

Exhibit B.1. Effective Clinical Care Domain Quality Indicators

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------|
| - | Diabetes Mellitus (DM): Composite (All or Nothing Scoring) (includes GPRO DM-2 and GPRO DM-7) | Effective Clinical Care |
| 1* (GPRO DM-2) | Diabetes: Hemoglobin A1c Poor Control | Effective Clinical Care |
| 1* (CMS122v4) | Diabetes: Hemoglobin A1c Poor Control (eCQM) | Effective Clinical Care |
| 117 (GPRO DM-7) | Diabetes: Eye Exam | Effective Clinical Care |
| 117 (CMS131v4) | Diabetes: Eye Exam (eCQM) | Effective Clinical Care |
| 2 (CMS163v4) | Diabetes: Low Density Lipoprotein (LDL-C) Control (< 100 mg/dL) (eCQM) | Effective Clinical Care |
| 5 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) | Effective Clinical Care |
| 5 (CMS135v4) | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) (eCQM) | Effective Clinical Care |
| 6 | Coronary Artery Disease (CAD): Antiplatelet Therapy | Effective Clinical Care |
| 7 | Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) | Effective Clinical Care |
| 7 (CMS145v3) | Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) (eCQM) | Effective Clinical Care |
| 8 (GPRO HF-6) | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) | Effective Clinical Care |

²⁴ EHR submissions use eCQM versions of PQRS measures. TINs can also submit eCQM versions of measures via QCDR based on eCQM measure specifications. All other reporting mechanisms use non-eCQM versions of PQRS measures, including QCDR submissions based on non-eCQM specifications.

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------|
| 8 (CMS144v4) | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) (eCQM) | Effective Clinical Care |
| 9 (CMS128v4) | Anti-Depressant Medication Management (eCQM) | Effective Clinical Care |
| 12 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation | Effective Clinical Care |
| 12 (CMS143v4) | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation (eCQM) | Effective Clinical Care |
| 14 | Age-Related Macular Degeneration (AMD): Dilated Macular Examination | Effective Clinical Care |
| 18 | Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy | Effective Clinical Care |
| 18 (CMS167v4) | Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy (eCQM) | Effective Clinical Care |
| 32 | Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy | Effective Clinical Care |
| 39 | Screening for Osteoporosis for Women Aged 65-85 Years of Age | Effective Clinical Care |
| 41 | Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older | Effective Clinical Care |
| 43 | Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery | Effective Clinical Care |
| 44 | Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery | Effective Clinical Care |
| 48 | Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older | Effective Clinical Care |
| 51 | Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation | Effective Clinical Care |
| 52 | Chronic Obstructive Pulmonary Disease (COPD): Inhaled Bronchodilator Therapy | Effective Clinical Care |
| 53 | Asthma: Pharmacologic Therapy for Persistent Asthma – Ambulatory Care Setting | Effective Clinical Care |
| 54 | Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain | Effective Clinical Care |
| 67 | Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemia: Baseline Cytogenetic Testing Performed on Bone Marrow | Effective Clinical Care |
| 68 | Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy | Effective Clinical Care |
| 69 | Hematology: Multiple Myeloma: Treatment with Bisphosphonates | Effective Clinical Care |
| 70 | Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------|
| 71 | Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer | Effective Clinical Care |
| 71 (CMS140v4) | Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer (eCQM) | Effective Clinical Care |
| 72 | Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients | Effective Clinical Care |
| 72 (CMS141v5) | Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients (eCQM) | Effective Clinical Care |
| 84 | Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment | Effective Clinical Care |
| 85 | Hepatitis C: Hepatitis C Virus (HCV) Genotype Testing Prior to Treatment | Effective Clinical Care |
| 87 | Hepatitis C: Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Testing Between 4-12 Weeks After Initiation of Treatment | Effective Clinical Care |
| 91 | Acute Otitis Externa (AOE): Topical Therapy | Effective Clinical Care |
| 99 | Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade | Effective Clinical Care |
| 100 | Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade | Effective Clinical Care |
| 104 | Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer | Effective Clinical Care |
| 107 (CMS161v4) | Adult Major Depressive Disorder (MDD): Suicide Risk Assessment (eCQM) | Effective Clinical Care |
| 108 | Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | Effective Clinical Care |
| 112 (GPRO PREV-5) | Breast Cancer Screening | Effective Clinical Care |
| 112 (CMS125v4) | Breast Cancer Screening (eCQM) | Effective Clinical Care |
| 113 (GPRO PREV-6) | Colorectal Cancer Screening | Effective Clinical Care |
| 113 (CMS130v4) | Colorectal Cancer Screening (eCQM) | Effective Clinical Care |
| 118 (GPRO CAD-7) | Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy -- Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%) | Effective Clinical Care |
| 119 | Diabetes: Medical Attention for Nephropathy | Effective Clinical Care |
| 119 (CMS134v4) | Diabetes: Medical Attention for Nephropathy (eCQM) | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------|
| 121 | Adult Kidney Disease: Laboratory Testing (Lipid Profile) | Effective Clinical Care |
| 122 | Adult Kidney Disease: Blood Pressure Management | Effective Clinical Care |
| 126 | Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation | Effective Clinical Care |
| 127 | Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear | Effective Clinical Care |
| 140 | Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement | Effective Clinical Care |
| 160 | HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis | Effective Clinical Care |
| 160 (CMS52v4) | HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis (eCQM) | Effective Clinical Care |
| 163 (CMS123v4) | Diabetes: Foot Exam (eCQM) | Effective Clinical Care |
| 164* | Coronary Artery Bypass Graft (CABG): Prolonged Intubation | Effective Clinical Care |
| 165* | Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate | Effective Clinical Care |
| 166* | Coronary Artery Bypass Graft (CABG): Stroke | Effective Clinical Care |
| 167* | Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure | Effective Clinical Care |
| 168* | Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration | Effective Clinical Care |
| 176 | Rheumatoid Arthritis (RA): Tuberculosis Screening | Effective Clinical Care |
| 177 | Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity | Effective Clinical Care |
| 178 | Rheumatoid Arthritis (RA): Functional Status Assessment | Effective Clinical Care |
| 179 | Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis | Effective Clinical Care |
| 180 | Rheumatoid Arthritis (RA): Glucocorticoid Management | Effective Clinical Care |
| 187 | Stroke and Stroke Rehabilitation: Thrombolytic Therapy | Effective Clinical Care |
| 191 | Cataracts: 20/40 or Better Visual Acuity Within 90 Days Following Cataract Surgery | Effective Clinical Care |
| 191 (CMS133v4) | Cataracts: 20/40 or Better Visual Acuity Within 90 Days Following Cataract Surgery (eCQM) | Effective Clinical Care |
| 195 | Radiology: Stenosis Measurement in Carotid Imaging Reports | Effective Clinical Care |
| 204 (GPRO IVD-2) | Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic | Effective Clinical Care |
| 204 (CMS164v4) | Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic (eCQM) | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------|
| 205 | HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis | Effective Clinical Care |
| 236 (GPRO HTN-2) | Controlling High Blood Pressure | Effective Clinical Care |
| 236 (CMS165v4) | Controlling High Blood Pressure (eCQM) | Effective Clinical Care |
| 241 (CMS182v5) | Ischemic Vascular Disease (IVD): Complete Lipid Profile and LDL-C Control (< 100 mg/dL) (eCQM) | Effective Clinical Care |
| 242 | Coronary Artery Disease (CAD): Symptom Management | Effective Clinical Care |
| 249 | Barrett's Esophagus | Effective Clinical Care |
| 250 | Radical Prostatectomy Pathology Reporting | Effective Clinical Care |
| 251 | Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients | Effective Clinical Care |
| 254 | Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain | Effective Clinical Care |
| 255 | Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure | Effective Clinical Care |
| 257 | Statin Therapy at Discharge After Lower Extremity Bypass (LEB) | Effective Clinical Care |
| 263 | Preoperative Diagnosis of Breast Cancer | Effective Clinical Care |
| 264 | Sentinel Lymph Node Biopsy for Invasive Breast Cancer | Effective Clinical Care |
| 268 | Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy | Effective Clinical Care |
| 270 | Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy | Effective Clinical Care |
| 271 | Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury – Bone Loss Assessment | Effective Clinical Care |
| 274 | Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy | Effective Clinical Care |
| 275 | Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy | Effective Clinical Care |
| 276 | Sleep Apnea: Assessment of Sleep Symptoms | Effective Clinical Care |
| 277 | Sleep Apnea: Severity Assessment at Initial Diagnosis | Effective Clinical Care |
| 278 | Sleep Apnea: Positive Airway Pressure Therapy Prescribed | Effective Clinical Care |
| 279 | Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------|
| 280 | Dementia: Staging of Dementia | Effective Clinical Care |
| 281 | Dementia: Cognitive Assessment | Effective Clinical Care |
| 281 (CMS149v4) | Dementia: Cognitive Assessment (eCQM) | Effective Clinical Care |
| 282 | Dementia: Functional Status Assessment | Effective Clinical Care |
| 283 | Dementia: Neuropsychiatric Symptom Assessment | Effective Clinical Care |
| 284 | Dementia: Management of Neuropsychiatric Symptoms | Effective Clinical Care |
| 287 | Dementia: Counseling Regarding Risks of Driving | Effective Clinical Care |
| 289 | Parkinson's Disease: Annual Parkinson's Disease Diagnosis Review | Effective Clinical Care |
| 290 | Parkinson's Disease: Psychiatric Disorders or Disturbances Assessment | Effective Clinical Care |
| 291 | Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment | Effective Clinical Care |
| 292 | Parkinson's Disease: Querying About Sleep Disturbances | Effective Clinical Care |
| 305 (CMS137v4) | Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (eCQM) | Effective Clinical Care |
| 309 (CMS124v3) | Cervical Cancer Screening (eCQM) | Effective Clinical Care |
| 311 (CMS126v4) | Use of Appropriate Medications for Asthma (eCQM) | Effective Clinical Care |
| 316a (CMS61v5) | Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed (eCQM) | Effective Clinical Care |
| 316b (CMS64v5) | Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C) (eCQM) | Effective Clinical Care |
| 326 | Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy | Effective Clinical Care |
| 327 | Pediatric Kidney Disease: Adequacy of Volume Management | Effective Clinical Care |
| 328* | Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10 g/Dl | Effective Clinical Care |
| 329* | Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis | Effective Clinical Care |
| 337 | Tuberculosis Prevention for Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier | Effective Clinical Care |
| 338 | HIV Viral Load Suppression | Effective Clinical Care |
| 339 | Prescription of HIV Antiretroviral Therapy | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------|
| 343 | Screening Colonoscopy Adenoma Detection Rate Measure | Effective Clinical Care |
| 344 | Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Postoperative Day #2) | Effective Clinical Care |
| 345* | Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS) | Effective Clinical Care |
| 346* | Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Endarterectomy (CEA) | Effective Clinical Care |
| 356* | Unplanned Hospital Readmission Within 30 Days of Principal Procedure | Effective Clinical Care |
| 357* | Surgical Site Infection (SSI) | Effective Clinical Care |
| 365 (CMS148v4) | Hemoglobin A1c Test for Pediatric Patients (eCQM) | Effective Clinical Care |
| 366 (CMS136v5) | ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication (eCQM) | Effective Clinical Care |
| 367 (CMS169v4) | Bipolar Disorder and Major Depression: Appraisal for Alcohol or Chemical Substance Use (eCQM) | Effective Clinical Care |
| 368 (CMS62v4) | HIV/AIDS: Medical Visit (eCQM) | Effective Clinical Care |
| 369 (CMS158v4) | Pregnant Women that Had HBsAg Testing (eCQM) | Effective Clinical Care |
| 370 (GPRO MH-1) | Depression Remission at Twelve Months | Effective Clinical Care |
| 370 (CMS159v4) | Depression Remission at Twelve Months (eCQM) | Effective Clinical Care |
| 371 (CMS160v4) | Depression Utilization of the PHQ-9 Tool (eCQM) | Effective Clinical Care |
| 373 (CMS65v5) | Hypertension: Improvement in Blood Pressure (eCQM) | Effective Clinical Care |
| 379 (CMS74v5) | Primary Caries Prevention Intervention as Offered by Primary Care Providers, Including Dentists (eCQM) | Effective Clinical Care |
| 381 (CMS77v4) | HIV/AIDS: RNA Control for Patients with HIV (eCQM) | Effective Clinical Care |
| 384 | Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room within 90 Days of Surgery | Effective Clinical Care |
| 385 | Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement within 90 Days of Surgery | Effective Clinical Care |
| 387 | Annual Hepatitis C Virus (HCV) Screening for Patients Who are Active Injection Drug Users | Effective Clinical Care |
| 389 | Cataract Surgery: Difference Between Planned and Final Refraction | Effective Clinical Care |
| 398 | Optimal Asthma Control | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------|
| 399 | Post-Procedural Optimal Medical Therapy Composite (Percutaneous Coronary Intervention) | Effective Clinical Care |
| 400 | One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk | Effective Clinical Care |
| 401 | Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis | Effective Clinical Care |
| 404 | Anesthesiology Smoking Abstinence | Effective Clinical Care |
| 405* | Appropriate Follow-Up Imaging for Incidental Abdominal Lesions | Effective Clinical Care |
| 406* | Appropriate Follow-Up Imaging for Incidental Thyroid Nodules in Patients | Effective Clinical Care |
| 407 | Appropriate Treatment of Meticillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia | Effective Clinical Care |
| 408 | Opioid Therapy Follow-Up Evaluation | Effective Clinical Care |
| 409 | Clinical Outcome Post-Endovascular Stroke Treatment | Effective Clinical Care |
| 412 | Documentation of Signed Opioid Treatment Agreement | Effective Clinical Care |
| 413 | Door to Puncture Time for Endovascular Stroke Treatment | Effective Clinical Care |
| 414 | Evaluation or Interview for Risk of Opioid Misuse | Effective Clinical Care |
| 418 | Osteoporosis Management in Women Who Had a Fracture | Effective Clinical Care |
| 420 | Varicose Vein Treatment with Saphenous Ablation: Outcome Survey | Effective Clinical Care |
| 421 | Appropriate Assessment of Retrievable Inferior Vena Cava Filters for Removal | Effective Clinical Care |
| 423 | Perioperative Anti-platelet Therapy for Patients Undergoing Carotid Endarterectomy | Effective Clinical Care |
| 425 | Photodocumentation of Cecal Intubation | Effective Clinical Care |
| 428 | Pelvic Organ Prolapse: Preoperative Assessment of Occult Stress Urinary Incontinence | Effective Clinical Care |
| 435 | Quality of Life Assessment for Patients with Primary Headache Disorders | Effective Clinical Care |
| 436 | Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques | Effective Clinical Care |
| 438 (GPRO PREV-13) | Statin Therapy for the Prevention and Treatment of Cardiovascular Disease | Effective Clinical Care |
| AAAAI 2 | Asthma: Assessment of Asthma Control – Ambulatory Care Setting | Effective Clinical Care |
| AAAAI 8 | Achievement of Projected Effective Dose of Standardized Allergens for Patient Treated with Allergen Immunotherapy for at Least One Year | Effective Clinical Care |
| AAAAI 11 | Asthma Assessment and Classification | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------|
| AAAAI 12 | Lung Function/Spirometry Evaluation | Effective Clinical Care |
| AAN 1 | Distal Symmetric Polyneuropathy: Prediabetes screening | Effective Clinical Care |
| AAN 3 | Epilepsy: Seizure Frequency and Seizure Intervention | Effective Clinical Care |
| AAN 4 | Epilepsy: Screening for Psychiatric or Behavioral Health Disorders | Effective Clinical Care |
| AAN 5 | Headache: Medication prescribed for acute migraine attack | Effective Clinical Care |
| AAO 1 | Otitis Media with Effusion: Diagnostic Evaluation - Assessment of Tympanic Membrane Mobility | Effective Clinical Care |
| ABG 1 | Intraoperative anesthesia safety | Effective Clinical Care |
| ABG 6* | Rate of Unplanned Use of Difficult Airway Equipment and/or Failed Airway | Effective Clinical Care |
| ABG 16 | Planned use of difficult airway equipment | Effective Clinical Care |
| ABG 21 | Preoperative OSA assessment | Effective Clinical Care |
| ACCCath 5 | STEMI Patients Receiving Immediate PCI Within 90 Minutes | Effective Clinical Care |
| ACCCath 6 | ACE-I or ARB Prescribed at Discharge for Patients with an Ejection Fraction < 40% Who Had a PCI During the Episode of Care | Effective Clinical Care |
| ACCCath 7 | Beta-Blockers Prescribed at Discharge for AMI Patients Who Had a PCI During Admission | Effective Clinical Care |
| ACCCath 8 | Percutaneous Coronary Intervention (PCI): Post-Procedural Optimal Medical Therapy | Effective Clinical Care |
| ACCPin 1 | Hypertension (HTN): Blood Pressure (BP) Management | Effective Clinical Care |
| ACCPin 2 | Coronary Artery Disease (CAD): Blood Pressure Control | Effective Clinical Care |
| ACCPin 5 | CAD: Beta-blocker Therapy: Prior MI or LVSD | Effective Clinical Care |
| ACR 1 | Disease Activity Measurement for Patients with Rheumatoid Arthritis (RA) | Effective Clinical Care |
| ACR 2 | Functional Status Assessment for Patients with Rheumatoid Arthritis (RA) | Effective Clinical Care |
| ACR 3 | Disease-Modifying Anti-Rheumatic Drug (DMARD) Therapy for Active Rheumatoid Arthritis (RA) | Effective Clinical Care |
| ACR 5 | Glucocorticosteroids and Other Secondary Causes | Effective Clinical Care |
| ACR 6 | Serum Urate Monitoring | Effective Clinical Care |
| ACR 7 | Gout: Serum Urate Target | Effective Clinical Care |
| ACR 8 | Gout: ULT Therapy | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------|
| ACRad 1 | CT Colonography True Positive Rate | Effective Clinical Care |
| ACRad 3 | Screening Mammography Cancer Detection Rate (CDR) | Effective Clinical Care |
| ACRad 4 | Screening Mammography Invasive Cancer Detection Rate (ICDR) | Effective Clinical Care |
| ACRad 6 | Screening Mammography Positive Predictive Value 2 (PPV2 – Biopsy Recommended) | Effective Clinical Care |
| ACRad 7 | Screening Mammography Node Negativity Rate | Effective Clinical Care |
| ACRad 8 | Screening Mammography Minimal Cancer Rate | Effective Clinical Care |
| ACRad 21 | Lung Cancer Screening Cancer Detection Rate (CDR) | Effective Clinical Care |
| ACRad 22 | Lung Cancer Screening Positive Predictive Value (PPV) | Effective Clinical Care |
| ACS 7* | Risk Standardized Mortality Rate Within 30 Days Following Trauma Operation | Effective Clinical Care |
| ACS 9* | Risk Standardized Urinary Tract Infection Rate Within 30 Days Following Operation | Effective Clinical Care |
| ACS 10* | Risk Standardized Decubitus Ulcer Rate Within 30 Days Following Operation | Effective Clinical Care |
| ACS 12* | Risk Standardized Superficial Surgical Site Infection Rate in Abdominal Trauma | Effective Clinical Care |
| ACS 13* | Risk Standardized Unplanned ICU Transfer Rate in Trauma | Effective Clinical Care |
| ACS 14* | Risk Standardized Unplanned Abdominal Reoperation Rate in Abdominal Trauma | Effective Clinical Care |
| AGA 1 | Hepatitis C Virus (HCV) - Sustained Virological Response | Effective Clinical Care |
| AHSQC 7 | Ventral Hernia Repair: Myofascial Release Preoperative Diabetes Assessment | Effective Clinical Care |
| AQI 18 | Coronary Artery Bypass Graft (CABG): Prolonged Intubation | Effective Clinical Care |
| AQI 30 | Composite Anesthesia Safety | Effective Clinical Care |
| AQI 41* | Coronary Artery Bypass Graft (CABG): Stroke | Effective Clinical Care |
| AQI 42* | Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure | Effective Clinical Care |
| AQI 43* | Rate of Postoperative stroke or death in asymptomatic patients undergoing Carotid Artery Stenting (CAS) | Effective Clinical Care |
| AQI 44* | Rate of Postoperative stroke or death in asymptomatic patients undergoing Carotid Endarterectomy (CEA) | Effective Clinical Care |
| AQI 45* | Rate of Endovascular aneurysm repair (EVAR) of small or moderate non-ruptured abdominal aortic aneurysms (AAA) who die while in the hospital | Effective Clinical Care |
| AQUA 1 | Prostate Cancer: Documentation of PSA, Gleason score and clinical stage for risk stratification | Effective Clinical Care |

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------|
| AQUA 2 | Prostate Cancer: Documentation of extent of biopsy involvement in the MD note | Effective Clinical Care |
| AQUA 4 | Hypogonadism: Testosterone lab ordered / reported within 6 months of starting testosterone replacement | Effective Clinical Care |
| AQUA 7 | Benign Prostate Hyperplasia: IPSS change 6 months after diagnosis | Effective Clinical Care |
| AQUA 9 | Prostate Cancer: Use of active surveillance / watchful waiting for low-risk prostate cancer | Effective Clinical Care |
| ARCO 10 | Trauma- Risk Standardized Mortality Rate within 30 days following Trauma Operation | Effective Clinical Care |
| ASBS 1 | Surgeon Assessment for Hereditary Cause of Breast Cancer | Effective Clinical Care |
| ASNC 15 | SPECT-MPI study quality excellent or good | Effective Clinical Care |
| ASNC 16 | PET-MPI study quality excellent or good | Effective Clinical Care |
| ASPIRE 2 | Train of Four Monitor Documented After Last Dose of Non-depolarizing Neuromuscular Blocker | Effective Clinical Care |
| ASPIRE 3 | Administration of Neostigmine Before Extubation for Cases with Nondepolarizing Neuromuscular Blockade | Effective Clinical Care |
| ASPIRE 4 | Administration of Insulin or Glucose Recheck for Patients with Hyperglycemia | Effective Clinical Care |
| ASPIRE 7 | Active Warming for All Patients at Risk of Intraoperative Hypothermia | Effective Clinical Care |
| ASPIRE 8 | Core Temperature Measurement for All General Anesthetics | Effective Clinical Care |
| ASPIRE 12 | Hemoglobin or Hematocrit Measurement for Patients Receiving Discretionary Intraoperative Red Blood Cell Transfusions | Effective Clinical Care |
| ASPIRE 17 | Avoiding Gaps in Systolic or Mean Arterial Pressure Measurement | Effective Clinical Care |
| ASPIRE 18* | Avoiding Myocardial Injury | Effective Clinical Care |
| ASPIRE 19* | Avoiding Acute Kidney Injury | Effective Clinical Care |
| ASPIRE 21* | All Cause 30-Day Mortality | Effective Clinical Care |
| ASPS 1 | Use of wound surface culture technique in patients with chronic skin ulcers (overuse measure) | Effective Clinical Care |
| ASPS 2 | Use of wet to dry dressings in patients with chronic skin ulcers (overuse measure) | Effective Clinical Care |
| ASPS 3 | Use of compression system in patients with venous ulcers | Effective Clinical Care |
| ASPS 4 | Off-loading (pressure relief) of diabetic foot ulcer | Effective Clinical Care |
| CDR 1 | Adequate Off-loading of Diabetic Foot Ulcers at each visit | Effective Clinical Care |
| CDR 3 | Plan of Care Creation for Diabetic Foot Ulcer (DFU) Patients not Achieving 30% Closure at 4 Weeks | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------|
| CDR 4 | Diabetic Foot & Ankle Care: Comprehensive Diabetic Foot Examination | Effective Clinical Care |
| CDR 5 | Adequate Compression at each visit for Patients with Venous Leg Ulcers (VLU) | Effective Clinical Care |
| CDR 7 | Plan of Care for Venous Leg Ulcer Patients not Achieving 30% Closure at 4 Weeks | Effective Clinical Care |
| CDR 9 | Appropriate use of Cellular or Tissue Based Products (CTP) for patients aged 18 years or older with a diabetic foot ulcer (DFU) or venous leg ulcer (VLU) | Effective Clinical Care |
| CDR 10 | Vascular Assessment of patients with chronic leg ulcers | Effective Clinical Care |
| CDR 11 | Wound Bed Preparation Through Debridement of Necrotic or Non-viable Tissue | Effective Clinical Care |
| ECPR 24 | Initiation of the Initial Sepsis Bundle | Effective Clinical Care |
| EPREOP 1 | Overall Anesthesia Safety | Effective Clinical Care |
| EPREOP 18 | Procedural Site Infection | Effective Clinical Care |
| EPREOP 22 | Preoperative Fluid Intake for Elective Intra-Abdominal Procedures | Effective Clinical Care |
| EPREOP 23* | Unplanned Readmission within 30 Days of Principal Procedure | Effective Clinical Care |
| FORCE 4 | Improvement in Function After Knee Replacement | Effective Clinical Care |
| FORCE 5 | Improvement in Pain After Knee Replacement | Effective Clinical Care |
| FORCE 9 | Improvement in Function After Hip Replacement | Effective Clinical Care |
| FORCE 10 | Improvement in Pain After Hip Replacement Measure | Effective Clinical Care |
| GIQIC 2 | Adequacy of Bowel Preparation | Effective Clinical Care |
| GIQIC 3 | Photodocumentation of the Cecum (also known as Cecal Intubation Rate) – All Colonoscopies | Effective Clinical Care |
| GIQIC 4 | Photodocumentation of the Cecum (also known as Cecal Intubation Rate) – Screening Colonoscopies | Effective Clinical Care |
| GIQIC 9 | Documentation of History and Physical Rate - Colonoscopy | Effective Clinical Care |
| GIQIC 12 | Appropriate Indication for Colonoscopy | Effective Clinical Care |
| GIQIC 16 | Adenoma detection rate | Effective Clinical Care |
| HCPR 14 | Stroke Patients Discharged on Statin Medication | Effective Clinical Care |
| ICLOPS 14* | Postoperative Sepsis Rate | Effective Clinical Care |
| IRIS 1 | Corneal Graft Surgery: Postoperative Improvement in Visual Acuity of 20/40 or greater | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------|
| IRIS 2 | Glaucoma: Intraocular Pressure (IOP) Reduction | Effective Clinical Care |
| IRIS 3* | Glaucoma: Visual Field Progression | Effective Clinical Care |
| IRIS 4 | Glaucoma: Intraocular Pressure Reduction Following Laser Trabeculoplasty | Effective Clinical Care |
| IRIS 5 | Surgery for Acquired Involutional Ptosis: Patients with an Improvement of Marginal Reflex Distance | Effective Clinical Care |
| IRIS 6 | Acquired Involutional Entropion: Normalized Lid Position after Surgical Repair | Effective Clinical Care |
| IRIS 7 | Amblyopia: Interocular Visual Acuity | Effective Clinical Care |
| IRIS 8 | Surgical Esotropia: Postoperative Alignment | Effective Clinical Care |
| IRIS 9 | Diabetic Retinopathy: Documentation of the Presence or Absence of Macular Edema and the Level of Severity of Retinopathy | Effective Clinical Care |
| IRIS 10 | Exudative Age-Related Macular Degeneration: Loss of Visual Acuity | Effective Clinical Care |
| IRIS 11 | Nonexudative Age-Related Macular Degeneration: Loss of Visual Acuity | Effective Clinical Care |
| IRIS 12* | Age-Related Macular Degeneration: Disease Progression | Effective Clinical Care |
| IRIS 13 | Diabetic Macular Edema: Loss of Visual Acuity | Effective Clinical Care |
| IRIS 16 | Acute Anterior Uveitis: Post-Treatment Visual Acuity | Effective Clinical Care |
| IRIS 17 | Acute Anterior Uveitis: Post-Treatment Grade 0 Anterior Chamber Cells | Effective Clinical Care |
| IRIS 18 | Chronic Anterior Uveitis: Post-Treatment Visual Acuity | Effective Clinical Care |
| IRIS 19 | Chronic Anterior Uveitis: Post-Treatment Grade 0 Anterior Chamber Cells | Effective Clinical Care |
| IRIS 20 | Idiopathic Intracranial Hypertension: No worsening or improvement of mean deviation | Effective Clinical Care |
| IRIS 21 | Ocular Myasthenia Gravis: Improvement of ocular deviation or absence of diplopia or functional improvement | Effective Clinical Care |
| IRIS 22 | Giant Cell Arteritis: Absence of fellow eye involvement after corticosteroid treatment | Effective Clinical Care |
| M2S 1 | Procedures with Statin and Antiplatelet Agents Prescribed at Discharge | Effective Clinical Care |
| M2S 7 | Ipsilateral stroke-free survival assessed at least 9 months following Carotid Artery Stenting for asymptomatic procedures | Effective Clinical Care |
| M2S 8 | Ipsilateral stroke-free survival assessed at least 9 months following isolated CEA for asymptomatic procedures | Effective Clinical Care |
| M2S 10 | Survival at least 9 months after elective repair of small thoracic aortic aneurysms | Effective Clinical Care |
| M2S 12 | Survival at least 9 months after elective repair of small abdominal aortic aneurysms | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------|
| M2S 13 | Survival at least 9 months after elective open repair of small abdominal aortic aneurysms | Effective Clinical Care |
| M2S 15 | Appropriate Management of Retrievable IVC Filters | Effective Clinical Care |
| MBS 4 | MBSC Venous Thromboembolism Prophylaxis Adherence Rates for Perioperative Care | Effective Clinical Care |
| MBS 5 | MBSC Venous Thromboembolism Prophylaxis Adherence Rates for Postoperative Care | Effective Clinical Care |
| MBS 6 | MBSC Venous Thromboembolism Prophylaxis Adherence Rates for Post-discharge Care | Effective Clinical Care |
| MBSAQIP 1* | Risk standardized rate of patients who experienced a postoperative complication within 30 days following a primary Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) or Laparoscopic Sleeve Gastrectomy (LSG) operation | Effective Clinical Care |
| MBSAQIP 4* | Risk standardized rate of patients who experienced an anastomotic/staple line leak within 30 days following primary LRYGB or LSG operation | Effective Clinical Care |
| MBSAQIP 5* | Risk standardized rate of patients who experienced a bleeding/hemorrhage event requiring transfusion, intervention/operation, or readmission within 30 days following primary LRYGB or LGS operation | Effective Clinical Care |
| MBSAQIP 6* | Risk standardized rate of patients who experienced a postoperative surgical site infection (SSI) (superficial incisional, deep incisional, or organ/space SSI) within 30 days following primary LRYGB or LSG operation | Effective Clinical Care |
| MBSAQIP 7* | Risk standardized rate of patients who experienced postoperative nausea, vomiting or fluid/electrolyte/nutritional depletion within 30 days following primary LRYGB or LSG operation | Effective Clinical Care |
| MIRAMED 10 | Unplanned Use of Difficult Airway Equipment and/or Failed Airway | Effective Clinical Care |
| MMA 1 | Utilization of Objective Scale to Measure Pain & Functionality | Effective Clinical Care |
| MMA 10 | Risk Assessment in Opiate Naive Patients | Effective Clinical Care |
| MMA 12 | Efficacy of Manipulative Medicine with Treatment Adjustment | Effective Clinical Care |
| MOA 1 | Utilization of Objective Scale to Measure Pain & Functionality | Effective Clinical Care |
| MOA 10 | Risk Assessment in Opiate Naive Patients | Effective Clinical Care |
| MOA 12 | Efficacy of Manipulative Medicine with Treatment Adjustment | Effective Clinical Care |
| MUSIC 2* | Unplanned Hospital Admission Within 30 Days of TRUS Biopsy | Effective Clinical Care |
| MUSIC 4 | Prostate Cancer: Proportion of Patients with Low-Risk Prostate Cancer Receiving Active Surveillance | Effective Clinical Care |
| MUSIC 5* | Prostate Cancer: Percentage of Prostate Cancer Cases with a Length of Stay > 2 Days | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------|
| MUSIC 7 | Prostate Biopsy: Proportion of Patients Undergoing Initial Prostate Biopsy in the Registry Found to Have Prostate Cancer | Effective Clinical Care |
| MUSIC 9 | Prostate Biopsy: Proportion of Patients Undergoing a Repeat Prostate Biopsy Within 12 Months of Their Initial Biopsy in the Registry as a Result of a Finding of Atypical Small Acinar Proliferation (ASAP) as per the NCCN Guidelines | Effective Clinical Care |
| NHBPC 5 | Depression Treatment Plan for Home-Based Primary Care and Palliative Care Patients Who Screen Positive for Depression | Effective Clinical Care |
| NHBPC 7 | New Cognitive Decline in Home-Based Primary Care and Palliative Care Patients: Medication List Reviewed and Offending Medications Discontinued | Effective Clinical Care |
| NHBPC 14 | Cognitive Assessment for Home-Based Primary Care and Palliative Care Patients | Effective Clinical Care |
| NHBPC 15 | Functional Assessment (Basic Activities of Daily Living [BADL] and Instrumental Activities of Daily Living [IADL]) for Home-Based Primary Care and Palliative Care Patients | Effective Clinical Care |
| NHCR 1 | Adequacy of Bowel Preparation | Effective Clinical Care |
| NHCR 2 | Successful Cecal Intubation | Effective Clinical Care |
| NHCR 5 | Repeat Colonoscopy Recommended Due to Piecemeal Resection | Effective Clinical Care |
| NHCR 7 | Documentation of Family History | Effective Clinical Care |
| NHCR 8 | Documentation of Indication for Exam | Effective Clinical Care |
| NJII 6 | Composite Cardiology testing measure: Rate of ECG, Stress Testing and Radionuclide Study | Effective Clinical Care |
| NJIISMD 17 | Result Requiring Follow-Up Protocol | Effective Clinical Care |
| NJIISMD 18 | Follow-Up Exam Obtained | Effective Clinical Care |
| NOF 1 | Laboratory Investigation for Secondary Causes of Fracture | Effective Clinical Care |
| NOF 4 | Osteoporosis Management in Women Who Had a Fracture | Effective Clinical Care |
| NOF 5 | Osteoporosis Testing in Older Women | Effective Clinical Care |
| NOF 6* | Hip Fracture Mortality Rate (IQI 19) | Effective Clinical Care |
| NOF 7 | Osteoporosis: Percentage of Patients, Any Age, with a Diagnosis of Osteoporosis Who Are Either Receiving Both Calcium & Vitamin D Intake, & Exercise at Least Once Within 12 Months | Effective Clinical Care |
| NOF 8 | Osteoporosis: Percentage of Patients Aged 50 Years and Older with a Diagnosis of Osteoporosis Who Were Prescribed Pharmacologic Therapy Within 12 Months | Effective Clinical Care |

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------|
| NOF 9 | Communication with the Physician or Other Clinician Managing On-Going Care Post Fracture for Men and Women Aged 50 Years and Older | Effective Clinical Care |
| NOF 11 | Care for Older Adults (COA) – Medication Review | Effective Clinical Care |
| NOF 12* | Median Time to Pain Management for Long Bone Fracture | Effective Clinical Care |
| NOF 13 | Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older | Effective Clinical Care |
| NOF 15 | Screening for Osteoporosis for Women 65-85 Years of Age | Effective Clinical Care |
| NPA 6* | Spine-Related Procedure Site Infection | Effective Clinical Care |
| NPA 7* | Complication Following Spine-Related Procedure | Effective Clinical Care |
| NPA 8* | Hospital Mortality Following Spine Procedure | Effective Clinical Care |
| NPA 9 | Referral for Post-Acute Care Rehabilitation Following Spine Procedure | Effective Clinical Care |
| NPAGSC 8* | Complication Following Percutaneous Spine-Related Procedure | Effective Clinical Care |
| OBBERD 10 | Quality of Life (VR-12 or Promis Global 10) Monitoring | Effective Clinical Care |
| OBBERD 11 | Quality of Life (VR-12 or Promis Global 10) Outcomes | Effective Clinical Care |
| OBBERD 13* | Orthopedic Functional and Pain Level Outcomes | Effective Clinical Care |
| OBBERD 14 | Orthopedic 3-Month Surgery Follow-Up | Effective Clinical Care |
| OBBERD 15 | Orthopedic 3-Month Surgery Outcome | Effective Clinical Care |
| OBBERD 16 | Orthopedic 3-Month Surgery Success Rate | Effective Clinical Care |
| OBBERD 18 | Orthopedic 3-Month Surgery Outcome with PROMIS | Effective Clinical Care |
| ONSQIR 1 | Symptom Assessment | Effective Clinical Care |
| ONSQIR 2 | Intervention for Psychosocial Distress | Effective Clinical Care |
| ONSQIR 3 | Intervention for Fatigue | Effective Clinical Care |
| ONSQIR 4 | Intervention for Sleep-Wake Disturbance | Effective Clinical Care |
| ONSQIR 5 | Assessment for Chemotherapy Induced Nausea and Vomiting | Effective Clinical Care |
| ONSQIR 6 | Education on Neutropenia Precautions | Effective Clinical Care |
| ONSQIR 7 | Post-Treatment Symptom Assessment | Effective Clinical Care |

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------|
| ONSQIR 8 | Post-Treatment Symptom Intervention | Effective Clinical Care |
| Plnc 48* | Composite Anesthesia Safety | Effective Clinical Care |
| Plnc 51* | Surgical Site Infection | Effective Clinical Care |
| PPRNET 1 | Diabetes Mellitus (DM): Hemoglobin A1c Control (< 8%) | Effective Clinical Care |
| PPRNET 2 | Diabetes Mellitus (DM): Nephropathy Assessment | Effective Clinical Care |
| PPRNET 4 | Hypertension (HTN): Appropriate Diagnosis | Effective Clinical Care |
| PPRNET 5 | Hypertension (HTN): Controlling Blood Pressure | Effective Clinical Care |
| PPRNET 6 | Concordance with ACC/AHA Cholesterol Guidelines for ASCVD Risk Reduction | Effective Clinical Care |
| PPRNET 8 | Antiplatelet Medication for High Risk Patients | Effective Clinical Care |
| PPRNET 9 | Antithrombotic Medication for Patients with Atrial Fibrillation | Effective Clinical Care |
| PPRNET 10 | Heart Failure (HF): ACEI or ARB Therapy | Effective Clinical Care |
| PPRNET 11 | Heart Failure (HF): Beta-Blocker Therapy | Effective Clinical Care |
| PPRNET 13 | Chronic Kidney Disease (CKD): eGFR Monitoring | Effective Clinical Care |
| PPRNET 14 | Chronic Kidney Disease (CKD): Hemoglobin Monitoring | Effective Clinical Care |
| PPRNET 27 | Use of Benzodiazepines in the Elderly | Effective Clinical Care |
| QOPI 1 | Staging Documented Within One Month of First Office Visit | Effective Clinical Care |
| QOPI 7 | Antiemetic Therapy Prescribed for Highly Emetogenic Chemotherapy | Effective Clinical Care |
| QOPI 8 | Antiemetic Therapy Prescribed for Moderately Emetogenic Chemotherapy | Effective Clinical Care |
| QOPI 11 | Combination Chemotherapy Received Within 4 Months of Diagnosis by Women Under 70 with AJCC Stage I (T1c) to III ER/PR Negative Breast Cancer | Effective Clinical Care |
| QOPI 12 | Test for Her2/neu Overexpression or Gene Amplification | Effective Clinical Care |
| QOPI 13 | Trastuzumab Received by Patients with AJCC Stage I (T1c) to III Her2/neu Positive Breast Cancer | Effective Clinical Care |
| QOPI 14 | Tamoxifen or AI Received Within 1 Year of Diagnosis by Patients with AJCC Stage I (T1c) to III ER or PR Positive Breast Cancer | Effective Clinical Care |
| QOPI 16 | Adjuvant Chemotherapy Received Within 4 Months of Diagnosis by Patients with AJCC Stage III Colon Cancer | Effective Clinical Care |
| QOPI 17 | Location of Death Documented (*Paired Measure) | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|--|--|-------------------------|
| QUANTUM 42* | Unplanned Hospital Admission | Effective Clinical Care |
| QUANTUM 51* | Unplanned ICU Admission | Effective Clinical Care |
| RPAQIR 1 | Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy (PCPI Measure #: AKID-2) | Effective Clinical Care |
| RPAQIR 2 | Adequacy of Volume Management (PCPI Measure #: AKID-4) | Effective Clinical Care |
| RPAQIR 3* | ESRD Patients Receiving Dialysis: Hemoglobin Level < 19g/dL (PCPI Measure #: AKID-6) | Effective Clinical Care |
| RPAQIR 4 | Arteriovenous Fistula Rate (PCPI Measure #: AKID-8) | Effective Clinical Care |
| RPAQIR 11* | Hospitalization Rate Following Procedures Performed under Procedure Sedation Analgesia | Effective Clinical Care |
| RPAQIR 14 | Arteriovenous Graft Thrombectomy Success Rate | Effective Clinical Care |
| RPAQIR 15 | Arteriovenous Fistulae Thrombectomy Success Rate | Effective Clinical Care |
| RPAQIR 16 | Peritoneal Dialysis Catheter Success Rate | Effective Clinical Care |
| RPAQIR 17* | Peritoneal Dialysis Catheter Exit Site Infection Rate | Effective Clinical Care |
| SPH 1 | Chronic Kidney Disease - Optimal Care | Effective Clinical Care |
| SPH 2 | Ischemic Vascular Disease - Optimal Vascular Care | Effective Clinical Care |
| SPH 3 | Diabetes - Optimal Care | Effective Clinical Care |
| SPINEIQ 1 | Change in Functional Outcome | Effective Clinical Care |
| SPINEIQ 2 | Change in Pain Intensity | Effective Clinical Care |
| SPINEIQ 4 | Patient Satisfaction Assessment | Effective Clinical Care |
| THPSO 2* | Post-Dural Puncture Headache Rate | Effective Clinical Care |
| THPSO 3* | Perioperative Peripheral Nerve Injury Rate | Effective Clinical Care |
| THPSO 5 | Ultrasound Guidance for Central Line Placement | Effective Clinical Care |
| USWR 15 | Healing or Closure of Wagner Grade 3, 4, or 5 Diabetic Foot Ulcers (DFUs) Treated with HBOT | Effective Clinical Care |
| USWR 16 | Major Amputation in Wagner Grade 3, 4, or 5 Diabetic Foot Ulcers (DFUs) Treated with HBOT | Effective Clinical Care |
| USWR 17 | Preservation of Function with a Minor Amputation Among Patients with Wagner Grade 3, 4, or 5 Diabetic Foot Ulcers (DFUs) Treated with HBOT | Effective Clinical Care |
| WCHQ 1 | Diabetes Care: A1C Blood Sugar Testing (Chronic Care) | Effective Clinical Care |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------|
| WCHQ 2 | Diabetes Care: A1C Blood Sugar Control (Chronic Care) | Effective Clinical Care |
| WCHQ 5 | Diabetes Care: Kidney Function Monitored (Chronic Care) | Effective Clinical Care |
| WCHQ 6 | Diabetes Care: Blood Pressure Control (Chronic Care) | Effective Clinical Care |
| WCHQ 7 | Diabetes Care: Tobacco Free (Chronic Care) | Effective Clinical Care |
| WCHQ 8 | Diabetes Care: Daily Aspirin or Other Antiplatelet unless Contraindicated (Chronic Care) | Effective Clinical Care |
| WCHQ 9 | Diabetes Care: All or None Process Measure: Optimal Testing (Chronic Care) | Effective Clinical Care |
| WCHQ 10 | Diabetes Care: All or None Outcome Measure: Optimal Control (Chronic Care) | Effective Clinical Care |
| WCHQ 11 | Controlling High Blood Pressure: Blood Pressure Control (Chronic Care) | Effective Clinical Care |
| WCHQ 12 | Ischemic Vascular Disease Care: Daily Aspirin or Antiplatelet Medication Usage unless Contraindicated (Chronic Care) | Effective Clinical Care |
| WCHQ 13 | Ischemic Vascular Disease Care: Blood Pressure Control (Chronic Care) | Effective Clinical Care |
| WCHQ 14 | Adults with Pneumococcal Vaccinations (Preventive Care) | Effective Clinical Care |
| WCHQ 15 | Screening for Osteoporosis (Preventive Care) | Effective Clinical Care |
| WCHQ 16 | Adult Tobacco Use Screening for Tobacco Use (Preventive Care) | Effective Clinical Care |
| WCHQ 17 | Adult Tobacco Use Tobacco User Receiving Cessation Advice (Preventive Care) | Effective Clinical Care |
| WCHQ 18 | Breast Cancer Screening (Preventive Care) | Effective Clinical Care |
| WCHQ 19 | Cervical Cancer Screening (Preventive Care) | Effective Clinical Care |
| WCHQ 20 | Colorectal Cancer Screening (Preventive Care) | Effective Clinical Care |
| WCHQ 21 | Diabetes Care: Statin Use for Patients Ages 40 Through 75 or Patients with IVD of Any Age (Chronic Care) | Effective Clinical Care |
| WCHQ 22 | Ischemic Vascular Disease Care: Statin Use (Chronic Care) | Effective Clinical Care |
| WCHQ 23 | Ischemic Vascular Disease Care: Tobacco Free (Chronic Care) | Effective Clinical Care |
| WCHQ 24 | Ischemic Vascular Disease Care: All or None Outcome Measure: Optimal Control (Chronic Care) | Effective Clinical Care |
| WCHQ 25 | Screening for CKD (Preventive Care) | Effective Clinical Care |
| WCHQ 26 | CKD Care in Stages I, II, and III. Annual eGFR (Estimated Glomerular Filtration Rate) Test (Chronic Care) | Effective Clinical Care |
| WCHQ 29 | CKD Care in Stages I, II, and III. Blood Pressure Control (Chronic Care) | Effective Clinical Care |

Exhibit B.1 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------|
| WCQIC 15 | Chronic Wound Care: The Gold Standard of Offloading of plantar Diabetic Foot Ulcers | Effective Clinical Care |
| WCQIC 16 | Process Measure: Nutritional Screening and Intervention Plan in Patients with Chronic Wounds and Ulcers | Effective Clinical Care |
| WCQIC 17 | Efficacy of Human Amnion/Chorion Membrane Allograft | Effective Clinical Care |
| WELL 14 | Chlamydia Screening for Women | Effective Clinical Care |
| WELL 21 | Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis | Effective Clinical Care |
| WELL 25 | Osteoporosis Management in Women Who Had a Fracture | Effective Clinical Care |

Source: CMS, "2016 PQRS Measures List," available at: https://www.cms.gov/apps/ama/license.asp?file=/PQRS/downloads/PQRS_2016_Measure_List_01072016.xlsx.

*Lower performance rates on these measures indicate better performance. However, when standardizing measures for inclusion in the domain score, CMS transforms these measures to ensure that for all standardized scores entering the domain score, positive (+) scores indicate better performance and negative (-) scores indicate worse performance.

Exhibit B.2. Person and Caregiver-Centered Experience and Outcomes Domain Quality Indicators

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|---|
| 50 | Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older | Person and Caregiver-Centered Experience and Outcomes |
| 109 | Osteoarthritis (OA): Function and Pain Assessment | Person and Caregiver-Centered Experience and Outcomes |
| 143 | Oncology: Medical and Radiation – Pain Intensity Quantified | Person and Caregiver-Centered Experience and Outcomes |
| 143 (CMS157v4) | Oncology: Medical and Radiation – Pain Intensity Quantified (eCQM) | Person and Caregiver-Centered Experience and Outcomes |
| 144 | Oncology: Medical and Radiation – Plan of Care for Pain | Person and Caregiver-Centered Experience and Outcomes |
| 303 | Cataracts: Improvement in Patient's Visual Function Within 90 Days Following Cataract Surgery | Person and Caregiver-Centered Experience and Outcomes |
| 304 | Cataracts: Patient Satisfaction Within 90 Days Following Cataract Surgery | Person and Caregiver-Centered Experience and Outcomes |
| 342 | Pain Brought Under Control Within 48 Hours | Person and Caregiver-Centered Experience and Outcomes |
| 358 | Patient-Centered Surgical Risk Assessment and Communication | Person and Caregiver-Centered Experience and Outcomes |
| 375 (CMS66v4) | Functional Status Assessment for Knee Replacement (eCQM) | Person and Caregiver-Centered Experience and Outcomes |
| 376 (CMS56v4) | Functional Status Assessment for Hip Replacement (eCQM) | Person and Caregiver-Centered Experience and Outcomes |
| 377 (CMS90v5) | Functional Status Assessment for Complex Chronic Conditions (eCQM) | Person and Caregiver-Centered Experience and Outcomes |
| 386 | Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences | Person and Caregiver-Centered Experience and Outcomes |
| 390 | Discussion and Shared Decision Making Surrounding Treatment Options | Person and Caregiver-Centered Experience and Outcomes |
| 403 | Adult Kidney Disease: Referral to Hospice | Person and Caregiver-Centered Experience and Outcomes |
| 410 | Psoriasis: Clinical Response to Oral Systemic or Biologic Medications | Person and Caregiver-Centered Experience and Outcomes |
| AAAAI 10 | Documentation of the Consent Process for Subcutaneous Allergen Immunotherapy in the Medical Record | Person and Caregiver-Centered Experience and Outcomes |
| AAAAI 14 | Patient Self-Management and Action Plan | Person and Caregiver-Centered Experience and Outcomes |
| AAAAI 17 | Asthma Control: Minimal Important Difference Improvement | Person and Caregiver-Centered Experience and Outcomes |
| AAO 2 | Otitis Media with Effusion: Resolution of Otitis Media with Effusion in Children | Person and Caregiver-Centered Experience and Outcomes |
| AAO 3 | Otitis Media with Effusion: Resolution of Otitis Media with Effusion in Adults | Person and Caregiver-Centered Experience and Outcomes |
| ABG 7 | Immediate Adult Postoperative Pain Management | Person and Caregiver-Centered Experience and Outcomes |
| ABG 12 | Anesthesia: Patient Experience Survey | Person and Caregiver-Centered Experience and Outcomes |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.2 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|---|
| ACEP 32* | ED Length of Stay (LOS) for Adult Patients Discharged from All EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 33* | ED Length of Stay (LOS) for Adult Patients Discharged from Supercenter EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 34* | ED Length of Stay (LOS) for Adult Patients Discharged from Very High Volume EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 35* | ED Length of Stay (LOS) for Adult Patients Discharged from High Volume EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 36* | ED Length of Stay (LOS) for Adult Patients Discharged from Average Volume EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 37* | ED Length of Stay (LOS) for Adult Patients Discharged from Moderate Volume EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 38* | ED Length of Stay (LOS) for Adult Patients Discharged from Low Volume EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 39* | ED Length of Stay (LOS) for Adult Patients Discharged from Freestanding EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 40* | ED Length of Stay for Pediatric Patients Discharged from All EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 41* | ED Length of Stay for Pediatric Patients Discharged from Supercenter EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 42* | ED Length of Stay (LOS) for Pediatric Patients Discharged from Very High Volume EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 43* | ED Length of Stay for Pediatric Patients Discharged from High Volume EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 44* | ED Length of Stay (LOS) for Pediatric Patients Discharged from Average Volume EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 45* | ED Length of Stay (LOS) for Pediatric Patients Discharged from Moderate Volume EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 46* | ED Length of Stay (LOS) for Pediatric Patients Discharged from Low Volume EDs | Person and Caregiver-Centered Experience and Outcomes |
| ACEP 47* | ED Length of Stay (LOS) for Pediatric Patients Discharged from Freestanding EDs | Person and Caregiver-Centered Experience and Outcomes |
| AHSQC 4 | Ventral Hernia Repair: Pain Status Assessment | Person and Caregiver-Centered Experience and Outcomes |
| AHSQC 5* | Ventral Hernia Repair: Functional Status Assessment | Person and Caregiver-Centered Experience and Outcomes |
| AJRR 2 | Health and Functional Improvement | Person and Caregiver-Centered Experience and Outcomes |
| AQI 28 | New Corneal Injury Not Diagnosed in the Postanesthesia Care Unit/Recovery Area after Anesthesia Care | Person and Caregiver-Centered Experience and Outcomes |
| AQI 29 | Prevention of Post-operative Vomiting (POV) – Combination Therapy (Pediatrics) | Person and Caregiver-Centered Experience and Outcomes |
| AQI 33 | Composite Patient Experience | Person and Caregiver-Centered Experience and Outcomes |
| AQI 36 | Assessment of Acute Postoperative Pain | Person and Caregiver-Centered Experience and Outcomes |
| AQUA 10 | Prostate Cancer: Patient report of Urinary function after treatment | Person and Caregiver-Centered Experience and Outcomes |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.2 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|---|
| AQUA 11 | Prostate Cancer: Patient report of Sexual function after treatment | Person and Caregiver-Centered Experience and Outcomes |
| ASBS 2* | Surgical Site Infection and Cellulitis After Breast and/or Axillary Surgery | Person and Caregiver-Centered Experience and Outcomes |
| ASPIRE 9 | At-Risk Adults Undergoing General Anesthesia Given 2 or More Classes of Anti-emetics | Person and Caregiver-Centered Experience and Outcomes |
| ASPIRE 10 | At-Risk Pediatric Patients Undergoing General Anesthesia Given 2 or More Classes of Anti-emetics | Person and Caregiver-Centered Experience and Outcomes |
| ASPIRE 20 | Preventing Uncontrolled Post-operative Pain | Person and Caregiver-Centered Experience and Outcomes |
| BIVARUS 11 | The Doctor Provided Follow-Up Care Instructions in a Way I Could Understand | Person and Caregiver-Centered Experience and Outcomes |
| BIVARUS 12 | I Was Involved in Developing My Care or Follow-Up Plan | Person and Caregiver-Centered Experience and Outcomes |
| BIVARUS 13 | My Pain Was Treated Effectively | Person and Caregiver-Centered Experience and Outcomes |
| BIVARUS 16 | My Doctor Listened to Me | Person and Caregiver-Centered Experience and Outcomes |
| BIVARUS 17 | My Doctor Made Me Feel Comfortable About Asking Questions | Person and Caregiver-Centered Experience and Outcomes |
| CDR 2 | Diabetic Foot Ulcer (DFU) Healing or Closure | Person and Caregiver-Centered Experience and Outcomes |
| CDR 6 | Venous Leg Ulcer outcome measure: Healing or Closure | Person and Caregiver-Centered Experience and Outcomes |
| CDR 12 | Wound Related Quality of Life | Person and Caregiver-Centered Experience and Outcomes |
| CODE 1 | Improved Functional Outcome Assessment for Shoulder Replacement | Person and Caregiver-Centered Experience and Outcomes |
| CODE 2 | Improved Functional Outcome Assessment for Anterior Cruciate Ligament Repair | Person and Caregiver-Centered Experience and Outcomes |
| CODE 3 | Improved Functional Outcome Assessment for Foot and Ankle Surgery | Person and Caregiver-Centered Experience and Outcomes |
| CODE 4 | Improved Functional Outcome Assessment for Hand Surgery | Person and Caregiver-Centered Experience and Outcomes |
| CODE 5 | Improved Functional Outcome Assessment for Spine Surgery | Person and Caregiver-Centered Experience and Outcomes |
| CUHSM 3 | CAHPS Clinician/Group Surveys – (Adult Primary Care, Pediatric Care, and Specialist Care Surveys) | Person and Caregiver-Centered Experience and Outcomes |
| CUHSM 4 | CAHPS Health Plan Survey v 4.0 – Adult Questionnaire | Person and Caregiver-Centered Experience and Outcomes |
| CUHSM 5 | Care for Older Adults (COA) – Medication Review | Person and Caregiver-Centered Experience and Outcomes |
| ECPR 4* | Mean Time from Emergency Department (ED) Arrival to ED Departure for All Discharged ED Patients | Person and Caregiver-Centered Experience and Outcomes |
| ECPR 5* | Mean Time from Emergency Department (ED) Arrival to ED Departure for Discharged Lower Acuity ED Patients | Person and Caregiver-Centered Experience and Outcomes |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.2 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|---|
| ECPR 6* | Mean Time from Emergency Department (ED) Arrival to ED Departure for Discharged Higher Acuity ED Patients | Person and Caregiver-Centered Experience and Outcomes |
| ECPR 32* | Mean Time from Urgent Care Clinic (UCC) Arrival to UCC Departure for All Discharged UCC Patients | Person and Caregiver-Centered Experience and Outcomes |
| ECPR 33* | Mean Time from Urgent Care Clinic (UCC) Arrival to UCC Departure for Adult Discharged UCC Patients | Person and Caregiver-Centered Experience and Outcomes |
| ECPR 34* | Mean Time from Urgent Care Clinic (UCC) Arrival to UCC Departure for Pediatric Discharged UCC Patients | Person and Caregiver-Centered Experience and Outcomes |
| ECPR 35* | Mean Time from Emergency Department (ED) Arrival to ED Departure for All Admitted ED Patients | Person and Caregiver-Centered Experience and Outcomes |
| ECPR 36* | Mean Time from Emergency Department (ED) Arrival to ED Departure for Admitted Adult ED Patients | Person and Caregiver-Centered Experience and Outcomes |
| ECPR 37* | Mean Time from Emergency Department (ED) Arrival to ED Departure for Admitted Pediatric ED Patients | Person and Caregiver-Centered Experience and Outcomes |
| ECPR 40 | Pain Management for Long Bone Fracture | Person and Caregiver-Centered Experience and Outcomes |
| EPREOP 4 | Short-term Pain Management/Maximum Pain Score | Person and Caregiver-Centered Experience and Outcomes |
| EPREOP 17 | PONV Pediatric | Person and Caregiver-Centered Experience and Outcomes |
| EPREOP 25 | Patient Experience | Person and Caregiver-Centered Experience and Outcomes |
| FORCE 1 | Functional Status Assessment for Knee Replacement | Person and Caregiver-Centered Experience and Outcomes |
| FORCE 2 | Pain Status Assessment for Knee Replacement | Person and Caregiver-Centered Experience and Outcomes |
| FORCE 6 | Functional Status Assessment for Hip Replacement | Person and Caregiver-Centered Experience and Outcomes |
| FORCE 7 | Pain Status Assessment for Hip Replacement | Person and Caregiver-Centered Experience and Outcomes |
| FORCE 11 | Functional Status Assessment for Patients with Knee OA | Person and Caregiver-Centered Experience and Outcomes |
| FORCE 12 | Pain Status Assessment for Patients with Knee OA | Person and Caregiver-Centered Experience and Outcomes |
| FORCE 14 | Functional Status Assessment for Patients with Hip OA | Person and Caregiver-Centered Experience and Outcomes |
| FORCE 15 | Pain Status Assessment for Patients with Hip OA | Person and Caregiver-Centered Experience and Outcomes |
| HCPR 10* | In-Hospital Mortality Rate for Inpatients with Pneumonia | Person and Caregiver-Centered Experience and Outcomes |
| HCPR 11* | In-Hospital Mortality Rate for Inpatients with CHF | Person and Caregiver-Centered Experience and Outcomes |
| HCPR 12* | In-Hospital Mortality Rate for Inpatients with COPD | Person and Caregiver-Centered Experience and Outcomes |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.2 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|---|
| ICLOPS 39 | Proactive treatment for patients with diabetes | Person and Caregiver-Centered Experience and Outcomes |
| ICLOPS 40 | Proactive treatment for patients with Heart Failure | Person and Caregiver-Centered Experience and Outcomes |
| ICLOPS 41 | Proactive treatment for patients with Chronic Obstructive Pulmonary Disease (COPD) | Person and Caregiver-Centered Experience and Outcomes |
| ICLOPS 42 | Proactive treatment for patients with Coronary Artery Disease (CAD) | Person and Caregiver-Centered Experience and Outcomes |
| ICLOPS 43 | Pain Brought Under Control within 2 Encounters | Person and Caregiver-Centered Experience and Outcomes |
| ICLOPS 46 | Patients Admitted to the ICU Who Have Care Preferences Documented | Person and Caregiver-Centered Experience and Outcomes |
| ICLOPS 52 | Palliative Care: Treatment Preferences | Person and Caregiver-Centered Experience and Outcomes |
| ICLOPS 53 | Percentage of Palliative Care Patients with Documentation in the Clinical Record of a Discussion of Spiritual/Religious Concerns or Documentation that the Patient/Caregiver Did Not want to Discuss | Person and Caregiver-Centered Experience and Outcomes |
| M2S 14 | Disease Specific Patient-Reported Outcome Surveys for Varicose Vein Procedures | Person and Caregiver-Centered Experience and Outcomes |
| MIRAMED 5 | Adult PACU Pain Management | Person and Caregiver-Centered Experience and Outcomes |
| NHBPC 8 | Documented Discussion of Preferences for Health Care Decision Making / Life Sustaining Treatment with Home-Based Primary Care and Palliative Care Patients | Person and Caregiver-Centered Experience and Outcomes |
| NHBPC 9 | Referral to Hospice for Appropriate Home-Based Primary Care and Palliative Care Patients | Person and Caregiver-Centered Experience and Outcomes |
| NHQI 25 | Prevention of Postoperative Vomiting (POV) - Combination Therapy (Pediatrics) | Person and Caregiver-Centered Experience and Outcomes |
| NHQI 29 | Assessment of Acute Postoperative Pain | Person and Caregiver-Centered Experience and Outcomes |
| NOF 10 | Advance Care Plan | Person and Caregiver-Centered Experience and Outcomes |
| NPA 1 | Spine Pain Assessment | Person and Caregiver-Centered Experience and Outcomes |
| NPA 2 | Extremity (Radicular) Pain Assessment | Person and Caregiver-Centered Experience and Outcomes |
| NPA 3 | Functional Outcome Assessment for Spine Intervention | Person and Caregiver-Centered Experience and Outcomes |
| NPA 4 | Quality-of-Life Assessment for Spine Intervention | Person and Caregiver-Centered Experience and Outcomes |
| NPA 5 | Patient Satisfaction with Spine Care | Person and Caregiver-Centered Experience and Outcomes |
| NPAGSC 1 | Spine Pain Assessment | Person and Caregiver-Centered Experience and Outcomes |
| NPAGSC 2 | Extremity (Radicular) Pain Assessment | Person and Caregiver-Centered Experience and Outcomes |
| NPAGSC 3 | Functional Outcome Assessment for Spine Intervention | Person and Caregiver-Centered Experience and Outcomes |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.2 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|---|
| NPAGSC 4 | Quality-of-Life Assessment for Spine Intervention | Person and Caregiver-Centered Experience and Outcomes |
| NPAGSC 5 | Patient Satisfaction with Spine Care | Person and Caregiver-Centered Experience and Outcomes |
| OBERD 3 | Back Pain: Shared Decision Making | Person and Caregiver-Centered Experience and Outcomes |
| OBERD 8 | Orthopedic Pain: Shared Decision Making | Person and Caregiver-Centered Experience and Outcomes |
| OBERD 12 | CG-CAHPS Adult Visit Composite Tracking | Person and Caregiver-Centered Experience and Outcomes |
| OBERD 17 | CG-CAHPS Patient Rating | Person and Caregiver-Centered Experience and Outcomes |
| ONQIR 10 | Post-Treatment Goal Setting | Person and Caregiver-Centered Experience and Outcomes |
| ONQIR 11 | Post-Treatment Goal Attainment | Person and Caregiver-Centered Experience and Outcomes |
| ONQIR 13* | Fatigue Improvement | Person and Caregiver-Centered Experience and Outcomes |
| ONQIR 14 | Psychosocial Distress Improvement | Person and Caregiver-Centered Experience and Outcomes |
| Plnc 27 | VTE Warfarin Therapy Discharge Instructions | Person and Caregiver-Centered Experience and Outcomes |
| Plnc 29* | Median Time from ED Arrival to ED Departure for Admitted ED Patients | Person and Caregiver-Centered Experience and Outcomes |
| Plnc 30* | Admit Decision Time to ED Departure Time for Admitted Patients | Person and Caregiver-Centered Experience and Outcomes |
| Plnc 44 | Prevention of Post-operative Nausea and Vomiting (PONV) – Combination Therapy (Pediatrics) | Person and Caregiver-Centered Experience and Outcomes |
| Plnc 49 | Short-term Pain Management | Person and Caregiver-Centered Experience and Outcomes |
| QOPI 2 | Pain Intensity Quantified by Second Office Visit | Person and Caregiver-Centered Experience and Outcomes |
| QOPI 3 | Chemotherapy Intent Documented Before or Within Two Weeks After Administration | Person and Caregiver-Centered Experience and Outcomes |
| QOPI 9 | Pain Intensity Quantified on Either of the Last Two Visits Before Death | Person and Caregiver-Centered Experience and Outcomes |
| QOPI 10 | Hospice Enrollment and Enrolled More than 3 Days Before Death | Person and Caregiver-Centered Experience and Outcomes |
| QOPI 18 | Death from Cancer in Intensive Care Unit (*Paired Measure) | Person and Caregiver-Centered Experience and Outcomes |
| QOPI 19* | Chemotherapy Administered Within Last 2 Weeks of Life (Lower Score Is Better) | Person and Caregiver-Centered Experience and Outcomes |
| QOPI 20 | Documentation of Patients Advance Directives by the Third Office Visit | Person and Caregiver-Centered Experience and Outcomes |
| QUANTUM 39 | Prevention of Postoperative Vomiting with an appropriate medical regimen guided by risk assessment in patients aged 3 to 18 years | Person and Caregiver-Centered Experience and Outcomes |
| RPAQIR 9 | Advance Care Planning (Pediatric Kidney Disease) (PCPI Measure #: PKID-4) | Person and Caregiver-Centered Experience and Outcomes |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.2 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|---|
| STS 7 | Patient Centered Surgical Risk Assessment and Communication Using the STS Risk Calculator | Person and Caregiver-Centered Experience and Outcomes |
| THPSO 9* | Postoperative Nausea and Vomiting Rate – Adults | Person and Caregiver-Centered Experience and Outcomes |
| THPSO 10* | Postoperative Nausea and Vomiting Rate – Pediatrics | Person and Caregiver-Centered Experience and Outcomes |
| THPSO 14 | Patient Experience: Post Anesthesia Follow-Up | Person and Caregiver-Centered Experience and Outcomes |
| USWR 20 | Nutritional Screening and Intervention Plan in Patients with Chronic Wounds and Ulcers | Person and Caregiver-Centered Experience and Outcomes |
| USWR 21 | Patient Reported Experience of Care: Wound Outcome | Person and Caregiver-Centered Experience and Outcomes |
| CAHPS | Getting Timely Care | Person and Caregiver-Centered Experience and Outcomes |
| CAHPS | Provider Communication | Person and Caregiver-Centered Experience and Outcomes |
| CAHPS | Rating of Provider | Person and Caregiver-Centered Experience and Outcomes |
| CAHPS | Access to Specialists | Person and Caregiver-Centered Experience and Outcomes |
| CAHPS | Health Promotion and Education | Person and Caregiver-Centered Experience and Outcomes |
| CAHPS | Shared Decision-Making | Person and Caregiver-Centered Experience and Outcomes |
| CAHPS | Health Status/Functional Status | Person and Caregiver-Centered Experience and Outcomes |
| CAHPS | Courteous/Helpful Office Staff | Person and Caregiver-Centered Experience and Outcomes |
| CAHPS | Care Coordination | Person and Caregiver-Centered Experience and Outcomes |
| CAHPS | Between Visit Communication | Person and Caregiver-Centered Experience and Outcomes |
| CAHPS | Education About Medication Adherence | Person and Caregiver-Centered Experience and Outcomes |
| CAHPS | Stewardship of Patient Resources | Person and Caregiver-Centered Experience and Outcomes |

Source: CMS, “2016 PQRS Measures List,” available at: https://www.cms.gov/apps/ama/license.asp?file=/PQRS/downloads/PQRS_2016_Measure_List_01072016.xlsx.

Note: CAHPS survey measures are scored on a 0 to 100 point scale. Data on the “Health Status/Functional Status” measure, a descriptive measure of beneficiary characteristics, is being provided to TINs for their information only. This measure is not used in the calculation of the 2018 Value Modifier.

*Lower performance rates on these measures indicate better performance. However, when standardizing measures for inclusion in the domain score, CMS transforms these measures to ensure that for all standardized scores entering the domain score, positive (+) scores indicate better performance and negative (-) scores indicate worse performance.

Exhibit B.3. Community/Population Health Domain Quality Indicators

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-----------------------------|
| 110 (GPRO PREV-7) | Preventive Care and Screening: Influenza Immunization | Community/Population Health |
| 110 (CMS147v5) | Preventive Care and Screening: Influenza Immunization (eCQM) | Community/Population Health |
| 111 (GPRO PREV-8) | Pneumonia Vaccination Status for Older Adults | Community/Population Health |
| 111 (CMS127v4) | Pneumonia Vaccination Status for Older Adults (eCQM) | Community/Population Health |
| 128 (GPRO PREV-9) | Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan | Community/Population Health |
| 128 (CMS69v4) | Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan (eCQM) | Community/Population Health |
| 134 (GPRO PREV-12) | Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan | Community/Population Health |
| 134 (CMS2v5) | Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan (eCQM) | Community/Population Health |
| 183 | Hepatitis C: Hepatitis A Vaccination | Community/Population Health |
| 226 (GPRO PREV-10) | Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention | Community/Population Health |
| 226 (CMS138v4) | Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention (eCQM) | Community/Population Health |
| 239 (CMS155v4) | Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents (eCQM) | Community/Population Health |
| 240 (CMS117v4) | Childhood Immunization Status (eCQM) | Community/Population Health |
| 310 (CMS153v4) | Chlamydia Screening for Women (eCQM) | Community/Population Health |
| 317 (GPRO PREV-11) | Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented | Community/Population Health |
| 317 (CMS22v4) | Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented (eCQM) | Community/Population Health |
| 372 (CMS82v3) | Maternal Depression Screening (eCQM) | Community/Population Health |
| 378* (CMS75v4) | Children Who Have Dental Decay or Cavities (eCQM) | Community/Population Health |
| 394 | Immunizations for Adolescents | Community/Population Health |
| 402 | Tobacco Use and Help with Quitting Among Adolescents | Community/Population Health |
| 431 | Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling | Community/Population Health |
| AAN 2 | Distal Symmetric Polyneuropathy: Screening for Unhealthy Alcohol Use | Community/Population Health |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.3 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-----------------------------|
| AAN 8 | Multiple Sclerosis: Exercise and Appropriate Physical Activity Counseling for Patients with MS | Community/Population Health |
| ACEP 25 | Tobacco Screening and Cessation Intervention for ED Patients with Cardiovascular and/or Pulmonary Conditions | Community/Population Health |
| ARCO 7 | Endocrine, Gastrointestinal (GI): Screening, Musculoskeletal: Osteoporosis: Laboratory Investigation for Secondary Causes of Fracture | Community/Population Health |
| ARCO 8 | Endocrine, Musculoskeletal: Osteoporosis: Risk Assessment/Treatment after Fracture | Community/Population Health |
| EPREOP 21 | Tobacco Use: Screening and Cessation Intervention | Community/Population Health |
| FORCE 3 | Mental Health Assessment for Knee Replacement | Community/Population Health |
| FORCE 8 | Mental Health Assessment for Hip Replacement | Community/Population Health |
| FORCE 13 | Mental Health Assessment for Patients with Knee OA | Community/Population Health |
| FORCE 16 | Mental Health Assessment for Patients with Hip OA | Community/Population Health |
| MMA 7 | Adherence to Controlled Substance Agreement/Opiate Agreement with Corrective Actions for Violations | Community/Population Health |
| MMA 8 | Urine Drug Screen Utilization in Pain Management | Community/Population Health |
| MMA 9 | Urine Drug Screen Utilization in Substance Use Disorder Management | Community/Population Health |
| MOA 7 | Adherence to Controlled Substance Agreement/Opiate Agreement with Corrective Actions for Violations | Community/Population Health |
| MOA 8 | Urine Drug Screen Utilization in Pain Management | Community/Population Health |
| MOA 9 | Urine Drug Screen Utilization in Substance Use Disorder Management | Community/Population Health |
| MUSIC 8* | Prostate Biopsy: Proportion of Patients Undergoing a Prostate Biopsy with a PSA < 4 | Community/Population Health |
| NHBPC 2 | Alcohol Problem Use Assessment for Home-Based Primary Care and Palliative Care Patients | Community/Population Health |
| NHBPC 3 | Depression Symptom Assessment for Home-Based Primary Care and Palliative Care Patients | Community/Population Health |
| NHBPC 4 | Pain Screen for Home-Based Primary Care and Palliative Care Patients | Community/Population Health |
| NJII 4 | Increase in billing for wellness visits | Community/Population Health |
| NPA 18 | Smoking Assessment and Cessation Coincident with Spine Related Therapies | Community/Population Health |
| NPA 19 | Body Mass Assessment and Follow-up Coincident with Spine Related Therapies | Community/Population Health |
| NPA 20 | Unhealthy Alcohol Use Assessment Coincident with Spine Care | Community/Population Health |
| NPA 21 | Participation in a Systematic National Database for Spine Care Interventions | Community/Population Health |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.3 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-----------------------------|
| OBERD 19 | Orthopedic Surgery 3-Month QoL Changes (VR-6D) | Community/Population Health |
| OBERD 20 | Orthopedic Surgery 3-Month QoL Changes (EQ-5D) | Community/Population Health |
| Plnc 28 | Tobacco Use Treatment Provided or Offered | Community/Population Health |
| PPRNET 12 | Screening for Abdominal Aortic Aneurysm | Community/Population Health |
| PPRNET 15 | Osteoporosis Screening for Women | Community/Population Health |
| PPRNET 16 | Cervical Cancer Screening | Community/Population Health |
| PPRNET 17 | Breast Cancer Screening | Community/Population Health |
| PPRNET 18 | Colorectal Cancer Screening | Community/Population Health |
| PPRNET 19 | Pneumococcal Vaccination in Elderly | Community/Population Health |
| PPRNET 20 | Zoster (Shingles) Vaccination | Community/Population Health |
| PPRNET 21 | Depression Screening | Community/Population Health |
| PPRNET 22 | Alcohol Misuse Screening | Community/Population Health |
| PPRNET 23 | Tobacco Use: Screening and Cessation Intervention | Community/Population Health |
| PPRNET 31 | Screening for Type 2 Diabetes | Community/Population Health |
| QOPI 6 | Smoking Status/Tobacco Use Documented in Past Year | Community/Population Health |
| SPH 4 | COPD – Pneumococcal Vaccine | Community/Population Health |
| SPH 5 | Tobacco Free Status | Community/Population Health |
| WCHQ 30 | Adolescent Immunization (Preventive Care) | Community/Population Health |
| WCHQ 31 | Childhood Immunization (Preventive Care) | Community/Population Health |
| WELL 15 | Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents | Community/Population Health |
| WELL 22 | Children and Adolescents Access to Primary Care Practitioners | Community/Population Health |

Source: CMS, “2016 PQRS Measures List,” available at: https://www.cms.gov/apps/ama/license.asp?file=/PQRS/downloads/PQRS_2016_Measure_List_01072016.xlsx.

*Lower performance rates on these measures indicate better performance. However, when standardizing measures for inclusion in the domain score, CMS transforms these measures to ensure that for all standardized scores entering the domain score, positive (+) scores indicate better performance and negative (-) scores indicate worse performance.

Exhibit B.4. Patient Safety Domain Quality Indicators

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|----------------|
| 21 | Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin | Patient Safety |
| 22 | Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures) | Patient Safety |
| 23 | Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) | Patient Safety |
| 76 | Prevention of Central Venous Catheter (CVC)-Related Bloodstream Infections | Patient Safety |
| 130 (GPRO CARE-3) | Documentation of Current Medications in the Medical Record | Patient Safety |
| 130 (CMS68v5) | Documentation of Current Medications in the Medical Record (eCQM) | Patient Safety |
| 145 | Radiology: Exposure Time Reported for Procedures Using Fluoroscopy | Patient Safety |
| 154 | Falls: Risk Assessment | Patient Safety |
| 156 | Oncology: Radiation Dose Limits to Normal Tissues | Patient Safety |
| 181 | Elder Maltreatment Screen and Follow-Up Plan | Patient Safety |
| 192* | Cataracts: Complications Within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures | Patient Safety |
| 192* (CMS132v4) | Cataracts: Complications Within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures (eCQM) | Patient Safety |
| 238* | Use of High-Risk Medications in the Elderly | Patient Safety |
| 238* (CMS156v4) | Use of High-Risk Medications in the Elderly (eCQM) | Patient Safety |
| 258 | Rate of Open Repair of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) Without Major Complications (Discharged to Home by Post-operative Day #7) | Patient Safety |
| 259 | Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) Without Major Complications (Discharged to Home by Post-operative Day #2) | Patient Safety |
| 260 | Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-operative Day #2) | Patient Safety |
| 262 | Image Confirmation of Successful Excision of Image-Localized Breast Lesion | Patient Safety |
| 286 | Dementia: Counseling Regarding Safety Concerns | Patient Safety |
| 318 (GPRO CARE-2) | Falls: Screening for Fall Risk | Patient Safety |
| 318 (CMS139v4) | Falls: Screening for Fall Risk (eCQM) | Patient Safety |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.4 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|----------------|
| 330* | Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days | Patient Safety |
| 335 | Maternity Care: Elective Delivery or Early Induction Without Medical Indication at ≥ 37 and < 39 Weeks | Patient Safety |
| 347* | Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital | Patient Safety |
| 348* | HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate | Patient Safety |
| 351 | Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation | Patient Safety |
| 352 | Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet | Patient Safety |
| 353 | Total Knee Replacement: Identification of Implanted Prosthesis in Operative Report | Patient Safety |
| 354* | Anastomotic Leak Intervention | Patient Safety |
| 355* | Unplanned Reoperation Within the 30 Day Postoperative Period | Patient Safety |
| 360 | Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies | Patient Safety |
| 361 | Optimizing Patient Exposure to Ionizing Radiation: Reporting to a Radiation Dose Index Registry | Patient Safety |
| 380 (CMS179v4) | ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range (eCQM) | Patient Safety |
| 382 (CMS177v4) | Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment (eCQM) | Patient Safety |
| 383 | Adherence to Antipsychotic Medications for Individuals with Schizophrenia | Patient Safety |
| 388* | Cataract Surgery with Intraoperative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy) | Patient Safety |
| 392* | HRS-12: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation | Patient Safety |
| 393* | HRS-9: Infection Within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision | Patient Safety |
| 417 | Rate of Open Repair of Ascending Abdominal Aortic Aneurysms (AAA) Where Patients Are Discharged Alive | Patient Safety |
| 422 | Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury | Patient Safety |
| 424 | Perioperative Temperature Management | Patient Safety |
| 429 | Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy | Patient Safety |
| 430 | Prevention of Postoperative Nausea and Vomiting (PONV) – Combination Therapy | Patient Safety |
| 432* | Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair | Patient Safety |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.4 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|----------------|
| 433* | Proportion of Patients Sustaining a Major Viscus Injury at the Time of Any Pelvic Organ Prolapse Repair | Patient Safety |
| 434* | Proportion of Patients Sustaining A Ureter Injury at the Time of any Pelvic Organ Prolapse Repair | Patient Safety |
| 437* | Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure | Patient Safety |
| AAAAI 5 | Allergen Immunotherapy Treatment: Allergen Specific Immunoglobulin E (IgE) Sensitivity Assessed and Documented Prior to Treatment | Patient Safety |
| AAAAI 9 | Assessment of Asthma Symptoms Prior to Administration of Allergen Immunotherapy Injection(s) | Patient Safety |
| AAO 4* | Tonsillectomy: Primary Post-Tonsillectomy Hemorrhage in Children | Patient Safety |
| AAO 5* | Tonsillectomy: Primary Post-Tonsillectomy Hemorrhage in Adults | Patient Safety |
| AAO 6* | Tonsillectomy: Secondary Post-Tonsillectomy Hemorrhage in Children | Patient Safety |
| AAO 7* | Tonsillectomy: Secondary Post-Tonsillectomy Hemorrhage in Adults | Patient Safety |
| ABG 2* | Total Perioperative Cardiac Arrest Rate | Patient Safety |
| ABG 3* | Total Perioperative Mortality Rate | Patient Safety |
| ABG 4* | PACU Intubation Rate | Patient Safety |
| ABG 5* | Composite Procedural Safety for All Vascular Access Procedures | Patient Safety |
| ABG 9* | OR Fire | Patient Safety |
| ABG 11* | Anaphylaxis During Anesthesia Care in the Operating Room | Patient Safety |
| ABG 13* | Malignant Hyperthermia | Patient Safety |
| ABG 14* | Corneal Abrasion | Patient Safety |
| ABG 15* | Dental Injury | Patient Safety |
| ABG 17* | Medication errors during surgery | Patient Safety |
| ABG 22* | Intraoperative Airway Fire | Patient Safety |
| ABG 23* | Intraoperative patient fall | Patient Safety |
| ABG 24* | Time out error – surgical | Patient Safety |
| ABG 25* | Time out error – regional block | Patient Safety |
| ABG 26* | Myocardial Ischemia requiring intervention during the operative period | Patient Safety |
| ABG 27* | Dysrhythmia requiring intervention during the operative period | Patient Safety |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.4 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|----------------|
| ACCCath 1* | Stroke Intra or Post-PCI Procedure in Patients Without CABG or Other Major Surgeries During Admission | Patient Safety |
| ACCCath 2* | New Requirement for Dialysis Post-PCI in Patients Without CABG or Other Major Surgeries During Admission | Patient Safety |
| ACCCath 3* | Vascular Access Site Injury Requiring Treatment or Major Bleeding Post-PCI in Patients Without CABG or Other Major Surgeries During Admission | Patient Safety |
| ACCCath 4* | Cardiac Tamponade Post-PCI in Patients Without CABG or Other Major Surgery During Admission | Patient Safety |
| ACCCath 14 | Contrast Dose Monitored and Recorded During the Procedure | Patient Safety |
| ACCPin 4 | AFIB: CHA2DS2–VASc Score Risk Score Documented | Patient Safety |
| ACEP 23 | Anti-coagulation for Acute Pulmonary Embolism Patients | Patient Safety |
| ACEP 24 | Pregnancy Test for Female Abdominal Pain Patients | Patient Safety |
| ACEP 26 | Sepsis Management: Septic Shock: Lactate Level Measurement | Patient Safety |
| ACEP 27 | Sepsis Management: Septic Shock: Antibiotics Ordered | Patient Safety |
| ACEP 28 | Sepsis Management: Septic Shock: Fluid Resuscitation | Patient Safety |
| ACEP 29 | Sepsis Management: Septic Shock: Repeat Lactate Level Measurement | Patient Safety |
| ACEP 30 | Sepsis Management: Septic Shock: Lactate Clearance Rate of \geq 10% | Patient Safety |
| ACEP 31 | Appropriate Foley Catheter Use in the Emergency Department | Patient Safety |
| ACR 4 | Tuberculosis Test Prior to First Course Biologic Therapy | Patient Safety |
| ACRad 9* | Median Dose Length Product for CT Head/Brain Without Contrast (Single Phase Scan) | Patient Safety |
| ACRad 10* | Median Size Specific Dose Estimate for CT Chest Without Contrast (Single Phase Scan) | Patient Safety |
| ACRad 11* | Median Dose Length Product for CT Chest Without Contrast (Single Phase Scan) | Patient Safety |
| ACRad 12* | Median Size Specific Dose Estimate for CT Abdomen-Pelvis with Contrast (Single Phase Scan) | Patient Safety |
| ACRad 13* | Median Dose Length Product for CT Abdomen-Pelvis with Contrast (Single Phase Scan) | Patient Safety |
| ACRad 14 | Participation in a National Dose Index Registry | Patient Safety |
| ACRad 20* | CT IV Contrast Extravasation Rate (Low Osmolar Contrast Media) | Patient Safety |
| ACRad 24 | Timing of Antibiotics-Ordering Physician | Patient Safety |
| ACS 1 | Prophylactic Antibiotics in Abdominal Trauma | Patient Safety |
| ACS 2 | Discontinuation of Prophylactic Antibiotics in Abdominal Trauma | Patient Safety |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.4 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|----------------|
| ACS 3 | Venous Thromboembolism (VTE) Prophylaxis in Trauma Patients | Patient Safety |
| ACS 5 | Documentation of Anticoagulation Use in the Medical Record | Patient Safety |
| ACS 11 | Trauma Surgeon Response within 30 Minutes of Hospital Arrival | Patient Safety |
| AHSQC 1* | Ventral Hernia Repair: Surgical Site Occurrence Requiring Procedural Intervention within the 30 Day Postoperative Period | Patient Safety |
| AHSQC 6* | Ventral Hernia Repair with Myofascial Release Surgical Site Occurrence Requiring Procedural Intervention within the 30 Day Postoperative Period | Patient Safety |
| AJRR 1 | Postoperative Complications within 90 Days Following the Procedure | Patient Safety |
| AJRR 4 | Venous Thromboembolic and Cardiovascular Risk Evaluation | Patient Safety |
| AQI 31* | Postanesthesia Care Unit (PACU) Re-intubation Rate | Patient Safety |
| AQI 32 | Composite Procedural Safety for Central Line Placement | Patient Safety |
| AQI 34* | Perioperative Cardiac Arrest | Patient Safety |
| AQI 35* | Perioperative Mortality Rate | Patient Safety |
| AQI 37 | Surgical Safety Checklist – Applicable Safety Checks Completed Before Induction of Anesthesia | Patient Safety |
| AQI 46 | Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation | Patient Safety |
| AQI 47 | Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet | Patient Safety |
| AQUA 8 | Hospital readmissions / complications within 30 days of TRUS Biopsy | Patient Safety |
| ASBS 7 | Unplanned 30 Day Reoperation After Mastectomy | Patient Safety |
| ASNC 19 | Imaging Protocols for SPECT and PET MPI studies - Use of stress only protocol | Patient Safety |
| ASNC 20 | SPECT-MPI studies performed without the use of thallium | Patient Safety |
| ASPIRE 5 | Administration of Dextrose Containing Solution or Glucose Recheck for Patients with Perioperative Glucose < 60 | Patient Safety |
| ASPIRE 6 | Avoiding Excessively High Tidal Volumes During Positive Pressure Ventilation | Patient Safety |
| ASPIRE 16 | Avoiding Intraoperative Hypotension | Patient Safety |
| ASPIRE 22 | Avoiding Medication Overdose | Patient Safety |
| ASPS 5 | Breast Reconstruction: Return to OR | Patient Safety |
| ASPS 6 | Breast Reconstruction: Flap Loss | Patient Safety |
| BIVARUS 1 | Hand Sanitation Performed by My Provider | Patient Safety |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.4 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-----------------------|
| BIVARUS 2 | Medication Reconciliation Performed at My Visit | Patient Safety |
| BIVARUS 3 | Practice Asked Me About Allergies | Patient Safety |
| BIVARUS 5 | Practice Explained Medications Before Giving Them | Patient Safety |
| BIVARUS 7 | Coordination of Care Among Physicians and Nurses | Patient Safety |
| BIVARUS 9 | I Was Told How to Arrange an Appointment for Follow-Up Care | Patient Safety |
| BIVARUS 10 | Overall Assessment of Safety | Patient Safety |
| CUHSM 6 | Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder | Patient Safety |
| CUHSM 7 | Diabetes Monitoring for People with Diabetes and Schizophrenia (SMD) | Patient Safety |
| CUHSM 8 | Cardiovascular Health Screening for People with Schizophrenia or Bipolar Disorder Who Are Prescribed Antipsychotic Medications | Patient Safety |
| ECPR 1* | Door to Diagnostic Evaluation by a Provider – All Emergency Department (ED) Patients | Patient Safety |
| ECPR 2* | Door to Diagnostic Evaluation by a Provider – Adult Emergency Department (ED) Patients | Patient Safety |
| ECPR 3* | Door to Diagnostic Evaluation by a Provider – Pediatric Emergency Department (ED) Patients | Patient Safety |
| ECPR 29* | Door to Diagnostic Evaluation by a Provider – All Urgent Care Patients | Patient Safety |
| ECPR 30* | Door to Diagnostic Evaluation by a Provider – Adult Urgent Care Patients | Patient Safety |
| ECPR 31* | Door to Diagnostic Evaluation by a Provider – Pediatric Urgent Care Patients | Patient Safety |
| EPREOP 2* | Overall Mortality | Patient Safety |
| EPREOP 3* | PACU Intubation Rate | Patient Safety |
| EPREOP 5 | Procedural Safety for Central Venous or Arterial Catheterization | Patient Safety |
| EPREOP 6 | Surgical Safety Checklist/Timeout | Patient Safety |
| EPREOP 7* | Corneal Injury | Patient Safety |
| EPREOP 8* | Failed Airway | Patient Safety |
| EPREOP 9 | Prophylactic Antibiotic Administration | Patient Safety |
| EPREOP 10* | Intraoperative Fire | Patient Safety |
| EPREOP 12* | Anaphylaxis | Patient Safety |
| EPREOP 13* | Malignant Hyperthermia | Patient Safety |
| EPREOP 14* | Dental Injury | Patient Safety |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.4 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|----------------|
| EPREOP 15* | Unplanned admission to ICU | Patient Safety |
| EPREOP 16* | Unplanned admission to Hospital | Patient Safety |
| EPREOP 19 | Documentation of Current Medications in the Medical Record | Patient Safety |
| EPREOP 24* | Overall Cardiac Arrest | Patient Safety |
| GIQIC 5* | Incidence of Perforation | Patient Safety |
| HCPR 13 | Stroke Venous Thromboembolism (VTE) Prophylaxis | Patient Safety |
| HCPR 15 | Venous Thromboembolism (VTE) Prophylaxis | Patient Safety |
| HCPR 16 | Venous Thromboembolism (VTE) Patients with Anticoagulation Overlap Therapy | Patient Safety |
| ICLOPS 45 | Patients Who Die an Expected Death with an ICD that Has Been Deactivated | Patient Safety |
| M2S 2 | Amputation-free survival assessed at least 9 months following Infra-Inguinal Bypass for intermittent claudication | Patient Safety |
| M2S 4 | Amputation-free survival assessed at least 9 months following Supra-Inguinal Bypass for claudication | Patient Safety |
| M2S 5 | Amputation-free survival assessed at least 9 months following Peripheral Vascular Intervention for intermittent claudication | Patient Safety |
| MBS 1* | Medical Complications | Patient Safety |
| MBS 2* | Surgical Site Complications | Patient Safety |
| MBS 3* | Serious Complications | Patient Safety |
| MBSAQIP 8* | Risk standardized rate of patients who experienced extended length of stay (> 7 days) following primary LRYGB or LSG operation | Patient Safety |
| MIRAMED 1 | Perioperative Cardiac Arrest Rate | Patient Safety |
| MIRAMED 2 | PACU Intubation Rate | Patient Safety |
| MIRAMED 3 | Dental Injury | Patient Safety |
| MIRAMED 4 | Perioperative Mortality Rate | Patient Safety |
| MIRAMED 6* | Anaphylaxis During Anesthesia Care | Patient Safety |
| MIRAMED 7* | Corneal Abrasion | Patient Safety |
| MMA 6 | Definitive Diagnosis for Chronic Pain Controlled Substance Utilization | Patient Safety |
| MMA 11 | Risk Assessment Patients Tolerant to Controlled Substances Due to Chronic Utilization in a Therapeutic Setting | Patient Safety |
| MOA 6 | Definitive Diagnosis for Chronic Pain Controlled Substance Utilization | Patient Safety |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.4 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|----------------|
| MOA 11 | Risk Assessment Patients Tolerant to Controlled Substances Due to Chronic Utilization in a Therapeutic Setting | Patient Safety |
| MUSIC 1 | Prostate Biopsy: Compliance with AUA Best Practices for Antibiotic Prophylaxis for Transrectal Ultrasound-Guided (TRUS) Biopsy | Patient Safety |
| NHBPC 1 | Abuse or Neglect Assessment for Home-Based Primary Care and Palliative Care Patients | Patient Safety |
| NHBPC 6 | Screen for Risk of Future Fall for Home-Based Primary Care and Palliative Care Patients | Patient Safety |
| NHBPC 12 | Management of Suspected Abuse or Neglect | Patient Safety |
| NHCR 3* | Incidence of Perforation | Patient Safety |
| NHQI 26 | Postanesthesia Care Unit (PACU) Re-intubation Rate | Patient Safety |
| NHQI 27* | Perioperative Cardiac Arrest | Patient Safety |
| NHQI 28* | Perioperative Mortality Rate | Patient Safety |
| NJII 3* | 30-day Rehospitalizations per 1,000 Medicare Fee-for-Service (FFS) Beneficiaries | Patient Safety |
| NJIISMD 1 | Critical Result: Pulmonary Embolism | Patient Safety |
| NJIISMD 2 | Critical Result: ICH | Patient Safety |
| NJIISMD 3 | Critical Result: Aortic Dissection | Patient Safety |
| NJIISMD 8 | Critical Result: Occlusive intracranial stroke | Patient Safety |
| NJIISMD 9 | Critical Result: Placental abruption | Patient Safety |
| NJIISMD 10 | Critical Result: Ruptured ectopic pregnancy | Patient Safety |
| NJIISMD 11 | Critical Result: New DVT | Patient Safety |
| NJIISMD 12 | Critical Result: Eptopic Pregnancy | Patient Safety |
| NJIISMD 14 | Critical Result Protocol | Patient Safety |
| NJIISMD 15 | Urgent Result Protocol | Patient Safety |
| NJIISMD 16 | Unexpected Result Protocol | Patient Safety |
| NPA 10* | Unplanned Reoperation Following Spine Procedure Within the 30 Day Postoperative Period | Patient Safety |
| NPA 11* | Unplanned Readmission Following Spine Procedure Within the 30 Day Postoperative Period | Patient Safety |
| NPA 12 | Selection of Prophylactic Antibiotic-First or Second Generation Cephalosporin Prior to Spine Procedure | Patient Safety |
| NPA 13 | Discontinuation of Prophylactic Parenteral Antibiotics Following Spine Procedure | Patient Safety |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.4 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|----------------|
| NPSGSC 9* | Unplanned Admission to Hospital Following Percutaneous Spine Procedure within the 30-Day Post-procedure Period | Patient Safety |
| ONSQIR 9 | Post-Treatment Education | Patient Safety |
| Plnc 4* | 30 Day Mortality for Acute Myocardial Infarction | Patient Safety |
| Plnc 5* | 30 Day Mortality for Heart Failure | Patient Safety |
| Plnc 6* | 30 Day Mortality for Pneumonia | Patient Safety |
| Plnc 7 | Venous Thromboembolism (VTE) Prophylaxis | Patient Safety |
| PPRNET 26 | Use of High-Risk Medications in the Elderly | Patient Safety |
| PPRNET 28 | NSAID or Cox 2 Inhibitor Use in Patients with Heart Failure (HF) or Chronic Kidney Disease (CKD) | Patient Safety |
| PPRNET 29 | Monitoring Serum Potassium | Patient Safety |
| PPRNET 30 | Treatment of Hypokalemia | Patient Safety |
| QUANTUM 31 | Central Venous Line: ultrasound used for placement | Patient Safety |
| QUANTUM 32* | Procedural Safety for Central Line Placement | Patient Safety |
| QUANTUM 33* | PACU Intubation Rate | Patient Safety |
| QUANTUM 34* | Dental Damage/Loss | Patient Safety |
| QUANTUM 35* | Inadvertent Dural Puncture during Epidural | Patient Safety |
| QUANTUM 36* | High Spinal requiring intubation and/or assisted ventilation | Patient Safety |
| QUANTUM 37* | Aspiration of Gastric Contents | Patient Safety |
| QUANTUM 40* | Surgical Fire | Patient Safety |
| QUANTUM 43* | Difficult Intubation due to unrecognized difficult airway | Patient Safety |
| QUANTUM 44* | Laryngospasm | Patient Safety |
| QUANTUM 45* | Major Systemic Local Anesthetic Toxicity | Patient Safety |
| QUANTUM 46* | Failed Regional Requiring General Anesthesia | Patient Safety |
| QUANTUM 47* | Medication Error by Anesthesia Care Team | Patient Safety |
| QUANTUM 48* | Anaphylaxis | Patient Safety |
| QUANTUM 49* | Immediate Perioperative Cardiac Arrest | Patient Safety |
| QUANTUM 50* | Immediate Perioperative Mortality | Patient Safety |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.4 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|----------------|
| RPAQIR 12* | Arterial Complication Rate Following Arteriovenous Access Intervention | Patient Safety |
| SCG 1 | Evaluation of high risk pain medications patient prescribed in last 6 months (polypharmacy) | Patient Safety |
| SPINEIQ 3* | Repeated X-Ray Imaging | Patient Safety |
| THPSO 1* | Perioperative Aspiration Pneumonia Rate | Patient Safety |
| THPSO 4* | Pneumothorax Rate as a Complication of Central Line Placement | Patient Safety |
| THPSO 6* | Perioperative Myocardial Infarction Rate in Low Risk Patients | Patient Safety |
| THPSO 7* | Perioperative Myocardial Infarction Rate in High Risk Patients | Patient Safety |
| THPSO 8* | New Perioperative Central Neurologic Deficit | Patient Safety |
| THPSO 11* | Post-obstructive Pulmonary Edema Rate Following Endo-Tracheal Intubation | Patient Safety |
| THPSO 12* | Respiratory Arrest in PACU Rate | Patient Safety |
| THPSO 13* | Dental Injury Rate Following Airway Management | Patient Safety |
| USWR 13 | Patient Vital Sign Assessment Prior to HBOT | Patient Safety |
| USWR 14 | Blood Glucose Check Prior to Hyperbaric Oxygen Therapy (HBOT) Treatment | Patient Safety |
| USWR 18 | Complications or Side Effects Among Patients Undergoing Treatment with HBOT | Patient Safety |
| USWR 19 | Completion of a Risk Assessment at the Time of HBOT Consultation | Patient Safety |
| WCQIC 10 | Chronic Wound Care: Arterial Testing in Venous Leg Ulcer Prior to Compression Therapy | Patient Safety |

Source: CMS, "2016 PQRS Measures List," available at: https://www.cms.gov/apps/ama/license.asp?file=/PQRS/downloads/PQRS_2016_Measure_List_01072016.xlsx.

*Lower performance rates on these measures indicate better performance. However, when standardizing measures for inclusion in the domain score, CMS transforms these measures to ensure that for all standardized scores entering the domain score, positive (+) scores indicate better performance and negative (-) scores indicate worse performance.

Exhibit B.5. Communication and Care Coordination Domain Quality Indicators

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------------------|
| 19 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care | Communication and Care Coordination |
| 19 (CMS142v4) | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care (eCQM) | Communication and Care Coordination |
| 24 | Osteoporosis: Communication with the Physician Managing On-Going Care Post-Fracture of Hip, Spine, or Distal Radius for Men and Women Aged 50 Years and Older | Communication and Care Coordination |
| 46 | Medication Reconciliation Post-discharge | Communication and Care Coordination |
| 47 | Care Plan | Communication and Care Coordination |
| 131 | Pain Assessment and Follow-Up | Communication and Care Coordination |
| 137 | Melanoma: Continuity of Care – Recall System | Communication and Care Coordination |
| 138 | Melanoma: Coordination of Care | Communication and Care Coordination |
| 141 | Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care | Communication and Care Coordination |
| 147 | Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy | Communication and Care Coordination |
| 155 | Falls: Plan of Care | Communication and Care Coordination |
| 182 | Functional Outcome Assessment | Communication and Care Coordination |
| 185 | Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use | Communication and Care Coordination |
| 217 | Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments | Communication and Care Coordination |
| 218 | Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments | Communication and Care Coordination |
| 219 | Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot, or Ankle Impairments | Communication and Care Coordination |
| 220 | Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments | Communication and Care Coordination |
| 221 | Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments | Communication and Care Coordination |
| 222 | Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist, or Hand Impairments | Communication and Care Coordination |
| 223 | Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments | Communication and Care Coordination |
| 225 | Radiology: Reminder System for Screening Mammograms | Communication and Care Coordination |
| 243 | Cardiac Rehabilitation Patient Referral from an Outpatient Setting | Communication and Care Coordination |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.5 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------------------|
| 261 | Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness | Communication and Care Coordination |
| 265 | Biopsy Follow-Up | Communication and Care Coordination |
| 288 | Dementia: Caregiver Education and Support | Communication and Care Coordination |
| 293 | Parkinson's Disease: Rehabilitative Therapy Options | Communication and Care Coordination |
| 294 | Parkinson's Disease: Parkinson's Disease Medical and Surgical Treatment Options Reviewed | Communication and Care Coordination |
| 320 | Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients | Communication and Care Coordination |
| 325 | Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions | Communication and Care Coordination |
| 336 | Maternity Care: Post-Partum Follow-Up and Care Coordination | Communication and Care Coordination |
| 350 | Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy | Communication and Care Coordination |
| 359 | Optimizing Patient Exposure to Ionizing Radiation: Utilization of a Standardized Nomenclature for Computed Tomography (CT) Imaging Description | Communication and Care Coordination |
| 362 | Optimizing Patient Exposure to Ionizing Radiation: Computed Tomography (CT) Images Available for Patient Follow-Up and Comparison Purposes | Communication and Care Coordination |
| 363 | Optimizing Patient Exposure to Ionizing Radiation: Search for Prior Computed Tomography (CT) Studies Through a Secure, Authorized, Media-Free, Shared Archive | Communication and Care Coordination |
| 364 | Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-Up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines | Communication and Care Coordination |
| 374 (CMS50v4) | Closing the Referral Loop: Receipt of Specialist Report (eCQM) | Communication and Care Coordination |
| 391 | Follow-Up After Hospitalization for Mental Illness (FUH) | Communication and Care Coordination |
| 395 | Lung Cancer Reporting (Biopsy/Cytology Specimens) | Communication and Care Coordination |
| 396 | Lung Cancer Reporting (Resection Specimens) | Communication and Care Coordination |
| 397 | Melanoma Reporting | Communication and Care Coordination |
| 411 | Depression Remission at Six Months | Communication and Care Coordination |
| 426 | Post-Anesthetic Transfer of Care Measure: Procedure Room to a Post Anesthesia Care Unit (PACU) | Communication and Care Coordination |
| 427 | Post-Anesthetic Transfer of Care: Use of Checklist or Protocol for Direct Transfer of Care from Procedure Room to Intensive Care Unit (ICU) | Communication and Care Coordination |
| AAAAI 6 | Documentation of Clinical Response to Allergen Immunotherapy Within One Year | Communication and Care Coordination |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.5 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------------------|
| AAAAI 18 | Penicillin Allergy: Appropriate Removal or Confirmation | Communication and Care Coordination |
| ABG 8 | Use of Checklist or Protocol for Transfer of Care in Phase I Recovery from Anesthesia Provider to PACU or ICU | Communication and Care Coordination |
| ABG 18 | Preoperative Attestation of documentation of current medications in the medical record | Communication and Care Coordination |
| ACCCath 12* | Stress Testing with Spect MPI Performed and the Results Were Not Available in the Medical Record | Communication and Care Coordination |
| ACCCath 13 | Cardiac Rehabilitation Patient Referral from an Inpatient Setting | Communication and Care Coordination |
| ACCPin 3 | HF: Patient Self Care Education | Communication and Care Coordination |
| ACCPin 6 | CAD: Cardiac Rehabilitation Patient Referral from an Outpatient Setting | Communication and Care Coordination |
| ACRad 15* | Report Turnaround Time: Radiography | Communication and Care Coordination |
| ACRad 16* | Report Turnaround Time: Ultrasound (Excluding Breast US) | Communication and Care Coordination |
| ACRad 17* | Report Turnaround Time: MRI | Communication and Care Coordination |
| ACRad 18* | Report Turnaround Time: CT | Communication and Care Coordination |
| ACRad 19* | Report Turnaround Time: PET | Communication and Care Coordination |
| ACS 6 | Documentation of Glasgow Coma Score at Time of Initial Evaluation | Communication and Care Coordination |
| AJRR 3 | Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy | Communication and Care Coordination |
| ARCO 1 | Neurology: Stroke/Transient Ischemic Attack (TIA): STK-06: Discharged on Statin Medication | Communication and Care Coordination |
| ARCO 2 | Behavioral Health: Screening, Neurology: Delirium: Persistent Indicators of Dementia without a Diagnosis—Short Stay | Communication and Care Coordination |
| ARCO 4 | Musculoskeletal: Median Time to Pain Management for Long Bone Fracture | Communication and Care Coordination |
| ARCO 6 | Musculoskeletal: Improvement in Ambulation/locomotion | Communication and Care Coordination |
| ARCO 9 | Musculoskeletal: Gout: Serum Urate Target | Communication and Care Coordination |
| ASBS 3 | Specimen Orientation for Partial Mastectomy or Excisional Breast Biopsy | Communication and Care Coordination |
| ASBS 11 | Surgeon documentation of clinical stage of breast cancer | Communication and Care Coordination |
| ASNC 4 | Utilization of Standardized Nomenclature and Reporting for Nuclear Cardiology Imaging Studies | Communication and Care Coordination |
| ASNC 12 | SPECT and PET MPI studies signed within two business days | Communication and Care Coordination |
| ASPIRE 14 | Appropriate Intraoperative Handoff Performed | Communication and Care Coordination |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.5 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------------------|
| ASPIRE 15 | Appropriate Postoperative Transition of Care Handoff Performed | Communication and Care Coordination |
| BIVARUS 19 | My Doctor Explained My Final Diagnosis | Communication and Care Coordination |
| BIVARUS 20 | I Understood what the Physician Told Me | Communication and Care Coordination |
| BIVARUS 22 | My Doctor Informed Me of My Treatment Options | Communication and Care Coordination |
| BIVARUS 23 | My Doctor Told Me how Long Things Would Take | Communication and Care Coordination |
| BIVARUS 24 | My Doctor Did Not Seem Rushed While with Me | Communication and Care Coordination |
| BIVARUS 25 | While In My Room, My Doctor Was Focused on Me/My Issues | Communication and Care Coordination |
| BIVARUS 26 | How Likely Are You to Recommend this Physician to Your Family and Friends | Communication and Care Coordination |
| CERORTHO 1 | Modified Functional Outcome Assessment with Additional Sports Medicine and Related Specialty Encounter Codes | Communication and Care Coordination |
| CUHSM 1 | Adherence to Statins | Communication and Care Coordination |
| CUHSM 2 | Proportion of Days Covered (PDC): 5 Rates by Therapeutic Category | Communication and Care Coordination |
| ECPR 11* | Three Day All Cause Return ED Visit Rate – All Patients | Communication and Care Coordination |
| ECPR 12* | Three Day All Cause Return ED Visit Rate – Adults | Communication and Care Coordination |
| ECPR 13* | Three Day All Cause Return ED Visit Rate – Pediatrics | Communication and Care Coordination |
| GIQIC 6 | Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients | Communication and Care Coordination |
| GIQIC 10 | Appropriate Management of Anticoagulation in the Peri-Procedural Period Rate – EGD | Communication and Care Coordination |
| GIQIC 11 | Helicobacter Pylori (H. pylori) Status Rate | Communication and Care Coordination |
| GIQIC 15 | Appropriate Follow-Up Interval of 3 Years Recommended Based on Pathology Findings from Screening Colonoscopy in Average-Risk Patients | Communication and Care Coordination |
| HCPR 6* | 30 Day All Cause Readmission Rate for All Discharged Inpatients | Communication and Care Coordination |
| HCPR 7* | 30 Day All Cause Readmission Rate Following Pneumonia Hospitalization | Communication and Care Coordination |
| HCPR 8* | 30 Day All Cause Readmission Rate Following CHF Hospitalization | Communication and Care Coordination |
| HCPR 9* | 30 Day All Cause Readmission Rate Following COPD Hospitalization | Communication and Care Coordination |
| ICLOPS 17 | Rate of Follow Up Visits Within 7 Days of Discharge (Including Physician Response) | Communication and Care Coordination |
| ICLOPS 34 | Screening for Clinical Depression | Communication and Care Coordination |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.5 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------------------|
| ICLOPS 44 | Patients Treated with an Opioid Who Are Given a Bowel Regimen | Communication and Care Coordination |
| ICLOPS 47 | Patients with Advanced Cancer Screened for Pain at Outpatient Visits | Communication and Care Coordination |
| ICLOPS 48 | Palliative Care: Pain Screening | Communication and Care Coordination |
| ICLOPS 49 | Palliative Care: Pain Assessment | Communication and Care Coordination |
| ICLOPS 50 | Palliative Care: Dyspnea Treatment | Communication and Care Coordination |
| ICLOPS 51 | Palliative Care: Dyspnea Screening | Communication and Care Coordination |
| M2S 3 | Infra-inguinal Bypass for Claudication Patency Assessed at Least 9 Months Following Surgery | Communication and Care Coordination |
| M2S 6 | Peripheral Vascular Intervention patency assessed at least 9 months following infra-inguinal PVI for claudication | Communication and Care Coordination |
| M2S 9 | Imaging-based maximum aortic diameter assessed at least 9 months following Thoracic and Complex EVAR procedures | Communication and Care Coordination |
| M2S 11 | Imaging-based maximum aortic diameter assessed at least 9 months following Endovascular AAA Repair procedures | Communication and Care Coordination |
| MBSAQIP 9 | Percentage of Patients Who Had Complete 30 Day Follow-Up Following Any Metabolic and Bariatric Procedure | Communication and Care Coordination |
| MSN 3* | Report Turnaround Time: Radiography | Communication and Care Coordination |
| MSN 4* | Report Turnaround Time: Ultrasound (Excluding Breast US) | Communication and Care Coordination |
| MSN 5* | Report Turnaround Time: MRI | Communication and Care Coordination |
| MSN 6* | Report Turnaround Time: CT | Communication and Care Coordination |
| MSN 7* | Report Turnaround Time: PET | Communication and Care Coordination |
| MUSIC 6* | Unplanned Hospital Readmission Within 30 Days of Radical Prostatectomy | Communication and Care Coordination |
| NHBPC 10 | Telephone Contact, Virtual, or In-person Visit within 48 Hours of Hospital Discharge of Home-Based Primary Care and Palliative Care Patients | Communication and Care Coordination |
| NHBPC 13 | Interdisciplinary Team Assessment for Home-Based Primary Care and Palliative Care Patients | Communication and Care Coordination |
| NHBPC 16 | Patient Reported Outcome for Home-Based Primary Care and Palliative Care Practices: After Hours Contact Process and Provider Trust (Multiperformance Measure) | Communication and Care Coordination |
| NHQI 24 | Patient Experience: Did the Patient Receive Adequate Instructions | Communication and Care Coordination |
| NJII 2 | Increase Transitional Care Management | Communication and Care Coordination |
| NJII 5 | Increase in billings for chronic care management (CCM) services | Communication and Care Coordination |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.5 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------------------|
| NJII 7 | Increase in patients seen w/in 7 days post hospital discharge | Communication and Care Coordination |
| NJIISMD 4 | Critical test: OR Foreign Body | Communication and Care Coordination |
| NJIISMD 5 | Critical test: Stroke | Communication and Care Coordination |
| NJIISMD 6 | Critical test: Intracranial Hemorrhage | Communication and Care Coordination |
| NJIISMD 7 | Critical test: Aortic Dissection | Communication and Care Coordination |
| NJIISMD 13 | Critical Test Protocol | Communication and Care Coordination |
| NOF 2 | Risk Assessment/Treatment After Fracture | Communication and Care Coordination |
| NOF 3 | Discharge Instructions: Emergency Department | Communication and Care Coordination |
| NPA 14 | Medicine Reconciliation Following Spine Related Procedure | Communication and Care Coordination |
| NPA 15 | Risk-Assessment for Elective Spine Procedure | Communication and Care Coordination |
| NPA 16 | Depression and Anxiety Assessment Prior to Spine-Related Therapies | Communication and Care Coordination |
| NPA 17 | Narcotic Pain Medicine Management Following Elective Spine Procedure | Communication and Care Coordination |
| NPAGSC 6 | Depression and Anxiety Assessment Prior to Spine-Related Therapies | Communication and Care Coordination |
| NPAGSC 7 | Narcotic Pain Medicine Management Prior to and Following Spine Therapy | Communication and Care Coordination |
| OBERD 1 | Back Pain: Mental Health Assessment | Communication and Care Coordination |
| OBERD 2 | Back Pain: Patient Reassessment | Communication and Care Coordination |
| OBERD 4 | Pain Assessment and Follow-Up | Communication and Care Coordination |
| OBERD 6 | Orthopedic Pain: Mental Health Assessment | Communication and Care Coordination |
| OBERD 7 | Orthopedic Pain: Patient Reassessment | Communication and Care Coordination |
| OBERD 9 | Orthopedic Pain: Assessment and Follow-Up | Communication and Care Coordination |
| OBERD 21 | Provider Follow-Up of Patient Post-Acute Self-care | Communication and Care Coordination |
| ONSQIR 12 | Post-Treatment Follow-Up Care | Communication and Care Coordination |
| PInc 1* | 30 Day Readmission for Acute Myocardial Infarction | Communication and Care Coordination |
| PInc 2* | 30 Day Readmission for Heart Failure | Communication and Care Coordination |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.5 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------------------|
| Plnc 3* | 30 Day Readmission for Pneumonia | Communication and Care Coordination |
| Plnc 21 | Thrombolytic Therapy | Communication and Care Coordination |
| Plnc 22 | Discharged on Statin Medication | Communication and Care Coordination |
| Plnc 23 | Stroke Education | Communication and Care Coordination |
| Plnc 31* | Median Time from ED Arrival to ED Departure for Discharged ED Patients | Communication and Care Coordination |
| Plnc 32* | Door to Diagnostic Evaluation by a Qualified Medical Professional | Communication and Care Coordination |
| QUANTUM 38 | Functional Outcome Assessment; Overall Pain control during Episode of care: General, Regional Anesthesia | Communication and Care Coordination |
| QUANTUM 41* | Surgical Case Cancellation | Communication and Care Coordination |
| RPAQIR 5 | Transplant Referral (PCPI Measure #: AKID-13) | Communication and Care Coordination |
| RPAQIR 13 | Rate of Timely Documentation Transmission to Dialysis Unit/Referring Physician | Communication and Care Coordination |
| RPAQIR 18 | Advance Directives Completed | Communication and Care Coordination |
| WCQIC 8* | Hyperbaric Oxygen Therapy: Timeliness of Starting HBOT | Communication and Care Coordination |
| WCQIC 14 | Chronic Wound Care: Timeliness of Referral of Pressure Ulcer Patients to Plastic/Reconstructive Surgeon | Communication and Care Coordination |
| WELL 19 | Adults Access to Preventive/Ambulatory Health Services | Communication and Care Coordination |
| WELL 23 | Follow-Up After Hospitalization for Mental Illness | Communication and Care Coordination |

Source: CMS, "2016 PQRS Measures List," available at: https://www.cms.gov/apps/ama/license.asp?file=/PQRS/downloads/PQRS_2016_Measure_List_01072016.xlsx.

*Lower performance rates on these measures indicate better performance. However, when standardizing measures for inclusion in the domain score, CMS transforms these measures to ensure that for all standardized scores entering the domain score, positive (+) scores indicate better performance and negative (-) scores indicate worse performance.

Exhibit B.6. Communication and Care Coordination Domain Quality Indicators (CMS-Calculated Quality Outcome Measures)

| PQRS Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|-----------------------------------|--|-------------------------------------|
| CMS-1* | Acute Conditions Composite | Communication and Care Coordination |
| - | Bacterial Pneumonia | Communication and Care Coordination |
| - | Urinary Tract Infection | Communication and Care Coordination |
| - | Dehydration | Communication and Care Coordination |
| CMS-2* | Chronic Conditions Composite | Communication and Care Coordination |
| - | Diabetes (Composite of 4 Indicators) | Communication and Care Coordination |
| - | Chronic Obstructive Pulmonary Disease (COPD) or Asthma | Communication and Care Coordination |
| - | Heart Failure | Communication and Care Coordination |
| CMS-3* | All-Cause Hospital Readmission | Communication and Care Coordination |

* Lower performance rates on these measures indicates better performance. However, when standardizing measures for inclusion in the domain score, CMS transforms these measures to ensure that for all standardized scores entering the domain score, positive (+) scores indicate better performance and negative (-) scores indicate worse performance. CMS-1, CMS-2, and CMS-3 are calculated by CMS using claims data.

Exhibit B.7. Efficiency and Cost Reduction Domain Quality Indicators

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------------|
| 65 | Appropriate Treatment for Children with Upper Respiratory Infection (URI) | Efficiency and Cost Reduction |
| 65 (CMS154v4) | Appropriate Treatment for Children with Upper Respiratory Infection (URI) (eCQM) | Efficiency and Cost Reduction |
| 66 | Appropriate Testing for Children with Pharyngitis | Efficiency and Cost Reduction |
| 66 (CMS146v4) | Appropriate Testing for Children with Pharyngitis (eCQM) | Efficiency and Cost Reduction |
| 93 | Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use | Efficiency and Cost Reduction |
| 102 | Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients | Efficiency and Cost Reduction |
| 102 (CMS129v5) | Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (eCQM) | Efficiency and Cost Reduction |
| 116 | Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use | Efficiency and Cost Reduction |
| 146* | Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening | Efficiency and Cost Reduction |
| 224 | Melanoma: Overutilization of Imaging Studies in Melanoma | Efficiency and Cost Reduction |
| 312 (CMS166v5) | Use of Imaging Studies for Low Back Pain (eCQM) | Efficiency and Cost Reduction |
| 322* | Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients | Efficiency and Cost Reduction |
| 323* | Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI) | Efficiency and Cost Reduction |
| 324* | Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients | Efficiency and Cost Reduction |
| 331* | Adult Sinusitis: Antibiotic Prescribed for Acute Sinusitis (Overuse) | Efficiency and Cost Reduction |
| 332 | Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin with or without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use) | Efficiency and Cost Reduction |
| 333* | Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse) | Efficiency and Cost Reduction |
| 334* | Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse) | Efficiency and Cost Reduction |
| 340 | HIV Medical Visit Frequency | Efficiency and Cost Reduction |
| 415 | Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Ages 18 Years and Older | Efficiency and Cost Reduction |
| 416* | Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Ages 2 through 17 Years | Efficiency and Cost Reduction |
| 419 | Overuse of Neuroimaging for Patients with Primary Headache and a Normal Neurological Examination | Efficiency and Cost Reduction |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.7 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------------|
| 439* | Age Appropriate Screening Colonoscopy | Efficiency and Cost Reduction |
| AAAAI 7 | Documented Rationale to Support Long-Term Aeroallergen Immunotherapy Beyond Five Years, as Indicated | Efficiency and Cost Reduction |
| AAN 6 | Headache: Overuse of Barbiturate Containing Medications for Primary Headache Disorders | Efficiency and Cost Reduction |
| AAN 7 | Headache: Overuse of Opioid Containing Medications for Primary Headache Disorders | Efficiency and Cost Reduction |
| ABG 10* | Day of Surgery Case Cancellation Rate | Efficiency and Cost Reduction |
| ABG 19* | Unplanned hospital admission post-op, including 23 hour stay | Efficiency and Cost Reduction |
| ABG 20* | Unplanned transfer ASC to hospital | Efficiency and Cost Reduction |
| ACCCath 9 | PCI Procedures that were Inappropriate for Patients with Acute Coronary Syndrome (ACS) | Efficiency and Cost Reduction |
| ACCCath 10* | Median Length of Stay Post-PCI Procedure for Patients with STEMI and Without CABG or Without Other Major Surgery During Admission | Efficiency and Cost Reduction |
| ACCCath 11* | Median Length of Stay Post-PCI Procedure for Patients with a PCI Indication that Is Not STEMI and Without CABG or Without Other Major Surgery During Admission | Efficiency and Cost Reduction |
| ACEP 19 | Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Ages 18 Years and Older | Efficiency and Cost Reduction |
| ACEP 20* | Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Ages 2 through 17 Years | Efficiency and Cost Reduction |
| ACEP 21* | Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding | Efficiency and Cost Reduction |
| ACEP 22 | Appropriate Emergency Department Utilization of CT for Pulmonary Embolism | Efficiency and Cost Reduction |
| ACRad 2 | CT Colonography Clinically Significant Extracolonic Findings | Efficiency and Cost Reduction |
| ACRad 5* | Screening Mammography Abnormal Interpretation Rate (Recall Rate) | Efficiency and Cost Reduction |
| ACRad 23* | Lung Cancer Screening Abnormal Interpretation Rate | Efficiency and Cost Reduction |
| AHSQC 2* | Unplanned Hospital Readmission or Observation Visit within the 30 Day Postoperative Period | Efficiency and Cost Reduction |
| AHSQC 3* | Emergency Room Visit within the 30 Day Postoperative Period | Efficiency and Cost Reduction |
| AHSQC 8* | Ventral Hernia Repair: Biologic Mesh Prosthesis Use in Low Risk Patients | Efficiency and Cost Reduction |
| AQI 38* | Day of Surgery Case Cancellation Rate - Adult | Efficiency and Cost Reduction |
| AQI 39* | Day of Surgery Case Cancellation Rate - Pediatric | Efficiency and Cost Reduction |
| AQI 40* | Unplanned Transfer or Admission to Hospital | Efficiency and Cost Reduction |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.7 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------------|
| AQUA 3 | Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys | Efficiency and Cost Reduction |
| AQUA 5* | Benign Prostate Hyperplasia: Do not order creatinine lab for patients | Efficiency and Cost Reduction |
| AQUA 6* | Benign Prostate Hyperplasia: Do not order upper-tract imaging | Efficiency and Cost Reduction |
| ARCO 3* | Behavioral Health, Neurology: Antipsychotic Use in Persons with Dementia | Efficiency and Cost Reduction |
| ARCO 5* | Musculoskeletal, Musculoskeletal: Low Back Pain: MRI Lumbar Spine for Low Back Pain | Efficiency and Cost Reduction |
| ASBS 10* | Management of the axilla in breast cancer patients undergoing breast conserving surgery with a positive sentinel node biopsy | Efficiency and Cost Reduction |
| ASNC 1* | Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients | Efficiency and Cost Reduction |
| ASNC 2* | Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI) | Efficiency and Cost Reduction |
| ASNC 3* | Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients | Efficiency and Cost Reduction |
| ASNC 13 | SPECT-MPI studies meeting appropriate use criteria | Efficiency and Cost Reduction |
| ASNC 14 | PET-MPI studies meeting appropriate use criteria | Efficiency and Cost Reduction |
| ASNC 17 | SPECT-MPI studies not Equivocal | Efficiency and Cost Reduction |
| ASNC 18 | PET-MPI studies not Equivocal | Efficiency and Cost Reduction |
| ASPIRE 11 | Colloid Use Limited in Cases with No Indication | Efficiency and Cost Reduction |
| ASPIRE 13 | Transfusion Goal of Hematocrit Less than 30 | Efficiency and Cost Reduction |
| CDR 8 | Appropriate Use of Hyperbaric Oxygen Therapy for Patients with Diabetic Foot Ulcers | Efficiency and Cost Reduction |
| ECPR 39 | Avoid Head CT for Patients with Uncomplicated Syncope | Efficiency and Cost Reduction |
| ECPR 41 | Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding | Efficiency and Cost Reduction |
| EPREOP 11* | Case Delay | Efficiency and Cost Reduction |
| GIQIC 8* | Age Appropriate Screening Colonoscopy | Efficiency and Cost Reduction |
| GIQIC 14 | Repeat Screening Colonoscopy Recommended Within One Year Due to Inadequate Bowel Preparation | Efficiency and Cost Reduction |
| HCPR 2* | Mean Length of Stay for Inpatients – All Patients | Efficiency and Cost Reduction |
| HCPR 3* | Mean Length of Stay for Inpatients – Pneumonia | Efficiency and Cost Reduction |
| HCPR 4* | Mean Length of Stay for Inpatients – CHF | Efficiency and Cost Reduction |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.7 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------------|
| HCPR 5* | Mean Length of Stay for Inpatients – COPD | Efficiency and Cost Reduction |
| ICLOPS 15 | Excess Days Rate and Degree of Excess (Including Physician Response) | Efficiency and Cost Reduction |
| ICLOPS 16 | Re-Admission Rate Within 30 Days (Including Physician Response) | Efficiency and Cost Reduction |
| ICLOPS 23 | Physician Response to ACSC Admissions: Diabetes Composite | Efficiency and Cost Reduction |
| ICLOPS 24 | Physician Response to ACSC Admissions: Cardiopulmonary Composite | Efficiency and Cost Reduction |
| ICLOPS 25 | Physician Response to ACSC Admissions: Acute Conditions Composite | Efficiency and Cost Reduction |
| ICLOPS 30 | Physician Response for Reoperation or Complication Following a Procedure | Efficiency and Cost Reduction |
| ICLOPS 32* | Patient seen in Emergency Department within 7 days after discharge from a hospital | Efficiency and Cost Reduction |
| ICLOPS 33* | Patient seen in Emergency Department within 90 days after discharge from a hospital | Efficiency and Cost Reduction |
| ICLOPS 35 | Medical Visit/ Telemedicine Contact Frequency: Diabetes | Efficiency and Cost Reduction |
| ICLOPS 36 | Medical Visit/ Telemedicine Contact Frequency: Heart Failure | Efficiency and Cost Reduction |
| ICLOPS 37 | Medical Visit/ Telemedicine Contact Frequency: Chronic Obstructive Pulmonary Disease (COPD) | Efficiency and Cost Reduction |
| ICLOPS 38 | Medical Visit/ Telemedicine Contact Frequency: Coronary Artery Disease (CAD) | Efficiency and Cost Reduction |
| MBS 7* | Extended Length of Stay (LOS) | Efficiency and Cost Reduction |
| MBS 8* | Unplanned Emergency Room (ER) Visits | Efficiency and Cost Reduction |
| MBS 9* | Unplanned Hospital Readmission Within 30 Days of Principal Procedure | Efficiency and Cost Reduction |
| MBSAQIP 2* | Risk standardized rate of patients who experienced an unplanned readmission within 30 days following primary LRYGB or LSG operation | Efficiency and Cost Reduction |
| MBSAQIP 3* | Risk standardized rate of patients who experienced a reoperation within 30 days following a primary LRYGB or LSG operation | Efficiency and Cost Reduction |
| MIRAMED 8 | Case Cancellation Rate | Efficiency and Cost Reduction |
| MIRAMED 9 | Case Delay Rate | Efficiency and Cost Reduction |
| MMA 2 | Appropriate Use of Advanced Imaging by Ordering Provider | Efficiency and Cost Reduction |
| MMA 3 | Glucocorticoid Use for Symptom Management and Motor Neuron Sparing while Awaiting Advanced Imaging | Efficiency and Cost Reduction |
| MMA 4 | Manipulative Medicine Treatment Adjustment Due to Clinical Improvement | Efficiency and Cost Reduction |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.7 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|---|-------------------------------|
| MMA 5 | Inappropriate Use of Urgent/Emergent Care in Chronic Pain | Efficiency and Cost Reduction |
| MOA 2 | Appropriate Use of Advanced Imaging by Ordering Provider | Efficiency and Cost Reduction |
| MOA 3 | Glucocorticoid Use for Symptom Management and Motor Neuron Sparing while Awaiting Advanced Imaging | Efficiency and Cost Reduction |
| MOA 4 | Manipulative Medicine Treatment Adjustment Due to Clinical Improvement | Efficiency and Cost Reduction |
| MOA 5 | Inappropriate Use of Urgent/Emergent Care in Chronic Pain | Efficiency and Cost Reduction |
| MSN 1 | CT Colonography Clinically Significant Extracolonic Findings | Efficiency and Cost Reduction |
| MSN 2 | Screening Mammography Abnormal Interpretation Rate (Recall Rate) | Efficiency and Cost Reduction |
| MUSIC 3 | Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients | Efficiency and Cost Reduction |
| NHBPC 11 | Medication Reconciliation within 2 Weeks of Hospital Discharge of Home-Based Primary Care and Palliative Care Patients | Efficiency and Cost Reduction |
| NHCR 4 | Repeat Colonoscopy Recommended Due to Poor Bowel Preparation | Efficiency and Cost Reduction |
| NHCR 6* | Age Inappropriate Screening Colonoscopy | Efficiency and Cost Reduction |
| NHQI 30* | Day of Surgery Case Cancellation Rate - Adult | Efficiency and Cost Reduction |
| NHQI 31* | Day of Surgery Case Cancellation Rate - Pediatric | Efficiency and Cost Reduction |
| NHQI 32* | Unplanned Transfer or Admission to Hospital | Efficiency and Cost Reduction |
| NJII 1* | Potentially Preventable ER Visits | Efficiency and Cost Reduction |
| OBERD 5* | Back Pain: Surgical Timing | Efficiency and Cost Reduction |
| Plnc 33* | Risk-Adjusted Average Length of Inpatient Hospital Stay for Acute Myocardial Infarction (AMI) | Efficiency and Cost Reduction |
| Plnc 34* | Risk-Adjusted Average Length of Inpatient Hospital Stay for Heart Failure (HF) | Efficiency and Cost Reduction |
| Plnc 35* | Risk-Adjusted Average Length of Inpatient Hospital Stay for Pneumonia (PN) | Efficiency and Cost Reduction |
| PPRNET 24 | Appropriate Treatment for Adults with Upper Respiratory Infection | Efficiency and Cost Reduction |
| PPRNET 25 | Appropriate Antibiotic Use | Efficiency and Cost Reduction |
| QOPI 4 | Performance Status Documented Prior to Initiating Chemotherapy | Efficiency and Cost Reduction |
| QOPI 5* | Chemotherapy Administered to Patients with Metastatic Solid Tumors and Performance Status of 3, 4, or Undocumented (Lower Score – Better) | Efficiency and Cost Reduction |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.7 (continued)

| PQRS or QCDR Number (GPRO/eCQM Number) | Measure Name | Quality Domain |
|---|--|-------------------------------|
| QOPI 15* | GCSF Administered to Patients Who Received Chemotherapy for Metastatic Cancer (Lower Score – Better) | Efficiency and Cost Reduction |
| STS 1* | Prolonged Length of Stay Following CABG | Efficiency and Cost Reduction |
| STS 2 | Short Length of Stay Following CABG | Efficiency and Cost Reduction |
| STS 3* | Prolonged Length of Stay Following CABG and Valve Surgery | Efficiency and Cost Reduction |
| STS 4 | Short Length of Stay Following CABG and Valve Surgery | Efficiency and Cost Reduction |
| STS 5* | Prolonged Length of Stay Following Valve Surgery | Efficiency and Cost Reduction |
| STS 6 | Short Length of Stay Following Valve Surgery | Efficiency and Cost Reduction |
| WELL 17 | Use of Imaging Studies for Low Back Pain | Efficiency and Cost Reduction |

Source: CMS, “2016 PQRS Measures List,” available at: https://www.cms.gov/apps/ama/license.asp?file=/PQRS/downloads/PQRS_2016_Measure_List_01072016.xlsx.

*Lower performance rates on these measures indicate better performance. However, the domain score for this domain has been calculated such that positive (+) scores indicate better performance and negative (-) scores indicate worse performance.

APPENDIX C

APPROACH TO PQRS MEASURES AND NON-PQRS QCDR MEASURES WITH MULTIPLE PERFORMANCE RATES OR TECHNICAL ISSUES

In 2016, several PQRS measures and non-PQRS QCDR measures included in the Annual QRUR have multiple sub-measures, where one sub-measure may or may not represent a single overall performance rate. Exhibit C.1 displays measures for which a single sub-measure represents the overall rate. Exhibit C.2 displays measures for which no sub-measure represents the overall performance rate and describes CMS' approach to measures with technical issues.

Exhibit C.1. Approach to PQRS Measures and non-PQRS QCDR Measures with Multiple Performance Rates

| PQRS Number (GPRO/eCQM Number) or Non-PQRS QCDR Measure Number | Measure Name | Reporting Method(s) Affected | Approach |
|--|---|---|--|
| 7 (CMS145v4) | Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVSD) (LVEF < 40%) | EHR, Registry, QCDR (using EHR or Registry measure specifications) | Overall rate is computed as the case-weighted mean of each sub-measure if reported through EHR or Registry, or through QCDR using EHR or Registry specifications. |
| 9 (CMS128v4) | Anti-Depressant Medication Management | EHR, QCDR (using EHR measure specifications) | Overall rate is computed as the simple mean of each sub-measure if reported through EHR or through QCDR using EHR specifications. |
| 46 | Medication Reconciliation Post-Discharge | Claims, Registry, QCDR (using Claims and Registry measure specifications) | The third sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through Claims or Registry, or through QCDR using Claims or Registry specifications. |
| 53 | Asthma: Pharmacologic Therapy for Persistent Asthma – Ambulatory Care Setting | Registry, QCDR (using Registry measure specifications) | The third sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through Registry or through QCDR using Registry specifications. |
| 122 | Adult Kidney Disease: Blood Pressure Management | Registry, QCDR (using Registry measure specifications) | The third sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through Registry or through QCDR using Registry specifications. |
| 128 (CMS69v4) | Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan | EHR, QCDR (using EHR measure specifications) | Overall rate is computed as the case-weighted mean of each sub-measure if reported through EHR or through QCDR using EHR specifications. |
| 160 (CMS52v4) | HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis | EHR, QCDR (using EHR measure specifications) | Overall rate is computed as the case-weighted mean of each sub-measure if reported through EHR or through QCDR using EHR specifications. |
| 238 (CMS156v4) | Use of High-Risk Medications in the Elderly | EHR, Registry, QCDR (using EHR or Registry measure specifications) | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through EHR or Registry, or through QCDR using EHR or Registry specifications. |

Exhibit C.1 (continued)

| PQRS Number (GPRO/eCQM Number) or Non-PQRS QCDR Measure Number | Measure Name | Reporting Method(s) Affected | Approach |
|--|---|--|--|
| 239 (CMS155v4) | Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents | EHR, QCDR (using EHR measure specifications) | Overall rate is computed as the simple mean of each sub-measure if reported through EHR or through QCDR using EHR specifications. |
| 241 (CMS182v5) | Ischemic Vascular Disease (IVD): Complete Lipid Profile and LDL-C Control (< 100 mg/dL) | EHR, QCDR (using EHR measure specifications) | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through EHR, or through QCDR using EHR specifications. |
| 305 (CMS137v4) | Initiation and Engagement of Alcohol and Other Drug Dependence Treatment | EHR, QCDR (using EHR measure specifications) | Overall rate is computed as the simple mean of each sub-measure if reported through EHR or through QCDR using EHR specifications. |
| 316a (CMS61v5) | Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL-C) Test Performed | EHR, QCDR (using EHR measure specifications) | Overall rate is computed as the case-weighted mean of each sub-measure if reported through EHR or through QCDR using EHR specifications. |
| 316b (CMS64v5) | Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C) | EHR, QCDR (using EHR measure specifications) | Overall rate is computed as the case-weighted mean of each sub-measure if reported through EHR or through QCDR using EHR specifications. |
| 348 | HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate | Registry, QCDR (using Registry measure specifications) | Overall rate is computed as the case-weighted mean of each sub-measure if reported through Registry or through QCDR using Registry specifications. |
| 366 (CMS136v5) | ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication | EHR, QCDR (using EHR measure specifications) | Overall rate is computed as the simple mean of each sub-measure if reported through EHR or through QCDR using EHR specifications. |
| 371 (CMS160v4) | Depression Utilization of the PHQ-9 Tool | EHR, QCDR (using EHR measure specifications) | Overall rate is computed as the case-weighted mean of each sub-measure if reported through EHR or through QCDR using EHR specifications. |
| 391 | Follow-up After Hospitalization for Mental Illness (FUH) | Registry, QCDR (using Registry measure specifications) | The second sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through Registry or through QCDR using Registry specifications. |
| 392 | HRS-12: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation | Registry, QCDR (using Registry measure specifications) | The fifth sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through Registry or through QCDR using Registry specifications. |

Exhibit C.1 (continued)

| PQRS Number (GPRO/eCQM Number) or Non-PQRS QCDR Measure Number | Measure Name | Reporting Method(s) Affected | Approach |
|--|---|--|---|
| 394 | Immunizations for Adolescents | Registry, QCDR (using Registry measure specifications) | The third sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported via Registry or via QCDR using Registry specifications. |
| 398 | Optimal Asthma Control | Registry, QCDR (using Registry measure specifications) | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through Registry or through QCDR using Registry specifications. |
| 399 | Post-Procedural Optimal Medical Therapy Composite (Percutaneous Coronary Intervention) | Registry, QCDR (using Registry measure specifications) | The first sub-measure, which measure specifications define as the overall rate is used as the overall rate if reported through Registry or through QCDR using Registry specifications. |
| ACCCath 3 | Vascular access site injury requiring treatment or major bleeding post PCI in patients without CABG or other major surgeries during admission | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACCCath 6 | ACE-I or ARB prescribed at discharge for patients with an ejection fraction < 40% who had a PCI during the episode of care | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACCCath 8 | Percutaneous Coronary Intervention (PCI): Post-procedural Optimal Medical Therapy | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 32 | ED Length of Stay (LOS) for Adult Patients Discharged from All EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 33 | ED Length of Stay (LOS) for Adult Patients Discharged from Supercenter EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 34 | ED Length of Stay (LOS) for Adult Patients Discharged from Very High Volume EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 35 | ED Length of Stay (LOS) for Adult Patients Discharged from High Volume EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 36 | ED Length of Stay (LOS) for Adult Patients Discharged from Average Volume EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |

Exhibit C.1 (continued)

| PQRS Number (GPRO/eCQM Number) or Non-PQRS QCDR Measure Number | Measure Name | Reporting Method(s) Affected | Approach |
|--|---|------------------------------|---|
| ACEP 37 | ED Length of Stay (LOS) for Adult Patients Discharged from Moderate Volume EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 38 | ED Length of Stay (LOS) for Adult Patients Discharged from Low Volume EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported via QCDR. |
| ACEP 39 | ED Length of Stay (LOS) for Adult Patients Discharged from Freestanding EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 40 | ED Length of Stay for Pediatric Patients Discharged from All EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 41 | ED Length of Stay for Pediatric Patients Discharged from Supercenter EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 42 | ED Length of Stay (LOS) for Pediatric Patients Discharged from Very High Volume EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 43 | ED Length of Stay for Pediatric Patients Discharged from High Volume EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 44 | ED Length of Stay (LOS) for Pediatric Patients Discharged from Average Volume EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 45 | ED Length of Stay (LOS) for Pediatric Patients Discharged from Moderate Volume EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 46 | ED Length of Stay (LOS) for Pediatric Patients Discharged from Low Volume EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ACEP 47 | ED Length of Stay (LOS) for Pediatric Patients Discharged from Freestanding EDs | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |

Exhibit C.1 (continued)

| PQRS Number (GPRO/eCQM Number) or Non-PQRS QCDR Measure Number | Measure Name | Reporting Method(s) Affected | Approach |
|--|---|------------------------------|--|
| AHSQC 6 | Ventral Hernia Repair with Myofascial Release Surgical Site Occurrence Requiring Procedural Intervention within the 30 Day Postoperative Period | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| AQUA 1 | Prostate Cancer: Documentation of PSA, Gleason score and clinical stage for risk stratification | QCDR | The fourth sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| CUHSM 2 | Proportion of Days Covered (PDC): 5 Rates by Therapeutic Category | QCDR | The sixth sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ICLOPS 15 | Excess Days Rate and Degree of Excess (Including Physician Response) | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ICLOPS 16 | Re-admission Rate Within 30 Days (Including Physician Response) | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| ICLOPS 17 | Rate of Follow Up Visits Within 7 Days of Discharge (Including Physician Response) | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| MBS 1 | Medical Complications | QCDR | The fifth sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| MBS 2 | Surgical Site Complications | QCDR | The fifth sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| MBS 3 | Serious Complications | QCDR | The twenty-third sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NHBPC 7 | New Cognitive Decline in Home-Based Primary Care and Palliative Care Patients: Medication List Reviewed and Offending Medications Discontinued | QCDR | The second sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |

Exhibit C.1 (continued)

| PQRS Number (GPRO/eCQM Number) or Non-PQRS QCDR Measure Number | Measure Name | Reporting Method(s) Affected | Approach |
|--|---|------------------------------|---|
| NHBPC 15 | Functional Assessment (Basic Activities of Daily Living [BADL] and Instrumental Activities of Daily Living [IADL]) for Home-Based Primary Care and Palliative Care Patients | QCDR | The third sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NHBPC 16 | Patient Reported Outcome for Home-Based Primary Care and Palliative Care Practices: After Hours Contact Process and Provider Trust (Multiperformance Measure) | QCDR | The third sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 1 | Spine Pain Assessment | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 2 | Extremity (Radicular) Pain Assessment | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 3 | Functional Outcome Assessment for Spine Intervention | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 4 | Quality-of-Life Assessment for Spine Intervention | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 5 | Patient Satisfaction with Spine Care | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 6 | Spine-related procedure site infection | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 7 | Complication Following Spine-Related Procedure | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 8 | Hospital Mortality Following Spine Procedure | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |

Exhibit C.1 (continued)

| PQRS Number (GPRO/eCQM Number) or Non-PQRS QCDR Measure Number | Measure Name | Reporting Method(s) Affected | Approach |
|--|---|------------------------------|---|
| NPA 9 | Referral for Post-Acute Care Rehabilitation | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 10 | Unplanned Reoperation Following Spine Procedure Within the 30 Day Post-Operative Period | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 11 | Unplanned Readmission Following Spine Procedure Within the 30 Day Post-Operative Period | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 12 | Selection of Prophylactic Antibiotic Prior to Spine Procedure | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 13 | Discontinuation of Prophylactic Parenteral Antibiotics Following Spine Procedure | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 14 | Medicine Reconciliation Following Spine Related Procedure | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 15 | Risk Assessment for Elective Spine Procedure | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 16 | Depression and Anxiety Assessment Prior to Spine-Related Therapies | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 17 | Narcotic Pain Medicine Management Following Elective Spine Procedure | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 18 | Smoking Assessment and Cessation Coincident with Spine Related Therapies | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 19 | Body Mass Assessment and Follow-Up Coincident with Spine Related Therapies | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| NPA 20 | Unhealthy Alcohol Use Assessment Coincident With Spine Care | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |

Exhibit C.1 (continued)

| PQRS Number (GPRO/eCQM Number) or Non-PQRS QCDR Measure Number | Measure Name | Reporting Method(s) Affected | Approach |
|--|---|------------------------------|--|
| NPA 21 | Participation in a Systematic National Database for Spine Care Interventions | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| OBERD 2 | Back Pain: Patient Reassessment | QCDR | The third sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| OBERD 7 | Orthopedic Pain: Patient Reassessment | QCDR | The third sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| OBERD 13 | Orthopedic Functional and Pain Level Outcomes | QCDR | The sixth sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| OBERD 16 | Orthopedic 3-Month Surgery Success Rate | QCDR | The second sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| OBERD 17 | CG-CAHPS Patient Rating | QCDR | The eighth sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| QUANTUM 40 | Surgical Fire | QCDR | The third sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| STS 2 | Short Length of Stay Following CABG | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| STS 4 | Short Length of Stay Following CABG and Valve Surgery | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| STS 6 | Short Length of Stay Following Valve Surgery | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| STS 7 | Patient Centered Surgical Risk Assessment and Communication using the STS Risk Calculator | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| WELL 15 | Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |

Exhibit C.1 (continued)

| PQRS Number (GPRO/eCQM Number) or Non-PQRS QCDR Measure Number | Measure Name | Reporting Method(s) Affected | Approach |
|---|--|------------------------------------|--|
| WELL 19 | Adults' Access to Preventive/Ambulatory Health Services | QCDR | The fourth sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| WELL 22 | Children and Adolescents' Access to Primary Care Practitioners | QCDR | The fifth sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |
| WELL 23 | Follow-Up After Hospitalization for Mental Illness | QCDR | The first sub-measure, which measure specifications define as the overall rate, is used as the overall rate if reported through QCDR. |

Exhibit C.2. Approach to PQRS Measures and non-PQRS QCDR Measures with Technical Issues

| PQRS Number (GPRO/eCQM Number) or Non-PQRS QCDR Measure Number | Measure Name | Reporting Method(s) Affected | Approach |
|--|---|------------------------------|---|
| 112 (CMS125v4) (GPRO PREV-5) | Breast Cancer Screening | All reporting methods | Submissions made through all reporting mechanisms are excluded from the QRUR and Value Modifier because of discrepancies in performance rates due to the use of 3D mammography. |
| 370 (GPRO MH-1) (CMS159v4) | Depression Remission at Twelve Months | GPRO Web Interface | Submissions made through the GPRO Web Interface are excluded from the QRUR and Value Modifier because many TINs do not use the PHQ-9 screening tool required for this measure. |
| AQUA 10 | Prostate Cancer: Patient report of Urinary function after treatment | QCDR | Submissions made through QCDR are excluded from the QRUR and Value Modifier because the measure was incorrectly submitted as a continuous measure, instead of a proportional measure. |
| AQUA 11 | Prostate Cancer: Patient report of Sexual function after treatment | QCDR | Submissions made through QCDR are excluded from the QRUR and Value Modifier because the measure was incorrectly submitted as a continuous measure, instead of a proportional measure. |
| ASPS 5 | Breast Reconstruction: Return to OR | QCDR | Submissions made through QCDR are excluded from the QRUR and Value Modifier because the measure was incorrectly submitted as a continuous measure, instead of a proportional measure. |
| ASPS 6 | QRUR Display: Submissions made via QCDR will not be displayed in the QRUR. | | Submissions made through QCDR are excluded from the QRUR and Value Modifier because the measure was incorrectly submitted as a continuous measure, instead of a proportional measure. |
| CDR 2 | Diabetic Foot Ulcer (DFU) Healing or Closure | QCDR | Submissions made through QCDR are excluded from the QRUR and Value Modifier because the measure was incorrectly submitted as a continuous measure, instead of a proportional measure. |
| CDR 6 | Venous Leg Ulcer outcome measure: Healing or Closure | QCDR | Submissions made through QCDR are excluded from the QRUR and Value Modifier because the measure was incorrectly submitted as a continuous measure, instead of a proportional measure. |
| USWR 15 | Healing or Closure of Wagner Grade 3, 4, or 5 Diabetic Foot Ulcers (DFUs) Treated with HBOT | QCDR | Submissions made through QCDR are excluded from the QRUR and Value Modifier because the measure was incorrectly submitted as a continuous measure, instead of a proportional measure. |

APPENDIX D

METHOD FOR DEFINING SERVICE CATEGORIES

For the purposes of reporting cost breakdowns by category of service for the per capita cost measures (shown in Tables 3A, 3B, 4A, 4B, 4C, and 4D of the Annual QRUR), each Medicare claim for an attributed beneficiary is categorized into one of the service categories displayed in Exhibit D.1. Claim costs are included in a given service category based on the claim type, Berenson-Eggers Type of Service (BETOS) code, place of service, type of bill, type of service, HCPCS modifier, and/or provider type.

For the purposes of reporting cost breakdowns by category of service for the MSPB measure (shown in Tables 5C and 5D of the Annual QRUR), each claim associated with an MSPB episode is categorized into one of the service categories displayed in Exhibit D.2. Episode costs are included in a given service category based on the claim type, BETOS code, claim criteria, and provider type.

CMS assigns a BETOS code to each HCPCS code that might appear on a carrier or outpatient hospital claim. CMS developed the BETOS coding system primarily for analyzing the growth in Medicare expenditures. The coding system covers all HCPCS codes, assigns a HCPCS code to one, and only one, BETOS code, consists of readily understood clinical categories (as opposed to statistical or financial categories), consists of categories that permit objective assignment, is stable over time, and is relatively immune to minor changes in technology or practice patterns. Exhibit D.3 lists BETOS code descriptions.

Exhibit D.1. Categorization Codes for Type of Service Categories for Per Capita Cost Measures

| Category | Claim Type(s) | Criteria for Including Claim (Line Item) in Category | | |
|--|-----------------------------------|--|--|--|
| | | Claim Criterion | Place of Service Criterion | Specialty Criterion |
| Outpatient E&M Services, Procedures, and Therapy (Excluding Emergency Department) | Sum of 1a, 1b, 2a, 2b, 2c, 2d, 2e | | | |
| 1a. E&M Services Billed by Eligible Professionals – Your TIN | Carrier claim line items | All Carrier line items with BETOS in {M1-M6}, HCPCS modifier* not equal to GN, GO, or GP (outpatient therapy), and Type of Service not equal to F (Ambulatory Surgical Center) | Place of Service not equal to 23 (emergency department), 21 (inpatient hospital), or 51 (inpatient psychiatric facility) | CMS specialty code NOT in {31, 45, 47, 49, 51–61, 63, 69, 73–75, 87–88, 95–96, A0–A8, B1–B5, C1, C2, or C4} AND limited to Carrier line items provided by a rendering NPI associated with the TIN (“Your TIN”) |

Exhibit D.1 (continued)

| Category | Claim Type(s) | Criteria for Including Claim (Line Item) in Category | | |
|---|--------------------------|--|--|---|
| | | Claim Criterion | Place of Service Criterion | Specialty Criterion |
| 1b. E&M Services Billed by Eligible Professionals – Other TINs | Carrier claim line items | All Carrier line items with BETOS in {M1-M6}, HCPCS modifier* not equal to GN, GO, or GP (outpatient therapy), and Type of Service not equal to F (Ambulatory Surgical Center) | Place of Service not equal to 23 (emergency room), 21 (inpatient hospital), or 51 (inpatient psychiatric facility) | CMS specialty code NOT in {31, 45, 47, 49, 51–61, 63, 69, 73–75, 87–88, 95–96, A0–A8, B1–B5, C1, C2, or C4} AND limited to Carrier line items provided by a rendering NPI NOT associated with the TIN (“Other TINs”) |
| 2a. Major Procedures Billed by Eligible Professionals – Your TIN | Carrier claim line items | All Carrier line items with BETOS in {P1-P3, P7}, HCPCS modifier* not in GN, GO, or GP (outpatient therapy), and Type of Service not equal to F (Ambulatory Surgical Center) | Place of Service not equal to 23 (emergency department), 21 (inpatient hospital), or 51 (inpatient psychiatric facility) | CMS specialty code NOT in {31, 45, 47, 49, 51–61, 63, 69, 73–75, 87–88, 95–96, A0–A8, B1–B5, C1, C2, or C4} AND limited to Carrier line items provided by a rendering NPI associated with the TIN (“Your TIN”) |
| 2b. Major Procedures Billed by Eligible Professionals – Other TINs | Carrier claim line items | All Carrier line items with BETOS in {P1-P3, P7}, HCPCS modifier* not in GN, GO, or GP (outpatient therapy), and Type of Service not equal to F (Ambulatory Surgical Center) | Place of Service not equal to 23 (emergency department), 21 (inpatient hospital), or 51 (inpatient psychiatric facility) | CMS specialty code NOT in {31, 45, 47, 49, 51–61, 63, 69, 73–75, 87–88, 95–96, A0–A8, B1–B5, C1, C2, or C4} AND limited to carrier line items provided by a rendering NPI NOT associated with the TIN (“Other TINs”) |
| 2c. Ambulatory/ Minor Procedures Billed by Eligible Professionals – Your TIN | Carrier claim line items | All carrier line items with BETOS in {P4-P6, P8}, HCPCS modifier* not equal to GN, GO, or GP (outpatient therapy), and Type of Service not equal to F (Ambulatory Surgical Center) | Place of Service not equal to 23 (emergency department), 21 (inpatient hospital), or 51 (inpatient psychiatric facility) | CMS specialty code NOT in {31, 45, 47, 49, 51–61, 63, 69, 73–75, 87–88, 95–96, A0–A8, B1–B5, C1, C2, or C4} AND limited to carrier line items provided by a rendering NPI associated with the TIN (“Your TIN”) |

Exhibit D.1 (continued)

| Category | Claim Type(s) | Criteria for Including Claim (Line Item) in Category | | |
|--|---|---|---|---|
| | | Claim Criterion | Place of Service Criterion | Specialty Criterion |
| 2d. Ambulatory/ Minor Procedures Billed by Eligible Professionals –Other TINs | Carrier claim line items | All carrier line items with BETOS in {P4-P6, P8}, HCPCS modifier* not equal to GN, GO, or GP (outpatient therapy), and Type of Service not equal to F (Ambulatory Surgical Center) | Place of Service not equal to 23 (emergency department), 21 (inpatient hospital), or 51 (inpatient psychiatric facility) | CMS specialty code NOT in {31, 45, 47, 49, 51–61, 63, 69, 73–75, 87–88, 95–96, A0–A8, B1–B5, C1, C2, or C4} AND limited to carrier line items provided by a rendering NPI NOT associated with the TIN (“Other TINs”) |
| 2e. Outpatient Physical, Occupational, or Speech and Language Pathology Therapy | Outpatient claim line items plus carrier claim line items | All claims/line items with HCPCS modifier* equal to GN, GO, or GP, BETOS code not in {P0, P9, O1A, O1D, O1E, or D1G}, and, for outpatient claims, Type of Bill not equal to 22x or 23x (SNF), 33x or 34x (Home Health), or 72x (dialysis) | For carrier claim line items, Place of Service not equal to 23 (emergency department), 21 (inpatient hospital), or 51 (inpatient psychiatric facility); For outpatient claims, Revenue Center line code is NOT in {0450-0459, 0981} (emergency department) | Not applicable |
| 3. Ancillary Services | Sum of 3a, 3b, 3c | | | |
| 3a. Ancillary services: Laboratory, Pathology, and Other Tests | Outpatient claim line items plus carrier claim line items | All BETOS codes in {T1, T2}; HCPCS modifier* not equal to GN, GO, or GP; and for outpatient Claims, Type of Bill not equal to 22x or 23x (SNF), 33x or 34x (Home Health), or 72x (dialysis) | For carrier claim line items, Place of Service not equal to 23 (emergency department), 21 (inpatient hospital), or 51 (inpatient psychiatric facility); For outpatient claims, Revenue Center line code is NOT in {0450-0459, 0981} | Not applicable |
| 3b. Ancillary services: Imaging Services | Outpatient claim line items plus carrier claim line items | All BETOS codes in {I1-I4}; HCPCS modifier* not equal to GN, GO, or GP; and for outpatient Claims, Type of Bill not equal to 22x or 23x (SNF), 33x or 34x (Home Health), or 72x (dialysis) | For carrier claim line items, Place of Service not equal to 23 (emergency department), 21 (inpatient hospital), or 51 (inpatient psychiatric facility); For outpatient claims, Revenue Center line code is NOT in {0450-0459, 0981} | Not applicable |

Exhibit D.1 (continued)

| Category | Claim Type(s) | Criteria for Including Claim (Line Item) in Category | | |
|--|---|---|--|--|
| | | Claim Criterion | Place of Service Criterion | Specialty Criterion |
| 3c. Ancillary services: Durable Medical Equipment and Supplies | Durable medical equipment claims | All DME claims with BETOS code not in {O1D, O1E, D1G} | Not applicable | Not applicable |
| 4. Hospital Inpatient Services | Sum of 4a, 4b, 4c | | | |
| 4a. Hospital Inpatient Services: Inpatient Hospital Facility Services | Inpatient claims | Inpatient short-stay and psychiatric inpatient claims | Provider (CCN) number ends in {0001-0899}, {1300-1399}, {4000-4499} or its third position is in {M, S} | Not applicable |
| 4b. Hospital Inpatient Services: Eligible Professional Services during Hospitalization—Your TIN | Carrier claim line items | All carrier line items with BETOS not in {P0, P9, O1A, O1D, O1E, or D1G} | Place of Service equal to 21 (inpatient hospital) or 51 (inpatient psychiatric facility) | CMS specialty code NOT in {31, 45, 47, 49, 51-61, 63, 69, 73-75, 87-88, 95-96, A0-A8, B1-B5, C1, C2, or C4} AND limited to carrier line items provided by a rendering NPI associated with the TIN ("Your TIN") |
| 4c. Hospital Inpatient Services: Eligible Professional Services during Hospitalization—Other TINs | Carrier claim line items | All carrier line items with BETOS not in {P0, P9, O1A, O1D, O1E, or D1G} | Place of Service equal to 21 (inpatient hospital) or 51 (inpatient psychiatric facility) | CMS specialty code NOT in {31, 45, 47, 49, 51-61, 63, 69, 73-75, 87-88, 95-96, A0-A8, B1-B5, C1, C2, or C4} AND limited to carrier line items provided by a rendering NPI NOT associated with the TIN ("Other TINs") |
| 5. Emergency Services That Did Not Result in a Hospital Admission | Sum of 5a, 5b, 5c, 5d | | | |
| 5a. Emergency Services: Emergency E&M Services | Outpatient claim line items plus carrier claim line items | All BETOS codes in {M1-M6} and, for outpatient claims, Type of Bill not equal to 72x (dialysis) | For carrier claim line items, Place of Service equal to 23; For outpatient claims, Revenue Center line code in {0450-0459, 0981} | None for outpatient claims;** for carrier claims: CMS specialty code NOT in {31, 45, 47, 49, 51-61, 63, 69, 73-75, 87-88, 95-96, A0-A8, B1-B5, C1, C2, or C4} |

Exhibit D.1 (continued)

| Category | Claim Type(s) | Criteria for Including Claim (Line Item) in Category | | |
|---|---|---|---|---|
| | | Claim Criterion | Place of Service Criterion | Specialty Criterion |
| 5b. Emergency Services: Procedures | Outpatient claim line items plus carrier claim line items | All BETOS codes in {P1-P8} and, for outpatient claims, Type of Bill not equal to 72x (dialysis) | For carrier claim line items, Place of Service equal to 23; For outpatient claims, Revenue Center line code in {0450-0459, 0981} | None for outpatient claims;** for carrier claims: CMS specialty code NOT in {31, 45, 47, 49, 51-61, 63, 69, 73-75, 87-88, 95-96, A0-A8, B1-B5, C1, C2, or C4} |
| 5c. Emergency Services: Laboratory, Pathology, and Other Tests | Outpatient claim line items plus carrier claim line items | All BETOS codes in {T1, T2} and, for outpatient claims, Type of Bill not equal to 72x (dialysis) | For carrier claim line items, Place of Service equal to 23; For outpatient claims, Revenue Center line code in {0450-0459, 0981} | Not applicable |
| 5d. Emergency Services: Imaging Services | Outpatient claim line items plus carrier claim line items | All BETOS codes in {I1-I4} and, for outpatient claims, type of bill not equal to 72x (dialysis) | For carrier claim line items, Place of Service equal to 23; For outpatient claims, Revenue Center line code in {0450-0459, 0981} | Not applicable |
| 6. Post-Acute Services | Sum of 6a, 6b, 6c | | | |
| 6a. Post-Acute Services: Home Health | Home health claims and outpatient claim line items | All home health claims and all outpatient claims with Type of Bill equal to 33x or 34x and BETOS code not in {P0, P9, O1A, O1D, O1E, D1G} | None for Home Health claims; For outpatient claims, Revenue Center line code is NOT in {0450-0459, 0981} (emergency department) | Not applicable |
| 6b. Post-Acute Services: Skilled Nursing Facilities | SNF claims and outpatient claim line items | All SNF claims and all outpatient claims with Type of Bill equal to 22x or 23x and BETOS code not in {P0, P9, O1A, O1D, O1E, D1G} | None for SNF claims; For outpatient claims, Revenue Center line code is NOT in {0450-0459, 0981} (emergency department) | Not applicable |
| 6c. Post-Acute services: Inpatient Rehabilitation or Long-Term Care Hospital | Inpatient claims | Not applicable | Provider (CCN) number ends in {2000-2299, 3025-3099} or its third position is in {R, T} | Not applicable |
| 7. Hospice | Hospice | All hospice claims | Not applicable | Not applicable |

Exhibit D.1 (continued)

| Category | Claim Type(s) | Criteria for Including Claim (Line Item) in Category | | |
|--|--|---|--|---------------------|
| | | Claim Criterion | Place of Service Criterion | Specialty Criterion |
| 8. All Other Services | Sum of 8a, 8b, 8c, 8d, 8e, 8f, 8g, 8h | | | |
| 8a. Ambulance Services | Outpatient hospital claims plus carrier claim line items | All claims with BETOS code equal to O1A, and, for outpatient claims, Type of Bill not equal to 72x (dialysis) | Not applicable | Not applicable |
| 8b. Chemotherapy and Other Part B–Covered Drugs | Outpatient hospital claims plus carrier claim line items plus durable medical equipment claims | All claims with BETOS code in {O1D, O1E, D1G}, and, for outpatient claims, Type of Bill not equal to 72x (dialysis) | Not applicable | Not applicable |
| 8c. Dialysis | Outpatient claim line items plus carrier claim line items | All Carrier claim line items or outpatient claims with BETOS code equal to P9 or outpatient claims with Type of Bill equal to 72x | Not applicable | Not applicable |
| 8d. Anesthesia Services | Outpatient claim line items plus carrier claim line items | All claims with BETOS code equal to P0, and, for outpatient claims, Type of Bill not equal to 72x (dialysis) | Not applicable | Not applicable |
| 8e. Other Facility-Billed E&M Expenses | Outpatient claim line items plus carrier claim line items | All claims/line items with BETOS in {M1-M6}; HCPCS modifier* not equal to GN, GO, or GP; for outpatient claims, Type of Bill not equal to 22x or 23x (SNF), 33x or 34x (Home Health), or 72x (dialysis); and, for carrier claims, CMS specialty code equal to 49 or Type of Service equal to F (Ambulatory Surgical Center) | For outpatient claims, Revenue Center line code is NOT in {0450-0459, 0981} (emergency department); For carrier claims, Place of Service not equal to 23 (emergency room), 21 (inpatient hospital), or 51 (inpatient psychiatric facility) | |

Exhibit D.1 (continued)

| Category | Claim Type(s) | Criteria for Including Claim (Line Item) in Category | | |
|---|---|--|--|---------------------|
| | | Claim Criterion | Place of Service Criterion | Specialty Criterion |
| 8f. Other Facility-Billed Expenses for Major Procedures | Outpatient claim line items plus carrier claim line items | All claims/line items with BETOS in {P1-P3, P7}; HCPCS modifier* not equal to GN, GO, or GP; for outpatient claims, Type of Bill not equal to 22x or 23x (SNF), 33x or 34x (Home Health), or 72x (dialysis); and, for carrier claims, CMS specialty code equal to 49 or Type of Service equal to F (Ambulatory Surgical Center) | For outpatient claims, Revenue Center line code is NOT in {0450-0459, 0981} (emergency department); For carrier claims, Place of Service not equal to 23 (emergency room), 21 (inpatient hospital), or 51 (inpatient psychiatric facility) | Not applicable |
| 8g. Other Facility-Billed Expenses for Ambulatory/Minor Procedures | Outpatient claim line items plus carrier claim line items | All claims/line items with BETOS in {P4-P6, P8}; HCPCS modifier* not equal to GN, GO, or GP (outpatient therapy); for outpatient claims, Type of Bill not equal to 22x or 23x (SNF), 33x or 34x (Home Health), or 72x (dialysis); and, for carrier claims, CMS specialty code equal to 49 or Type of Service equal to F (Ambulatory Surgical Center) | For outpatient claims, Revenue Center line code is NOT in {0450-0459, 0981} (emergency department); For carrier claims, Place of Service not equal to 23 (emergency room), 21 (inpatient hospital), or 51 (inpatient psychiatric facility) | Not applicable |
| 8h. All Other Services Not Otherwise Classified | Remainder of total costs from claims files (excluding Part D) | Total costs associated with all claims and/or line items not identified in rows above | Not applicable | Not applicable |

* Only the first four HCPCS modifiers are considered due to data constraints.

** Under the “Emergency Services” category, in the “Lab Tests,” and “Imaging” subcategories, CMS includes services from non-eligible professionals, which is consistent with the definition of the “Ancillary Services” subcategories “Laboratory, Pathology, and Other Tests” and “Imaging Services” (3a, 3b). In the “E&M Services” and “Procedures” subcategories, CMS limits carrier claims to those provided by an eligible professional, which is consistent with the definition of the “E&M Services,” and “Procedures” type-of-service categories (1a, 1b, 2a, 2b, 2c, 2d).

Exhibit D.2. Definitions for Service Categories for the MSPB Measure

| Category | Claim Type(s) | Criteria for Including Claim (Line Item) in Category | | |
|---|-------------------------|--|---|---|
| | | BETOS | Claim Criterion | Provider Number Criterion Additional Criterion |
| Acute Inpatient Services | | | | |
| Inpatient Hospital: Index Admission | Inpatient | | | MSPB-eligible hospitals Acute inpatient hospitalization that triggered the MSPB episode |
| Inpatient Hospital: Readmission | Inpatient | | | Provider number with '0' in third digit (Acute Hospital) or with third and fourth digit = '13' (Critical Access Hospital [CAH]) or a Psychiatric hospital as identified by provider number ending in {4000-4499} or its third position is in {M, S}. Any acute inpatient hospitalization other than the one that triggered the episode |
| Physician Services During Hospitalization | Carrier | | Carrier claims line items between from_dt and thru_dt (exclusive) of trigger or readmission inpatient claim with no place of service restriction. For Acute and CAH inpatient stays, carrier claims line items on the from_dt must have Place of Service 21, 22, or 23 while carrier claims on the thru_dt must have Place of Service 21. For Psychiatric inpatient stays, carrier claims line items on the from_dt or thru_dt must have Place of Service 51. | |
| Post-Acute Care Services | | | | |
| Home Health | Home Health, Outpatient | | All Home Health claims. Outpatient claims with Type of Bill 34x | |
| Skilled Nursing Facility | SNF, Outpatient | | All SNF claims. Outpatient claims with Type of Bill 22x or 23x | |
| Inpatient Rehabilitation or Long-Term Care Hospital | Inpatient | | | Provider number ending in {2000-2299, 3025-3099} or with third position in {R, T} |

Exhibit D.2 (continued)

| Category | Claim Type(s) | Criteria for Including Claim (Line Item) in Category | | |
|---|---------------------|--|--|---|
| | | BETOS | Claim Criterion | Provider Number Criterion |
| Emergency Room Outpatient Hospital Services | | | | |
| Emergency Room E&M Services | Outpatient, Carrier | All M Codes | Outpatient revenue center line code in {0450-0459, 0981}, or carrier claim line items occurring during such an Outpatient claim and Place of Service 23. | Must not be counted in any categories above |
| Emergency Room Procedures | Outpatient, Carrier | P0, P1, P2, P3, P4, P5, P6, P7, P8 | Outpatient revenue center line code in {0450-0459, 0981}, or carrier claim occurring during such an Outpatient claim and Place of Service 23 | Must not be counted in any categories above |
| Emergency Room Laboratory, Pathology and Other Tests | Outpatient, Carrier | All T codes | Outpatient revenue center line code in {0450-0459, 0981}, or carrier claim occurring during such an Outpatient claim and Place of Service 23 | Must not be counted in any categories above |
| Emergency Room Imaging Services | Outpatient, Carrier | All I codes | Outpatient revenue center line code in {0450-0459, 0981}, or carrier claim occurring during such an Outpatient claim and Place of Service 23 | Must not be counted in any categories above |
| Outpatient (Non-Emergency Room) Hospital and Physician Office Services | | | | |
| Outpatient Physical, Occupational, or Speech and Language Pathology Therapy | Outpatient, Carrier | | | Any modifier GN, GO, or GP |
| Dialysis | Outpatient, Carrier | | Outpatient claims Type of Bill 72x. Carrier claim line items with BETOS code P9 | Must not be counted in any categories above |
| Outpatient Non-Emergency Room E&M Services | Outpatient, Carrier | All M Codes | | Must not be counted in any categories above |
| Major Procedures and Anesthesia | Outpatient, Carrier | P0, P1, P2, P3, P7 | | Must not be counted in any categories above |
| Ambulatory/Minor procedures | Outpatient, Carrier | P4, P5, P6, P8 | | Must not be counted in any categories above |

Exhibit D.2 (continued)

| Category | Claim Type(s) | Criteria for Including Claim (Line Item) in Category | | | |
|---|---|--|-----------------|---------------------------|---|
| | | BETOS | Claim Criterion | Provider Number Criterion | Additional Criterion |
| Ancillary Services in All Non-Inpatient Settings | | | | | |
| Ancillary Laboratory, Pathology, and Other Tests | Outpatient, Carrier | All T codes | | | Must not be counted in any categories above |
| Ancillary Imaging Services | Outpatient, Carrier | All I codes | | | Must not be counted in any categories above |
| DME and Supplies | DME | All codes except O1D (chemotherapy), O1E and D1G (drugs) | | | Must not be counted in any categories above |
| Hospice | | | | | |
| Hospice | Hospice | | | | |
| Other Services | | | | | |
| Ambulance Services | Outpatient, Carrier | O1A | | | |
| Chemotherapy And Other Part B-Covered Drugs | Outpatient, Carrier, Durable Medical Equipment | O1D, O1E, D1G | | | |
| All Other Services Not Otherwise Classified | All remaining costs from all Medicare Part A and Part B claim types | | | | |

Exhibit D.3. 2016 BETOS Codes and Descriptions

| Code | Description |
|----------------------------------|---|
| Evaluation and management | |
| M1A | Office visits—new |
| M1B | Office visits—established |
| M2A | Hospital visit—initial |
| M2B | Hospital visit—subsequent |
| M2C | Hospital visit—critical care |
| M3 | Emergency room visit |
| M4A | Home visit |
| M4B | Nursing home visit |
| M5A | Specialist—pathology |
| M5B | Specialist—psychiatry |
| M5C | Specialist—ophthalmology |
| M5D | Specialist—other |
| M6 | Consultations |
| Procedures | |
| P0 | Anesthesia |
| P1A | Major procedure—breast |
| P1B | Major procedure—colectomy |
| P1C | Major procedure—cholecystectomy |
| P1D | Major procedure—transurethral resection of the prostate |
| P1E | Major procedure—hysterectomy |
| P1F | Major procedure—explor/decompr/excisdisc |
| P1G | Major procedure—other |
| P2A | Major procedure, cardiovascular—coronary artery bypass grafting |
| P2B | Major procedure, cardiovascular—aneurysm repair |
| P2C | Major procedure, cardiovascular—thromboendarterectomy |
| P2D | Major procedure, cardiovascular—percutaneous transluminal coronary angioplasty (PTCA) |
| P2E | Major procedure, cardiovascular—pacemaker insertion |
| P2F | Major procedure, cardiovascular—other |
| P3A | Major procedure, orthopedic—hip fracture repair |
| P3B | Major procedure, orthopedic—hip replacement |
| P3C | Major procedure, orthopedic—knee replacement |
| P3D | Major procedure, orthopedic—other |
| P4A | Eye procedure—corneal transplant |
| P4B | Eye procedure—cataract removal/lens insertion |
| P4C | Eye procedure—retinal detachment |
| P4D | Eye procedure—treatment of retinal lesions |
| P4E | Eye procedure—other |
| P5A | Ambulatory procedures—skin |
| P5B | Ambulatory procedures—musculoskeletal |
| P5C | Ambulatory procedures—inguinal hernia repair |
| P5D | Ambulatory procedures—lithotripsy |

Exhibit D.3 (continued)

| Code | Description |
|----------------|--|
| P5E | Ambulatory procedures—other |
| P6A | Minor procedures—skin |
| P6B | Minor procedures—musculoskeletal |
| P6C | Minor procedures—other (Medicare fee schedule) |
| P6D | Minor procedures—other (non-Medicare fee schedule) |
| P7A | Oncology—radiation therapy |
| P7B | Oncology—other |
| P8A | Endoscopy—arthroscopy |
| P8B | Endoscopy—upper gastrointestinal |
| P8C | Endoscopy—sigmoidoscopy |
| P8D | Endoscopy—colonoscopy |
| P8E | Endoscopy—cystoscopy |
| P8F | Endoscopy—bronchoscopy |
| P8G | Endoscopy—laparoscopic cholecystectomy |
| P8H | Endoscopy—laryngoscopy |
| P8I | Endoscopy—other |
| P9A | Dialysis services (Medicare fee schedule) |
| P9B | Dialysis services (non-Medicare fee schedule) |
| Imaging | |
| I1A | Standard imaging—chest |
| I1B | Standard imaging—musculoskeletal |
| I1C | Standard imaging—breast |
| I1D | Standard imaging—contrast gastrointestinal |
| I1E | Standard imaging—nuclear medicine |
| I1F | Standard imaging—other |
| I2A | Advanced imaging—CAT: head |
| I2B | Advanced imaging—CAT: other |
| I2C | Advanced imaging—MRI: brain |
| I2D | Advanced imaging—MRI: other |
| I3A | Echography—eye |
| I3B | Echography—abdomen/pelvis |
| I3C | Echography—heart |
| I3D | Echography—carotid arteries |
| I3E | Echography—prostate, transrectal |
| I3F | Echography—other |
| I4A | Imaging/procedure—heart including cardiac catheterization |
| I4B | Imaging/procedure—other |
| Tests | |
| T1A | Lab tests—routine venipuncture (non-Medicare fee schedule) |
| T1B | Lab tests—automated general profiles |
| T1C | Lab tests—urinalysis |
| T1D | Lab tests—blood counts |
| T1E | Lab tests—glucose |

Exhibit D.3 (continued)

| Code | Description |
|----------------------------------|---|
| T1F | Lab tests—bacterial cultures |
| T1G | Lab tests—other (Medicare fee schedule) |
| T1H | Lab tests—other (non-Medicare fee schedule) |
| T2A | Other tests—electrocardiograms |
| T2B | Other tests—cardiovascular stress tests |
| T2C | Other tests—electrocardiogram monitoring |
| T2D | Other tests—other |
| Durable medical equipment | |
| D1A | Medical/surgical supplies |
| D1B | Hospital beds |
| D1C | Oxygen and supplies |
| D1D | Wheelchairs |
| D1E | Other DME |
| D1F | Orthotic devices |
| D1G | Drugs administered through DME |
| Other | |
| O1A | Ambulance |
| O1B | Chiropractic |
| O1C | Enteral and parenteral |
| O1D | Chemotherapy |
| O1E | Other drugs |
| O1F | Vision, hearing, and speech services |
| O1G | Influenza immunization |
| Exceptions/unclassified | |
| Y1 | Other—Medicare fee schedule |
| Y2 | Other—non-Medicare fee schedule |
| Z1 | Local codes |
| Z2 | Undefined codes |

Source: Centers for Medicare & Medicaid Services Health Care Common Procedure Coding System, BETOS Codes available at: <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareFeeforSvcPartsAB/downloads/betosdescodes.pdf>.

Note: CAT = computerized axial tomography; MRI = magnetic resonance imaging.

APPENDIX E

PROVIDER SPECIALTIES AND PROFESSIONAL STRATIFICATION
CATEGORIES

Exhibit E.1 identifies which specialties are physician specialties, and the broad professional stratification categories to which each specialty is assigned. Specialty codes for which the provider stratification category is not applicable generally indicate nonmedical professionals, such as facilities or medical supply companies.

Exhibit E.1. Provider Specialties and Professional Stratification Categories

| Provider or supplier specialty description | CMS specialty code | Eligible professional | Physician | Provider stratification category |
|--|--------------------|-----------------------|-----------|----------------------------------|
| Primary care specialties | | | | |
| Family practice | 08 | Yes | Yes | PCPs |
| General practice | 01 | Yes | Yes | PCPs |
| Geriatric medicine | 38 | Yes | Yes | PCPs |
| Internal medicine | 11 | Yes | Yes | PCPs |
| All other specialties | | | | |
| Addiction medicine | 79 | Yes | Yes | Medical specialists |
| All other suppliers (for example, drug stores) | 87 | No | No | Not applicable |
| Allergy/immunology | 03 | Yes | Yes | Medical specialists |
| Ambulance service supplier (for example, private ambulance companies, funeral homes) | 59 | No | No | Not applicable |
| Ambulatory surgical center | 49 | No | No | Not applicable |
| Anesthesiologist assistant | 32 | Yes | No | Other eligible professionals |
| Anesthesiology | 05 | Yes | Yes | Other eligible professionals |
| Audiologist (billing independently) | 64 | Yes | No | Other eligible professionals |
| Cardiac electrophysiology | 21 | Yes | Yes | Medical specialists |
| Cardiac surgery | 78 | Yes | Yes | Surgeons |
| Cardiology | 06 | Yes | Yes | Medical specialists |
| Centralized flu | C1 | No | No | Not applicable |
| Certified clinical nurse specialist (CNS) | 89 | Yes | No | Other eligible professionals |
| Certified nurse midwife | 42 | Yes | No | Other eligible professionals |
| Certified registered nurse anesthetist (CRNA) | 43 | Yes | No | Other eligible professionals |
| Chiropractic | 35 | Yes | Yes | Other eligible professionals |
| Clinical laboratory (billing independently) | 69 | No | No | Not applicable |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit E.1 (continued)

| Provider or supplier specialty description | CMS specialty code | Eligible professional | Physician | Provider stratification category |
|---|--------------------|-----------------------|-----------|----------------------------------|
| Clinical psychologist | 68 | Yes | No | Other eligible professionals |
| Psychologist (billing independently) | 62 | Yes | No | Other eligible professionals |
| Colorectal surgery (formerly proctology) | 28 | Yes | Yes | Surgeons |
| Critical care (intensivists) | 81 | Yes | Yes | Medical specialists |
| Dentist | C5 | Yes | Yes | Medical specialists |
| Department store | A7 | No | No | Not applicable |
| Dermatology | 07 | Yes | Yes | Medical specialists |
| Diagnostic radiology | 30 | Yes | Yes | Other eligible professionals |
| Emergency medicine | 93 | Yes | Yes | Other eligible professionals |
| Endocrinology | 46 | Yes | Yes | Medical specialists |
| Gastroenterology | 10 | Yes | Yes | Medical specialists |
| General surgery | 02 | Yes | Yes | Surgeons |
| Geriatric psychiatry | 27 | Yes | Yes | Medical specialists |
| Grocery store | A8 | No | No | Not applicable |
| Gynecological/oncology | 98 | Yes | Yes | Surgeons |
| Hand surgery | 40 | Yes | Yes | Surgeons |
| Hematology | 82 | Yes | Yes | Medical specialists |
| Hematology/oncology | 83 | Yes | Yes | Medical specialists |
| Home health agency | A4 | No | No | Not applicable |
| Hospice and palliative care | 17 | Yes | Yes | Medical specialists |
| Hospital | A0 | No | No | Not applicable |
| Independent diagnostic testing facility (IDTF) | 47 | No | No | Not applicable |
| Indirect payment procedure | C2 | No | No | Not applicable |
| Individual orthotic personnel certified by an accrediting organization | 55 | No | No | Not applicable |
| Individual prosthetic personnel certified by an accrediting organization | 56 | No | No | Not applicable |
| Individual prosthetic/orthotic personnel certified by an accrediting organization | 57 | No | No | Not applicable |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit E.1 (continued)

| Provider or supplier specialty description | CMS specialty code | Eligible professional | Physician | Provider stratification category |
|--|--------------------|-----------------------|-----------|----------------------------------|
| Infectious disease | 44 | Yes | Yes | Medical specialists |
| Intensive cardiac rehabilitation | 31 | No | No | Not applicable |
| Intermediate care nursing facility | A2 | No | No | Not applicable |
| Interventional Cardiology | C3 | Yes | Yes | Medical specialists |
| Interventional pain management | 09 | Yes | Yes | Medical specialists |
| Interventional radiology | 94 | Yes | Yes | Other eligible professionals |
| Licensed clinical social worker | 80 | Yes | No | Other eligible professionals |
| Mammography screening center | 45 | No | No | Not applicable |
| Mass immunization roster biller | 73 | No | No | Not applicable |
| Maxillofacial surgery | 85 | Yes | Yes | Surgeons |
| Medical oncology | 90 | Yes | Yes | Medical specialists |
| Medical supply company not included in 51, 52, or 53 | 54 | No | No | Not applicable |
| Medical supply company with orthotic personnel certified by an accrediting organization | 51 | No | No | Not applicable |
| Medical supply company with prosthetic personnel certified by an accrediting organization | 52 | No | No | Not applicable |
| Medical supply company with prosthetic/orthotic personnel certified by an accrediting organization | 53 | No | No | Not applicable |
| Medical supply company with pedorthic personnel | B3 | No | No | Not applicable |
| Medical supply company with registered pharmacist | 58 | No | No | Not applicable |
| Medical supply company with respiratory therapist | A6 | No | No | Not applicable |
| Nephrology | 39 | Yes | Yes | Medical specialists |
| Neurology | 13 | Yes | Yes | Medical specialists |
| Neuropsychiatry | 86 | Yes | Yes | Medical specialists |
| Neurosurgery | 14 | Yes | Yes | Surgeons |
| Nuclear medicine | 36 | Yes | Yes | Other eligible professionals |
| Nurse practitioner (NP) | 50 | Yes | No | Other eligible professionals |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit E.1 (continued)

| Provider or supplier specialty description | CMS specialty code | Eligible professional | Physician | Provider stratification category |
|---|--------------------|-----------------------|-----------|----------------------------------|
| Nursing facility, other | A3 | No | No | Not applicable |
| Obstetrics/gynecology | 16 | Yes | Yes | Surgeons |
| Occupational therapist in private practice | 67 | Yes | No | Other eligible professionals |
| Ocularist | B5 | No | No | Not applicable |
| Ophthalmology | 18 | Yes | Yes | Surgeons |
| Optician | 96 | No | No | Not applicable |
| Optometry | 41 | Yes | Yes | Other eligible professionals |
| Oral surgery (dentists only) | 19 | Yes | Yes | Surgeons |
| Orthopedic surgery | 20 | Yes | Yes | Surgeons |
| Osteopathic manipulative medicine | 12 | Yes | Yes | Medical specialists |
| Otolaryngology | 04 | Yes | Yes | Surgeons |
| Oxygen/Oxygen Related Equipment | B1 | No | No | Not applicable |
| Pain management | 72 | Yes | Yes | Other eligible professionals |
| Pathology | 22 | Yes | Yes | Other eligible professionals |
| Pediatric medicine | 37 | Yes | Yes | Other eligible professionals |
| Pedorthic personnel | B2 | No | No | Not applicable |
| Peripheral vascular disease | 76 | Yes | Yes | Surgeons |
| Pharmacy | A5 | No | No | Not applicable |
| Physical medicine and rehabilitation | 25 | Yes | Yes | Medical specialists |
| Physical therapist in private practice | 65 | Yes | No | Other eligible professionals |
| Physician assistant (PA) | 97 | Yes | No | Other eligible professionals |
| Plastic and reconstructive surgery | 24 | Yes | Yes | Surgeons |
| Podiatry | 48 | Yes | Yes | Other eligible professionals |
| Portable x-ray supplier (billing independently) | 63 | No | No | Not applicable |
| Preventive medicine | 84 | Yes | Yes | Medical specialists |
| Psychiatry | 26 | Yes | Yes | Medical specialists |
| Public health or welfare agencies (federal, state, and local) | 60 | No | No | Not applicable |
| Pulmonary disease | 29 | Yes | Yes | Medical specialists |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit E.1 (continued)

| Provider or supplier specialty description | CMS specialty code | Eligible professional | Physician | Provider stratification category |
|--|--------------------|-----------------------|-----------|----------------------------------|
| Radiation oncology | 92 | Yes | Yes | Other eligible professionals |
| Radiation therapy centers | 74 | No | No | Not applicable |
| Registered dietician/nutrition professional | 71 | Yes | No | Other eligible professionals |
| Rehabilitation agency | B4 | No | No | Not applicable |
| Restricted use | C4 | No | No | Not applicable |
| Rheumatology | 66 | Yes | Yes | Medical specialists |
| Single or multispecialty clinic or group practice | 70 | Yes | Yes | Other eligible professionals |
| Skilled Nursing Facility | A1 | No | No | Not applicable |
| Sleep medicine | C0 | Yes | Yes | Medical specialists |
| Slide preparation facilities | 75 | No | No | Not applicable |
| Speech language pathologists | 15 | Yes | No | Other eligible professionals |
| Sports medicine | 23 | Yes | Yes | Other eligible professionals |
| Surgical oncology | 91 | Yes | Yes | Surgeons |
| Thoracic surgery | 33 | Yes | Yes | Surgeons |
| Unknown supplier | 95 | No | No | Not applicable |
| Unknown physician specialty | 99 | Yes | Yes | Other eligible professionals |
| Unknown provider | 88 | No | No | Not applicable |
| Urology | 34 | Yes | Yes | Surgeons |
| Vascular surgery | 77 | Yes | Yes | Surgeons |
| Voluntary health or charitable agencies (for example, National Cancer Society, National Heart Association, Catholic Charities) | 61 | No | No | Not applicable |

Note: Physician specialties are those identified as such in the Medicare Claims Processing Manual, Chapter 26—Completing and Processing Form CMS-1500 Data Set, available at the following URL: <http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c26.pdf>. Nonphysician eligible professional specialties are those identified in the PQR List of Eligible Professionals, available at the following URL: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/Downloads/2016_PQRS_List_of_EPs.pdf.

APPENDIX F

HIERARCHY OF PQRS DATA USED IN THE 2018 VALUE MODIFIER

Exhibit F.1 PQRS Data Used in the 2018 Value Modifier

| Did TIN register for GPRO? | Did TIN report under elected GPRO mechanism and avoid the 2018 PQRS payment adjustment? | Did TIN report through another GPRO mechanism and avoid the 2018 PQRS payment adjustment? | Did TIN report Individual Eligible Professional (IEP) PQRS data? | Data used in the Value Modifier |
|----------------------------|---|---|--|--|
| Yes | Yes | No | No | GPRO data of the elected mechanism |
| Yes | Yes | Yes | No | GPRO data of the elected mechanism |
| Yes | Yes | No | Yes | GPRO data of the elected mechanism |
| Yes | Yes | Yes | Yes | GPRO data of the elected mechanism |
| Yes | No | Yes | No | GPRO data through which the TIN avoided the 2018 PQRS payment adjustment (<u>not</u> GPRO mechanism elected by TIN) |
| Yes | No | No | Yes | IEP data (if Category 1) |
| Yes | No | No | No | N/A |
| Yes | No | Yes | Yes | GPRO data through which the TIN avoided the 2018 PQRS payment adjustment (<u>not</u> GPRO mechanism elected by TIN) |
| No | N/A | Yes | Yes | GPRO data through which the TIN avoided the 2018 PQRS payment adjustment |
| No | N/A | Yes | No | GPRO data through which the TIN avoided the 2018 PQRS payment adjustment |
| No | N/A | No | Yes | IEP data (if Category 1) |
| No | N/A | No | No | N/A |

APPENDIX G

LIST OF ACRONYMS

Exhibit G.1 List of Acronyms in the Detailed Methodology

| Acronym | Description |
|---------|--|
| ACA | Affordable Care Act |
| ACO | Accountable Care Organization |
| ACSC | Ambulatory Care-Sensitive Condition |
| AF | Adjustment Factor |
| AMA | Against Medical Advice |
| BETOS | Berenson-Eggers Type of Service |
| CAD | Coronary Artery Disease |
| CAH | Critical Access Hospital |
| CAHPS | Consumer Assessment of Healthcare Providers and Systems |
| CARC | Claim Adjustment Reason Code |
| CCN | CMS Certification Number |
| CEHRT | Certified Electronic Health Record Technology |
| CMS | Centers for Medicare & Medicaid Services |
| CMS-HCC | Centers for Medicare & Medicaid Services Hierarchical Condition Category |
| CNS | Clinical Nurse Specialist |
| COPD | Chronic Obstructive Pulmonary Disease |
| CPC | Comprehensive Primary Care (initiative) |
| CRNA | Certified Registered Nurse Anesthetist |
| DME | Durable Medical Equipment |
| DMEPOS | Durable Medical Equipment, Prosthetics, Orthotics, and Supplies |
| eCQM | Electronic Clinical Quality Measure |
| E&M | Evaluation and Management |
| EHR | Electronic Health Record |
| ESRD | End Stage Renal Disease |
| FFS | Fee-for-Service |
| GPRO | Group Practice Reporting Option |
| HCPCS | Healthcare Common Procedure Coding System |
| HIC | Health Insurance Claim (Number) |
| ICD-10 | International Classification of Diseases, 10th Revision, Clinical Modification |
| IDR | Integrated Data Repository |
| IEP | Individual Eligible Professional |
| MAC | Medicare Administrative Contractor |
| MSPB | Medicare Spending per Beneficiary |
| NP | Nurse Practitioner |

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit G.1 (continued)

| Acronym | Description |
|---------|--|
| NPI | National Provider Identifier |
| OACT | CMS Office of the Actuary |
| PA | Physician Assistant |
| PCP | Primary Care Physician |
| PECOS | Provider Enrollment, Chain, and Ownership System |
| PFS | Physician Fee Schedule |
| PQRS | Physician Quality Reporting System |
| QCDR | Qualified Clinical Data Registry |
| QRUR | Quality and Resource Use Report |
| QRDA | Quality Reporting Document Architecture (I or III) |
| ResDAC | Research Data Assistance Center |
| RARC | Remittance Advice Remark Code |
| SNF | Skilled Nursing Facility |
| TIN | Taxpayer Identification Number |
| UDS | Universal Data Set |